

Supporting Information


Improvement of Pharmacological Properties of Irreversible Thyroid Receptor Coactivator Binding Inhibitors

Jong Yeon Hwang¹, Leggy A. Arnold¹, Fangyi Zhu¹, Aaron Kosinski¹, Thomas J. Mangano², Vincent Setola², Bryan L. Roth², and R. Kiplin Guy^{1}*

R. Kiplin Guy, St Jude Children's Hospital, Department of Chemical Biology and Therapeutics,
262 Danny Thomas Place, Memphis TN, 38105-3678, USA. Tel (901) 595-5714; Fax (901) 595-
5715 e-mail: kip.guy@stjude.org

Contents

Table 1. Summary of β -Aminophenylketones Regioisomers and Ring Substitution	S2
Table 2. Summary of β -Aminoarylketones with Alternate Aromatic Rings.....	S4
Table 3. Summary of α -Substituted β -Aminophenylketones	S4
Table 4. Summary of β -Aminophenylketones Bearing Different Nitrogen Substituents	S5
Table 5. Summary the Activities of Hydrophobic Side Chain Modified β -Aminophenylketones....	S6
Table 6. Summary of the Second Generation Compounds	S7
Experimental and Synthetic Procedures and Tabulated Spectral Data	S11
Spectral and Chromatographic Data	S84

Table 1. Summary of β -Aminophenylketones Regioisomers and Ring Substitution

Compound		SRC Binding Inhibition (IC ₅₀ , μ M) ^a		Cell viability HepG 2 (EC ₅₀ , μ M) ^b	Solubility (μ M) ^c	Permeability (10 ⁻⁶ cm/s) ^d	Synthetic Method ^e
No.	R	TR α	TR β				
1	H	7.4 \pm 1.0	9.6 \pm 1.1	54 \pm 9	21 \pm 1	1550 \pm 340	A
9	H	16.6 \pm 1.8	16.5 \pm 1.5	65 \pm 19	180 \pm 10	1040 \pm 100	A
10	H	5.3 \pm 0.6	7.1 \pm 0.8	45 \pm 5	160 \pm 10	830 \pm 70	B
11	5-Me	>50	>50	>100	140 \pm 11	1100 \pm 10	A
12{1}	2-Me	3.5 \pm 0.3	10.1 \pm 1.2	38 \pm 26	130 \pm 20	1230 \pm 120	A
12{2}	3-Me	4.0 \pm 0.3	5.3 \pm 0.6	32 \pm 8	130 \pm 10	750 \pm 90	A
12{3}	2-MeO	3.8 \pm 0.3	7.0 \pm 1.1	100 \pm 37	160 \pm 2	950 \pm 70	A
12{4}	3-MeO	22.2 \pm 6.5	25.3 \pm 7.0	62 \pm 13	160 \pm 10	1040 \pm 260	B
12{5}	2-MeS	4.3 \pm 0.5	5.1 \pm 0.5	29 \pm 6	90 \pm 10	1270 \pm 160	A
12{6}	3-MeS	5.8 \pm 0.6	10.4 \pm 2.1	>100	110 \pm 3	1450 \pm 530	B
12{7}	3-Me ₂ N	>50	>50	>100	180 \pm 10	170 \pm 30	A
12{8}	2- <i>tert</i> Bu	5.4 \pm 0.5	5.0 \pm 0.7	16 \pm 2	6 \pm 1	190 \pm 60	A
12{9}	2-F	3.5 \pm 0.4	4.7 \pm 0.4	37 \pm 10	110 \pm 10	700 \pm 100	A
12{10}	2-Cl	2.6 \pm 0.2	4.3 \pm 1.9	32 \pm 13	30 \pm 10	1020 \pm 230	A
12{11}	3-Cl	3.2 \pm 0.4	1.8 \pm 0.2	53 \pm 9	72 \pm 7	1960 \pm 940	A
12{12}	2-Br	2.3 \pm 0.2	2.6 \pm 0.3	33 \pm 11	19 \pm 7	460 \pm 70	A
12{13}	3-Br	1.1 \pm 0.1	1.4 \pm 0.2	54 \pm 13	78 \pm 2	80 \pm 6	A
12{14}	2-I	1.2 \pm 0.1	2.7 \pm 0.3	31 \pm 11	14 \pm 3	540 \pm 60	A
12{15}	3-I	1.9 \pm 0.4	2.1 \pm 0.4	55 \pm 10	48 \pm 8	270 \pm 110	A
12{16}	2-MeSO ₂	9.3 \pm 1.1	8.4 \pm 1.1	>100	130 \pm 1	730 \pm 50	A
12{17}	3-MeSO ₂	4.7 \pm 0.6	2.4 \pm 0.3	45 \pm 12	40 \pm 10	850 \pm 220	B
12{18}	2-CF ₃	3.4 \pm 0.3	2.7 \pm 0.3	34 \pm 9	6 \pm 2	930 \pm 130	B
12{19}	3-CF ₃	1.4 \pm 0.1	1.9 \pm 0.2	10 \pm 13	20 \pm 10	500 \pm 230	B
12{20}	2-NO ₂	3.7 \pm 0.3	3.0 \pm 0.4	43 \pm 7	54 \pm 8	1340 \pm 410	B
12{21}	2,6-Me ₂	7.7 \pm 0.6	5.0 \pm 0.6	41 \pm 5	51 \pm 8	730 \pm 80	B
12{22}	3,5-Me ₂	1.3 \pm 0.1	1.7 \pm 0.1	15 \pm 1	30 \pm 20	650 \pm 120	A
12{23}	2-Me-5- <i>i</i> Pr	3.0 \pm 0.4	1.79 \pm 1.28	26 \pm 4	20 \pm 5	860 \pm 370	B

12 {24}	2,3-Cl ₂	0.81±0.1	1.1±0.1	31±2	10±1	600±330	B
12 {25}	2,5-Cl ₂	0.6±0.1	0.6±0.1	62±23	20±1	1040±190	B
12 {26}	3,5-Cl ₂	^f	0.69±0.1	18±2	2±1	700±300	B
12 {27}	2-Ph	7.1±1.1	14.1±5.1	16±3	5±3	830±200	A
12 {28}	2-Bn	14.8±7.2	>50	24±3	3±1	230±60	A




^aValues are the mean of three independent experiments in triplicate. ^{b,c,d}Values are means of two independent experiments in triplicate. ^eA is Friedel-Crafts acylation and B is Mannich reaction.

Table 2. Summary of β -Aminoarylketones with Alternate Aromatic Rings

No	SRC Binding Inhibition (IC ₅₀ , μ M) ^a		Cell viability HepG 2 (EC ₅₀ , μ M) ^b	Solubility (μ M) ^c	Permeability (10 ⁻⁶ cm/s) ^d	Synthetic Method ^e
	TR α	TR β				
9	16.6 \pm 1.8	16.5 \pm 1.5	65 \pm 19	180 \pm 10	1040 \pm 100	A
13 {1}	4.1 \pm 0.4	4.0 \pm 0.4	38 \pm 6	22 \pm 4	660 \pm 90	A
13 {2}	>50	>50	>100	1.0 \pm 0.2	150 \pm 80	A
13 {3}	13.4 \pm 10.8	>50	65 \pm 14	8 \pm 4	1420 \pm 140	B


^aValues are the mean of three independent experiments in triplicate. ^{b,c,d}Values are means of two independent experiments in triplicate. ^eA is Friedel-Crafts acylation and B is Mannich reaction.












Table 3. Summary of α -Substituted β -Aminophenylketones

No.	R	SRC Binding Inhibition (IC ₅₀ , μ M) ^a		Cell viability HepG 2 (EC ₅₀ , μ M) ^b	Solubility (μ M) ^c	Permeability (10 ⁻⁶ cm/s) ^d	Synthetic Method ^e
		TR α	TR β				
9	H	16.6 \pm 1.8	16.5 \pm 1.5	65 \pm 19	180 \pm 10	1040 \pm 100	A
14 {1}	Me	>50	>50	56 \pm 18	196 \pm 2	1350 \pm 630	B
14 {2}	iPr	>50	>50	62 \pm 27	145 \pm 6	1260 \pm 170	B
14 {3}	Ph	>50	>50	27 \pm 19	11 \pm 1	910 \pm 90	B
14 {4}		1.9 \pm 0.2	1.7 \pm 0.3	14 \pm 2	7 \pm 2	230 \pm 40	B
14 {5}		1.9 \pm 0.3	2.3 \pm 0.2	12 \pm 2	90 \pm 10	710 \pm 90	B
14 {6}		1.3 \pm 0.1	1.6 \pm 0.1	12 \pm 1	13 \pm 10	700 \pm 130	B

^aValues are the mean of three independent experiments in triplicate. ^{b,c,d}Values are means of two independent experiments in triplicate. ^eA is Friedel-Crafts acylation and B is Mannich reaction.


Table 4. Summary of β -Aminophenylketones Bearing Different Nitrogen Substituents



	R ₁ R ₂ NH	SRC Binding Inhibition (IC ₅₀ , μ M) ^a		Cell viability HepG 2 (EC ₅₀ , μ M) ^b	Solubility (μ M) ^c	Permeability (10 ⁻⁶ cm/s) ^d	hERG ^e	pKa
		TR α	TR β					
9	Me ₂ NH	16.6 \pm 1.8	16.5 \pm 1.5	65 \pm 19	180 \pm 10	1040 \pm 100	61 \pm 9	9.12
15{1}	Bu ₂ NH	6.3 \pm 0.5	2.7 \pm 0.4	48 \pm 20	4 \pm 0.3	560 \pm 170	48 \pm 15	9.95
15{2}	 NH	9.2 \pm 1.0	9.1 \pm 1.2	66 \pm 34	195 \pm 2	2130 \pm 700	75 \pm 2	9.61
15{3}	 NH	4.8 \pm 0.5	18.9 \pm 6.8	59 \pm 17	186 \pm 4	1280 \pm 110	69 \pm 9	9.28
15{4}	 NH	19.8 \pm 2.0	22.0 \pm 2.4	67 \pm 22	74 \pm 3	1660 \pm 70	35 \pm 4	6.45
15{5}		8.4 \pm 0.6	5.6 \pm 0.9	54 \pm 13	160 \pm 20	2300 \pm 420	60 \pm 7	8.1
15{6}		3.0 \pm 0.3	3.8 \pm 0.3	81 \pm 32	2 \pm 0.4	undetected	29 \pm 12	6.13
15{7}		7.7 \pm 0.6	4.1 \pm 0.5	56 \pm 19	78 \pm 6	1790 \pm 360	32 \pm 13	6.5
15{8}		>50	>50	>130	1 \pm 0.1	Undetected	8 \pm 11	5.26
15{9}		>50	>50	>130	1 \pm 0.5	0.2 \pm 0.4	22 \pm 1	4.38
15{10}		>50	>50	>130	0.2 \pm 0.2	2.0 \pm 2	18 \pm 3	3.67
15{11}		>50	>50	54 \pm 31	48 \pm 5	1490 \pm 140	32 \pm 3	^f
15{12}		>50	>50	>130	29 \pm 3	1300 \pm 150	-11 \pm 6	^f

^aValues are the mean of three independent experiments in triplicate. ^{b,c,d}Values are means of two independent experiments in triplicate. ^eValues are the mean of two independent experiments in quadruplicate. ^fNot available.

Table 5. Summary the Activities of Hydrophobic Side Chain Modified β -Aminophenylketones



No	R	SRC Binding Inhibition (IC ₅₀ , μ M) ^a		Cell viability HepG 2 (EC ₅₀ , μ M) ^b	Solubility (μ M) ^c	Permeability (Pe, 10 ⁻⁶ cm/s) ^d	hERG ^e	Synthetic Route ^f
		TR α	TR β					
1		7.5 \pm 1.0	9.6 \pm 1.1	54 \pm 9	22 \pm 1	1550 \pm 340	68 \pm 12	A
9		16.6 \pm 1.8	16.5 \pm 1.5	65 \pm 19	180 \pm 10	1040 \pm 100	61 \pm 9	A
16{1}		30.9 \pm 11.1	>50	>100	220 \pm 3	160 \pm 30	3 \pm 1	A
16{2}		>50	>50	>100	200 \pm 10	140 \pm 30	16 \pm 10	A
16{3}		>50	>50	>100	240 \pm 3	320 \pm 60	35 \pm 10	B
16{4}		6.8 \pm 0.7	5.9 \pm 0.6	34 \pm 15	83 \pm 2	1470 \pm 200	48 \pm 4	A
16{5}		6.2 \pm 0.7	4.9 \pm 0.7	>100	58 \pm 6	780 \pm 80	36 \pm 9	A
16{6}		16.8 \pm 2.8	8.1 \pm 1.4	>100	96 \pm 10	770 \pm 70	15 \pm 7	B
16{7}		9.8 \pm 1.5	12.4 \pm 3.2	>100	210 \pm 4	560 \pm 80	38 \pm 7	B
16{8}		33.3 \pm 10.2	>50	>100	170 \pm 5	50 \pm 20	15 \pm 20	B
16{9}		>50	>50	>100	221 \pm 1	10 \pm 3	23 \pm 15	B

^aValues are the mean of three independent experiments in triplicate. ^{b,c,d}Values are means of two independent experiments in triplicate. ^eValues are the mean of two independent experiments in quadruplicate. ^fA is Friedel-Crafts acylation and B is Mannich reaction.

Table 6. Summary of the Second Generation Compounds

No	SRC Binding Inhibition, TR β (IC ₅₀ , μ M) ^a	Cell viability HepG 2 (EC ₅₀ , μ M) ^b	TI ^c	Solubility (μ M) ^d	Permeability (Pe, 10 ⁻⁶ cm/s) ^e	hERG ^f
17{1,1,1}	1.8±0.3	26±2	14	72±7	1960±940	-
17{1,1,2}	4.6±0.8	51±3	11	14±1	870±90	-
17{1,1,3}	1.8±0.2	39±2	21	10±2	Eq. ^g	-
17{1,1,4}	4.8±0.7	60± 13	13	36±2	Eq. ^g	-
17{1,1,5}	1.2±0.2	43±2	35	12±1	Eq. ^g	-
17{1,1,6}	2.0±0.5	28±1	14	0.6±0.1	Eq. ^g	-
17{1,2,1}	2.6±0.5	31±2	12	10±1	600±330	-
17{1,2,2}	5.0±0.9	39±2	8	1±0.1	370±90	-
17{1,2,3}	0.7±0.1	25±2	36	0.5±0.2	930±150	-
17{1,2,4}	1.2±0.2	47±5	40	6±1	Und. ^h	-
17{1,2,5}	0.6±0.5	17±2	27	2±0.2	Eq. ^g	-
17{1,2,6}	1.2±0.2	28±2	23	0.09±0.03	>1	-
17{1,3,1}	1.5±0.2	89±15	59	20±1	1040±190	-
17{1,3,2}	5.0±1.0	57±4	11	2±0.3	810±50	-
17{1,3,3}	1.4±0.2	28±4	20	1.4±0.1	1770±770	-
17{1,3,4}	2.0±0.3	54±11	27	6±1	Eq. ^g	-
17{1,3,5}	0.8±0.1	28±6	35	2.7±0.4	1540±760	-
17{1,3,6}	1.7±0.2	31±3	19	1.3±0.3	Eq. ^g	-
17{1,4,1}	0.7±0.1	18±2	26	2±1	700±300	-
17{1,4,2}	4.7±1.0	43±4	9	0.3±.1	>1	-
17{1,4,3}	0.8±0.1	17±1	22	1.4±0.2	>1	-
17{1,4,4}	1.5±0.1	23±3	15	15±1	1380±580	-

17{1,4,5}	0.6±0.1	15±1	25	1.8±0.7	Eq. ^g	-
17{1,4,6}	0.8±0.2	18±2	23	0.7±0.7	860	-
17{1,5,1}	0.7±0.1	17±1	25	26±19	650±120	-
17{1,5,2}	6.5±1.1	33±1	5	14±1	930±500	-
17{1,5,3}	2.0±0.3	31±1	15	6±1	Eq. ^g	-
17{1,5,4}	18.9±3.3	39±2	2	16±1	Eq. ^g	-
17{1,5,5}	1.9±0.3	34±1	18	14±2	1550±1080	-
17{1,5,6}	4.0±0.8	39±3	10	0.2±0.1	Eq. ^g	-
17{2,1,1}	1.5±0.3	36±4	24	2.4±0.3	610±100	-
17{2,1,2}	5.4±0.8	55±3	10	1.2±0.1	500±80	-
17{2,1,3}	0.8±0.1	37±2	45	0.3±0.1	2050±650	-
17{2,1,4}	2.0±0.3	47±8	24	6±1	1360±310	-
17{2,1,5}	0.6±0.1	31±2	51	1.3±0.1	1420±250	-
17{2,1,6}	1.7±0.2	34±2	20	0.02±0.01	740±270	-
17{2,2,1}	1.3±0.2	62±24	46	0.06±0.01	140±90	-
17{2,2,2}	3.6±0.9	62±6	17	0.05±0.01	70±50	-
17{2,2,3}	1.3±0.2	20±2	16	0.07±0.03	170±70	-
17{2,2,4}	0.8±0.2	24±4	31	0.24±0.03	1600±810	-
17{2,2,5}	0.9±0.2	23±2	25	0.05±0.02	2300±720	-
17{2,2,6}	0.7±0.1	26±3	36	0.2±0.1	30±50	-
17{2,3,1}	1.2±0.2	27±2	22	0.02±0.03	330±40	-
17{2,3,2}	4.2±0.6	78±16	19	0.14±0.01	140±20	-
17{2,3,3}	1.0±0.2	19±1	19	0.04±0.04	1310±500	-
17{2,3,4}	0.6±0.1	43±12	68	0.1±0.07	810±480	-
17{2,3,5}	0.8±0.1	24±3	32	0.05±0.03	1010±310	-

17{2,3,6}	0.7±0.1	32±3	44	0.02±0.0	20±10	-
17{2,4,1}	1.7±0.4	46±15	27	0.02±0.01	350±390	-
17{2,4,2}	2.4±0.4	29±2	12	0.05±0.02	190±320	-
17{2,4,3}	1.1±0.2	13±1	12	0.03±0.01	10±20	-
17{2,4,4}	1.7±0.2	16±3	10	1.4±0.13	Eq. ^g	-
17{2,4,5}	1.1±0.2	14±1	13	0.2±0.01	1060	-
17{2,4,6}	1.3±0.2	12±1	9	0.2±0.02	50±90	-
17{2,5,1}	1.5±0.3	26±1	18	2.2±0.2	Eq. ^g	-
17{2,5,2}	5.3±1.2	35±1	7	0.9±0.3	770±630	-
17{2,5,3}	1.6±0.3	35±2	22	0.8±0.1	Eq. ^g	-
17{2,5,4}	11.2±2.4	48±3	4	12±1	Eq. ^g	-
17{2,5,5}	0.9±0.1	26±2	29	2.8±0.4	Eq. ^g	-
17{2,5,6}	4.0±1.0	25±1	6	0.9±0.1	160±220	-
17{3,1,1}	3.6±1.0	66±12	18	5.5±0.6	380±30	10±18
17{3,1,2}	2.3±0.3	164±1	73	26±0.3	160±100	2±14
17{3,1,3}	0.6±0.1	98±16	177	38±2	760±70	48±18
17{3,1,4}	0.7±0.1	99±19	138	55±5	240±340	61±5
17{3,1,5}	0.5±0.1	107±25	202	44±4	360±60	45±19
17{3,1,6}	0.4±0.1	100±26	267	25±1	300±110	54±20
17{3,2,1}	2.9±0.8	66±11	23	3.4±0.4	220±90	2±12
17{3,2,2}	1.2±0.8	82±7	68	10±0.2	440±110	14±9
17{3,2,3}	0.7±0.2	56±9	79	10±1	560±80	4±12
17{3,2,4}	0.8±0.1	92±16	118	31±3	1100±610	6±13
17{3,2,5}	1.0±0.2	97±15	96	20±1	770±550	-7±5
17{3,2,6}	0.9±0.1	73±10	81	4.7±0.1	380±220	4±13

17{3,3,1}	2.1±0.5	63±9	30	7.2±0.5	90±30	1±6
17{3,3,2}	1.7±0.2	152±29	90	7.3±0.7	260±30	11±6
17{3,3,3}	0.9±0.2	72±22	79	13±2	680±200	15±16
17{3,3,4}	0.6±0.1	101±20	166	36±1	540±180	3±14
17{3,3,5}	0.8±0.1	87±20	104	19±2	670±80	1±6
17{3,3,6}	0.8±0.1	60±11	74	5.5±0.3	730±280	-7±12
17{3,4,1}	1.1±0.2	54±10	50	6.5±0.6	170±160	-5±17
17{3,4,2}	2.1±0.3	57±8	28	22±4	980±530	5±17
17{3,4,3}	0.8±0.2	39±3	47	4±1	470±120	9±14
17{3,4,4}	1.0±0.2	61±13	62	26±1	430±100	5±13
17{3,4,5}	0.7±0.1	43±8	62	14±1	480±50	4±10
17{3,4,6}	0.8±0.2	32±3	38	6±1	Und. ^h	13±12
17{3,5,1}	1.1±0.2	29±2	28	47±10	1880±910	26±11
17{3,5,2}	3.5±0.3	35±3	10	21±1	1200±370	18±10
17{3,5,3}	0.9±0.1	32±3	36	27±1	1140±170	36±11
17{3,5,4}	5.4±0.4	50±6	9	27±1	480±120	18±12
17{3,5,5}	1.2±0.1	28±3	24	28±1	470±80	32±8
17{3,5,6}	1.5±0.1	38±5	26	30±2	1010±410	20±15


^aValues are the mean of three independent experiments in triplicate. ^bValues are means of two independent experiments in triplicate. ^cValues are EC₅₀ over IC₅₀. ^{d,e}Values are the mean in triplicate. ^fValues are the mean of two independent experiments in quadruplicate. ^gEquilibration. ^hUndetected.

Chemistry. All materials were obtained from commercial suppliers and used without further purification. All solvents used were dried using an aluminum oxide column. Thin-layer chromatography was performed on pre-coated silica gel 60 F254 plates. Purification of compounds was carried out by normal phase column chromatography (SP1 [Biotage], Silica gel 230-400 mesh) followed by evaporation (HT-4X evaporator [Genevac]). Initiator [Biotage] was used for microwave reaction.


Chromatographic separation was performed using a UPLC-MS (BEH C18 1.7 μ , 2.1 x 50 mm column, Waters Corp.). Data were acquired using Masslynx v.4.1 and analyzed using the Openlynx software suite. The flow was then split to an evaporative light scattering detector (ELSD) and SQ mass spectrometer. The total flow rate was 1.0 mL/min and gradient program started at 90% A (0.1% formic acid in H₂O), changed to 95 % B (0.1% formic acid in ACN), then to 90% A. The mass spectrometer was operated in positive-ion mode with electrospray ionization. The conditions were as follows: capillary voltage 3.4 kV, cone voltage 30 V, source temperature 130 °C, desolvation temperature 400 °C, desolvation gas 800 L/hr, cone gas 100 L/hr. A full scan range from m/z = 110-1000 in 0.2 s was used to acquire MS data. The ELSD-drift tube temperature was set at 52 °C

NMR spectra are recorded on a Bruker 400 MHz and referenced internally to the residual resonance in CDCl₃ (δ 7.26 ppm) for hydrogen and (δ = 77 ppm) for carbon atoms. NMR peaks were assigned by MestRec (4.9.9.6) and MestReNova (5.2.2)

i) Friedel-Crafts Acylation



ii) Mannich Reaction



Reagent and condition. (a) Hexyl bromide, K_2CO_3 , DMF, 80-90 °C, 12 h; (b) 2-Chloropropyl chloride, AlCl_3 , DCM, 0 °C; (c) 2 M dimethylamine/THF, THF, rt, 30 min; (d) *m*CPBA, DCM, 0 °C, 1 h; (e) dimethylamine hydrochloride, DMF, MW, 110 °C, 1 h (f) paraformaldehyde, dimethylamine hydrochloride, *c*-HCl, $\text{H}_2\text{O}/\text{MeCN}$ (1/9, v/v), MW, 120 °C, 2 h; (g) NaSMe, DMF, rt, 1 h.

General procedure for 18 and 22: To a solution the corresponding phenol **2** or **21** (5.3 mmol, 1 eq.) in DMF was added K_2CO_2 (10.6 mmol, 2 eq.) and n-hexylbromide (8.0 mmol, 1.5 eq.), and then stirred at 85 °C for overnight. The reaction mixture was poured to water and extracted with Et_2O . The combined organic layer were washed with brine and dried over MgSO_4 and concentrated *in vacuo* to yield crude compound **18** or **22**. The crude product **18** or **22** was used for next step without any purification. **Hexyloxybenzene 18.** ^1H NMR (400 MHz, CDCl_3) δ 7.28 (m, 2H), 6.92

(m, 2H), 3.96 (t, 2H, $J = 6.6$ Hz), 1.79 (m, 2H), 1.47 (m, 2H), 1.35 (m, 4H), 0.91 (t, 3H, $J = 8.0$ Hz);
159.11, 129.36, 120.41, 114.47, 67.85, 31.59, 29.26, 25.73, 22.60, 14.02.

1-(Hexyloxy)-2-methylbenzene 18{1}. ^1H NMR (400 MHz, CDCl_3) δ 7.14 (m, 2H), 6.83 (m, 2H), 3.96 (t, 2H, $J = 6.4$ Hz), 2.23 (s, 3H), 1.80 (m, 2H), 1.47 (m, 2H), 1.36 (m, 4H), 0.92 (m, 3H);
 ^{13}C NMR (100 MHz, CDCl_3) δ 157.25, 130.52, 126.82, 126.65, 120.00, 110.91, 67.88, 31.58, 29.34, 25.82, 22.61, 16.20, 14.01.

1-(Hexyloxy)-3-methylbenzene 18{2}. ^1H NMR (400 MHz, CDCl_3) δ 7.17 (t, 1H, $J = 7.8$ Hz), 6.74 (m, 3H), 3.95 (m, 2H), 2.34 (m, 3H), 1.78 (m, 2H), 1.47 (m, 2H), 1.35 (m, 4H), 0.92 (t, 3H, $J = 7.0$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 159.14, 139.36, 129.10, 121.24, 115.35, 111.31, 67.80, 31.59, 29.29, 25.74, 22.60, 21.50, 14.02.

1-(Hexyloxy)-3-methoxybenzene 18{4}. ^1H NMR (400 MHz, CDCl_3) δ 7.17 (t, 1H, $J = 8.2$ Hz), 6.49 (m, 3H), 3.94 (t, 2H, $J = 6.6$ Hz), 3.79 (s, 3H), 1.77 (m, 2H), 1.45 (m, 2H), 1.34 (m, 4H), 0.91 (t, 3H, $J = 6.8$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 160.81, 160.41, 129.78, 106.70, 106.08, 100.94, 68.00, 55.24, 31.58, 29.23, 25.73, 22.59, 14.02.

1-tert-Butyl-2-(hexyloxy)benzene 18{8}. ^1H NMR (400 MHz, CDCl_3) δ 7.30 (m, 1H), 7.18 (m, 1H), 6.89 (t, 2H, $J = 7.7$ Hz), 4.00 (t, 2H, $J = 6.5$ Hz), 1.87 (m, 2H), 1.54 (m, 2H), 1.41 (m, 13H), 0.94 (t, 3H, $J = 7.0$); ^{13}C NMR (100 MHz, CDCl_3) δ 157.89, 137.95, 126.90, 126.50, 119.90, 111.72, 67.67, 34.82, 31.54, 29.77, 29.44, 26.04, 22.57, 14.00.

1-Fluoro-2-(hexyloxy)benzene 18{9}. ^1H NMR (400 MHz, CDCl_3) δ 7.05 (m, 2H), 6.96 (m, 1H), 6.87 (m, 1H), 4.03 (t, 2H, $J = 6.6$ Hz), 1.82 (m, 2H), 1.47 (m, 2H), 1.33 (m, 4H), 0.90 (m, 3H).

1-Chloro-2-(hexyloxy)benzene 18{10}. ^1H NMR (400 MHz, CDCl_3) δ 7.35 (m, 1H), 7.19 (m, 1H), 6.89 (m, 2H), 4.02 (t, 2H, $J = 6.6$ Hz), 1.84 (m, 2H), 1.50 (m, 2H), 1.36 (m, 4H), 0.91 (t, 3H, $J = 8.0$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 154.62, 130.20, 127.58, 122.92, 121.05, 113.36, 69.10, 31.52, 29.07, 25.62, 22.57, 14.01.

1-Chloro-3-(hexyloxy)benzene 18{11}. ^1H NMR (400 MHz, CDCl_3) δ 7.20 (t, 1H, $J = 8.1$ Hz), 6.93 (m, 2H), 6.80 (m, 1H), 3.96 (t, 2H, $J = 6.6$ Hz), 1.79 (m, 2H), 1.47 (m, 2H), 1.36 (m, 4H), 0.93 (t, 3H, $J = 6.7$); ^{13}C NMR (100 MHz, CDCl_3) δ 159.91, 134.78, 130.11, 120.59, 114.82, 113.06, 68.24, 31.53, 29.10, 25.66, 22.58, 14.01.

1-Bromo-2-(hexyloxy)benzene 18{12}. ^1H NMR (400 MHz, CDCl_3) δ 7.53 (dd, 1H, $J = 1.6, 7.9$ Hz), 7.23 (m, 1H), 6.88 (m, 1H), 6.81 (m, 1H), 4.02 (t, 2H, $J = 6.5$), 1.84 (m, 2H), 1.51 (m, 2H), 1.35 (m, 4H), 0.91 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 155.47, 133.28, 128.33, 121.55, 113.19, 112.25, 77.31, 77.00, 76.68, 69.14, 31.50, 29.05, 25.65, 22.57, 14.01.

1-Bromo-3-(hexyloxy)benzene 18{13}. ^1H NMR (400 MHz, CDCl_3) δ 7.13 (dd, 1H, $J = 6.9, 9.6$ Hz), 7.06 (m, 2H), 6.82 (m, 1H), 3.93 (t, 2H, $J = 6.6$ Hz), 1.77 (m, 2H), 1.44 (m, 2H), 1.34 (m, 4H), 0.91 (t, 3H, $J = 6.8$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 159.95, 130.44, 123.51, 122.75, 117.71, 113.55, 68.25, 31.53, 29.09, 25.65, 22.57, 14.01.

1-(Hexyloxy)-2-iodobenzene 18{14}. ^1H NMR (400 MHz, CDCl_3) δ 7.77 (dd, 1H, $J = 1.6, 7.8$ Hz), 7.28 (m, 1H), 6.80 (m, 1H), 6.69 (m, 1H), 3.99 (m, 2H), 1.84 (m, 2H), 1.53 (m, 2H), 1.37 (m, 4H), 0.92 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 157.61, 139.36, 129.33, 122.23, 112.06, 86.71, 69.16, 31.48, 29.05, 25.74, 22.57, 14.02.

1-(Hexyloxy)-3-iodobenzene 18{15}. ^1H NMR (400 MHz, CDCl_3) δ 7.26 (m, 2H), 6.99 (t, 1H, $J = 7.9$ Hz), 6.86 (m, 1H), 3.92 (t, 2H, $J = 6.5$ Hz), 1.77 (m, 2H), 1.46 (m, 2H), 1.34 (m, 4H), 0.92 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 159.72, 130.68, 129.57, 123.61, 114.21, 94.33, 68.17, 31.52, 29.10, 25.65, 22.57, 14.01.

(2-(Hexyloxy)phenyl)(methyl)sulfane 18{16}. ^1H NMR (400 MHz, CDCl_3) δ 7.11 (m, 2H), 6.93 (m, 1H), 6.81 (m, 1H), 4.01 (t, 2H, $J = 6.6$ Hz), 2.41 (s, 3H), 1.82 (m, 2H), 1.49 (m, 2H), 1.33 (m, 4H), 0.90 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 155.76, 127.26, 125.83, 125.67, 120.96, 111.10, 68.64, 31.55, 29.17, 25.72, 22.58, 14.56, 14.02.

3-Chloro-1-(4-(hexyloxy)-2,6-dimethylphenyl)propan-1-one 18{22}. ^1H NMR (400 MHz, CDCl_3) δ 6.54 (s, 1H), 3.93 (t, $J = 6.6$, 1H), 2.28 (t, $J = 3.6$, 3H), 1.82 – 1.70 (m, 1H), 1.53 – 1.40 (m, 1H), 1.40 – 1.28 (m, 2H), 0.92 (dd, $J = 4.5, 9.6$, 2H).

2-(Hexyloxy)biphenyl 18{27}. ^1H NMR (400 MHz, CDCl_3) δ 7.56 (m, 2H), 7.40 (m, 2H), 7.31 (m, 3H), 7.01 (m, 2H), 3.96 (t, 2H, $J = 6.5$ Hz), 1.71 (m, 2H), 1.39 (m, 2H), 1.28 (m, 4H), 0.88 (t, 3H, $J = 6.9$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 156.03, 138.62, 130.92, 130.82, 129.59, 128.49, 127.75, 126.68, 120.69, 112.50, 68.42, 31.43, 29.12, 25.72, 22.56, 13.97.

1-Benzyl-2-(hexyloxy)benzene 18{28} ^1H NMR (400 MHz, CDCl_3) δ 7.26 (m, 4H), 7.19 (m, 2H), 7.11 (m, 1H), 6.88 (m, 2H), 4.00 (s, 2H), 3.96 (t, 2H, $J = 6.4$ Hz), 1.77 (m, 2H), 1.44 (m, 2H), 1.33 (m, 4H), 0.92 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 156.83, 141.20, 130.31, 129.79, 128.94, 128.14, 127.32, 125.66, 120.16, 111.17, 67.87, 36.13, 31.56, 29.31, 25.79, 22.59, 14.03.

General procedure for 19 and 20: To a solution phenol **18** (0.50 g, 2.81 mmol) in DCM was added 3-chloropropanoic chloride (0.35 mL, 3.65 mmol) and AlCl₃ (0.49 g, 3.65 mmol) at 0 °C and stirred for 1 h. The reaction mixture was poured into ice water and extracted with DCM. The combined organic layer were washed with brine and dried over MgSO₄ and concentrated in vacuo to yield crude compound **19**. **3-Chloro-1-(4-(hexyloxy)phenyl)propan-1-one 19**. White solid; 82% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.95 (d, 1H, *J* = 8.9 Hz), 6.95 (d, 1H, *J* = 8.9 Hz), 4.04 (t, 1H, *J* = 6.6 Hz), 3.94 (t, 1H, *J* = 6.9 Hz), 3.42 (t, 1H, *J* = 6.9 Hz), 1.82 (m, 1H), 1.49 (m, 1H), 1.37 (m, 2H), 0.93 (t, 2H, *J* = 7.0 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 238.90, 214.67, 182.95, 149.81, 148.72, 133.79, 87.80, 60.36, 58.47, 50.98, 48.50, 45.10, 42.03, 33.47

3-Chloro-1-(4-(hexyloxy)-3-methylphenyl)propan-1-one 19{1}. Yield 58%; ¹H NMR (400 MHz, CDCl₃) δ 7.79 (m, 2H), 6.83 (d, 1H, *J* = 8.5 Hz), 4.03 (t, 2H, *J* = 6.4 Hz), 3.91 (t, 2H, *J* = 7.0 Hz), 3.40 (t, 2H, *J* = 6.9 Hz), 2.25 (s, 3H), 1.82 (m, 2H), 1.49 (M, 2H), 1.35 (m, 4H), 0.91 (t, 3H, *J* = 7.1 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 195.47, 161.70, 130.60, 128.70, 128.17, 127.09, 110.02, 68.24, 40.85, 39.12, 31.48, 29.05, 25.70, 22.56, 16.25, 13.97.

3-Chloro-1-(4-(hexyloxy)-2-methylphenyl)propan-1-one 19{2}. Yield 52%; ¹H NMR (400 MHz, CDCl₃) δ 7.72 (d, 1H, *J* = 9.4 Hz), 6.76 (m, 2H), 4.00 (m, 2H), 3.89 (t, 2H, *J* = 6.8 Hz), 3.37 (t, 2H, *J* = 6.8 Hz), 2.56 (s, 3H), 1.79 (m, 2H), 1.55 (s, 1H), 1.46 (s, 2H), 1.35 (m, 4H), 0.91 (t, 3H, *J* = 6.9 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 197.83, 161.86, 142.57, 131.77, 128.89, 118.18, 111.15, 77.31, 77.00, 76.68, 68.10, 43.02, 39.39, 31.53, 31.52, 29.06, 25.64, 22.57, 22.50, 14.01,

1-(3-*tert*-Butyl-4-(hexyloxy)phenyl)prop-2-en-1-one 19{8}. This compound was shown enone as a major product and chloroketone as a minor product in crude NMR. The crude mixture was reacted with DBU to give eliminated product enone. Two step yield 18%, para/meta=49/51; ^1H NMR (400 MHz, CDCl_3) δ 7.61 (d, 1H, $J = 2.5$ Hz), 7.45 (dd, 1H, $J = 2.6, 8.7$ Hz), 7.09 (m, 1H), 6.87 (d, 1H, $J = 8.7$ Hz), 6.29 (m, 1H, $J = 1.8, 17.2$ Hz), 5.73 (dd, 1H, $J = 1.8, 10.4$ Hz), 4.00 (t, 2H, $J = 6.4$ Hz), 1.77 (m, 2H), 1.44 (s, 3H), 1.31 (m, 14H), 0.91 (d, 3H, $J = 7.0$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 189.67, 162.09, 138.27, 132.38, 129.30, 128.93, 128.73, 127.72, 111.10, 68.23, 35.01, 31.45, 29.57, 29.18, 25.94, 22.51, 13.96,

3-Chloro-1-(4-(hexyloxy)-2-methoxyphenyl)propan-1-one 19{4}. Yield 16%; ^1H NMR (400 MHz, CDCl_3) δ 7.84 (d, 1H, $J = 8.8$ Hz), 6.52 (dd, 1H, $J = 2.2, 8.8$ Hz), 6.45 (d, 1H, $J = 2.2$ Hz), 4.00 (t, 2H, $J = 6.6$ Hz), 3.87 (m, 5H), 3.43 (t, 2H, $J = 6.9$ Hz), 1.79 (m, 2H), 1.46 (m, 2H), 1.34 (m, 4H), 0.91 (t, 3H, $J = 6.9$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 196.07, 164.50, 161.07, 132.80, 119.88, 105.85, 98.64, 68.34, 55.43, 46.42, 39.44, 31.49, 29.04, 25.60, 22.53, 13.97,

3-Chloro-1-(4-(hexyloxy)-3-(methylthio)phenyl)propan-1-one 19{5}. Yield 59%; ^1H NMR (400 MHz, CDCl_3) δ 7.75 (d, 1H, $J = 2.0$ Hz), 7.71 (dd, 1H, $J = 2.1, 8.5$ Hz), 6.82 (d, 1H, $J = 8.5$ Hz), 4.08 (t, 2H, $J = 6.5$ Hz), 3.90 (t, 2H, $J = 6.9$ Hz), 3.40 (m, 2H), 2.45 (m, 3H), 1.85 (m, 2H), 1.50 (m, 2H), 1.33 (m, 4H), 0.89 (t, 3H, $J = 7.1$ Hz)

3-Chloro-1-(2-fluoro-4-(hexyloxy)phenyl)propan-1-one 19{7}. Yield 34%; ^1H NMR (400 MHz, CDCl_3) δ 7.89 (t, 1H, $J = 8.8$ Hz), 6.75 (dd, 1H, $J = 2.4, 8.9$ Hz), 6.60 (dd, 1H, $J = 2.3, 13.4$ Hz), 4.00 (t, 2H, $J = 6.6$ Hz), 3.89 (m, 2H), 3.42 (m, 2H), 1.80 (m, 2H), 1.46 (m, 2H), 1.34 (m, 4H), 0.91

(t, 3H, $J = 7.1$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 194.32, 158.78, 130.38, 129.62, 128.44, 123.33, 112.14, 77.31, 77.00, 76.68, 69.42, 40.88, 38.70, 31.43, 28.82, 25.53, 22.53, 13.98.

3-Chloro-1-(3-fluoro-4-(hexyloxy)phenyl)propan-1-one 19{9}. Yield 91%; ^1H NMR (400 MHz, CDCl_3) δ 7.70 (m, 2H), 6.99 (t, 1H, $J = 8.4$ Hz), 4.10 (m, 2H), 3.90 (t, 2H, $J = 6.8$ Hz), 3.38 (t, 1H, $J = 6.8$ Hz), 1.84 (m, 2H), 1.47 (m, 2H), 1.33 (m, 5H), 0.90 (m, 3H)

3-Chloro-1-(3-chloro-4-(hexyloxy)phenyl)propan-1-one 19{10}. Yield 92%; ^1H NMR (400 MHz, CDCl_3) δ 7.99 (d, 1H, $J = 2.2$ Hz), 7.85 (dd, 1H, $J = 2.2, 8.6$ Hz), 6.95 (d, 1H, $J = 8.6$ Hz), 4.10 (t, 2H, $J = 6.5$ Hz), 3.91 (t, 2H, $J = 6.8$ Hz), 3.39 (t, 2H, $J = 6.8$ Hz), 1.87 (m, 2H), 1.52 (m, 2H), 1.36 (m, 4H), 0.91 (t, 3H, $J = 7.0$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 194.32, 158.78, 130.38, 129.62, 128.44, 123.33, 112.14, 77.31, 77.00, 76.68, 69.42, 40.88, 38.70, 31.43, 28.82, 25.53, 22.53, 13.98,

3-Chloro-1-(2-chloro-4-(hexyloxy)phenyl)propan-1-one 19{11}. Beta-chloro/enone 1:0.7 Yield 14%; ^1H NMR (400 MHz, CDCl_3) δ 7.65 (d, 1H, $J = 8.7$ Hz), 6.93 (d, 1H, $J = 3.2$ Hz), 6.83 (m, 1H), 3.99 (t, 2H, $J = 6.5$ Hz), 3.89 (m, 2H), 3.46 (t, 2H, $J = 6.7$ Hz), 1.79 (m, 2H), 1.46 (m, 2H), 1.34 (m, 4H), 0.91 (t, 3H, $J = 6.7$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 197.19, 162.22, 136.04, 133.75, 132.01, 130.28, 116.63, 113.34, 68.67, 45.13, 38.99, 31.47, 28.92, 25.57, 22.56, 14.00,

1-(3-Bromo-4-(hexyloxy)phenyl)-3-chloropropan-1-one 19{12}. Yield 90%; ^1H NMR (400 MHz, CDCl_3) δ 8.16 (d, 1H, $J = 2.2$ Hz), 7.89 (dd, 1H, $J = 2.2, 8.6$ Hz), 6.91 (d, 1H, $J = 8.7$ Hz), 4.10 (t, 2H, $J = 6.5$ Hz), 3.90 (t, 2H, $J = 6.8$ Hz), 3.38 (t, 2H, $J = 6.8$ Hz), 1.86 (m, 2H), 1.53 (m, 2H), 1.36 (m, 4H), 0.91 (t, 3H, $J = 7.0$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 194.19, 159.60, 133.56, 130.08, 129.16, 112.45, 111.96, 77.31, 77.00, 76.68, 69.49, 40.87, 38.70, 31.41, 28.81, 25.55, 22.52, 13.98,

1-(2-Bromo-4-(hexyloxy)phenyl)-3-chloropropan-1-one 19{13}. Beta-chloro/eneone 0.8/1 Yield 9%; ^1H NMR (400 MHz, CDCl_3) δ 7.56 (d, 1H, $J = 8.7$ Hz), 7.40 (d, 1H, $J = 8.6$ Hz), 7.14 (s, 1H), 6.87 (d, 1H, $J = 8.6$ Hz), 3.98 (t, 2H, $J = 6.5$ Hz), 3.88 (t, 2H, $J = 6.7$ Hz), 3.43 (t, 2H, $J = 6.9$ Hz), 1.78 (m, 2H), 1.45 (m, 2H), 1.34 (m, 4H), 0.91 (t, 3H, $J = 6.9$ Hz).

3-Chloro-1-(4-(hexyloxy)-3-iodophenyl)propan-1-one 19{14}. Yield 56%; ^1H NMR (400 MHz, CDCl_3) δ 8.38 (d, 1H, $J = 2.2$ Hz), 7.93 (dd, 1H, $J = 2.2, 8.6$ Hz), 6.82 (d, 1H, $J = 8.7$ Hz), 4.09 (t, 2H, $J = 6.4$ Hz), 3.90 (t, 2H, $J = 6.8$ Hz), 3.38 (t, 2H, $J = 6.8$ Hz), 1.86 (m, 2H), 1.54 (d, 2H, $J = 5.5$ Hz), 1.36 (m, 4H), 0.92 (t, 3H, $J = 7.0$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 194.04, 161.67, 139.81, 130.77, 130.19, 110.88, 86.60, 69.60, 40.87, 38.72, 31.40, 28.83, 25.65, 22.54, 13.99,

3-Chloro-1-(4-(hexyloxy)-2-iodophenyl)propan-1-one 19{15}. beta-chloro/eneone 1/0.7 Yield 11%; ^1H NMR (400 MHz, CDCl_3) δ 7.54 (d, 1H, $J = 8.7$ Hz), 7.50 (d, 1H, $J = 2.5$ Hz), 6.91 (m, 1H), 3.97 (m, 2H), 3.88 (t, 2H, $J = 6.8$ Hz), 3.38 (t, 2H, $J = 6.8$ Hz), 1.78 (m, 2H), 1.45 (m, 2H), 1.33 (m, 4H), 0.90 (t, 3H, $J = 6.9$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 204.20, 167.94, 141.77, 137.15, 134.27, 133.18, 120.45, 99.61, 75.05, 49.78, 45.47, 37.93, 35.41, 32.03, 29.01, 20.46.

General procedure for oxidation of thioether to sulfonyl compound- Synthesis of compound 21{16} To a solution of **19{5}** in DCM was added *m*CPBA (2.2 eq) at 0 °C and stirred for 1 h. The reaction mixture was poured to water and extracted with DCM. The combined organic layer was washed with NaHCO_3 and brine, dried over MgSO_4 , and concentrated *in vacuo* to yield the corresponding sulfonyl compound. **3-Chloro-1-(4-(hexyloxy)-3-(methylsulfonyl)phenyl)propan-1-one 19{16}**. ^1H NMR (400 MHz, CDCl_3) δ 8.51 (d, 1H, $J = 2.3$ Hz), 8.21 (dd, 1H, $J = 2.3, 8.8$

Hz), 7.11 (d, 1H, $J = 8.8$ Hz), 4.22 (t, 2H, $J = 6.6$ Hz), 3.89 (t, 2H, $J = 6.6$ Hz), 3.43 (t, 2H, $J = 6.6$ Hz), 3.23 (s, 3H), 1.90 (m, 2H), 1.50 (m, 2H), 1.34 (m, 4H), 0.89 (m, 3H).

3-Chloro-1-(4-(hexyloxy)-2,6-dimethylphenyl)propan-1-one 19{22}. Beta-chloro/enone 1/1
Yield 10%; ^1H NMR (400 MHz, CDCl_3) δ 6.55 (s, 2H), 3.93 (m, 2H), 3.86 (m, 2H), 3.16 (t, 2H, $J = 6.5$ Hz), 2.23 (s, 6H), 2.15 (s, 6H), 1.76 (m, 2H), 1.45 (m, 2H), 1.34 (m, 4H), 0.91 (t, 3H, $J = 7.1$ Hz)

3-Chloro-1-(6-(hexyloxy)biphenyl-3-yl)propan-1-one 19{27}. ^1H NMR (400 MHz, CDCl_3) δ 7.95 (m, 2H), 7.54 (m, 2H), 7.42 (dd, 2H, $J = 6.9, 7.6$ Hz), 7.36 (dd, 1H, $J = 4.6, 11.4$ Hz), 7.01 (m, 1H), 4.06 (t, 2H, $J = 6.5$ Hz), 3.93 (t, 2H, $J = 6.9$ Hz), 3.44 (t, 2H, $J = 6.9$ Hz), 1.75 (m, 2H), 1.40 (m, 2H), 1.29 (m, 4H), 0.88 (t, 3H, $J = 6.8$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 195.29, 160.33, 137.42, 131.17, 130.89, 129.49, 129.41, 129.23, 127.96, 127.31, 111.55, 68.64, 40.93, 39.01, 31.33, 28.83, 25.60, 22.50, 13.93.

1-(3-Benzyl-4-(hexyloxy)phenyl)-3-chloropropan-1-one 19{28}. ^1H NMR (400 MHz, CDCl_3) δ 7.83 (dd, 1H, $J = 2.3, 8.6$ Hz), 7.77 (d, 1H, $J = 2.2$ Hz), 7.27 (m, 2H), 7.19 (m, 3H), 6.87 (d, 1H, $J = 8.6$ Hz), 4.01 (m, 4H), 3.89 (t, 2H, $J = 6.9$ Hz), 3.37 (t, 2H, $J = 6.9$ Hz), 1.77 (m, 2H), 1.40 (m, 2H), 1.31 (m, 4H), 0.90 (t, 3H, $J = 6.6$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 195.34, 161.29, 140.23, 130.54, 130.10, 128.90, 128.77, 128.28, 126.00, 110.55, 68.33, 40.83, 39.04, 36.26, 31.48, 29.03, 25.66, 22.54, 14.00.

3-Chloro-1-(2-(hexyloxy)-4-methylphenyl)propan-1-one 20. Yield 36%; ^1H NMR (400 MHz, CDCl_3) δ 7.71 (d, 1H, $J = 7.9$ Hz), 6.80 (d, 1H, $J = 7.9$ Hz), 6.75 (s, 1H), 4.06 (t, 2H, $J = 6.5$ Hz),

3.86 (m, 2H), 3.49 (t, 2H, $J = 7.0$ Hz), 2.36 (s, 3H), 1.86 (m, 2H), 1.50 (m, 2H), 1.36 (m, 4H), 0.91 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 217.21, 178.24, 164.84, 150.21, 143.85, 140.93, 132.38, 88.03, 66.35, 58.85, 50.99, 48.66, 45.46, 42.04, 41.37, 33.49.

General procedure for 11 and 12: To a solution compound **19** or **20** in THF was added 1 M dimethylamine solution (5 eq.) in THF and stirred at rt for 1 h. The reaction mixture was subjected to empty SPE cartridge to filter solid HCl salt off and washed with ether. The combined organic layer were concentrated in vacuo to yield aminoketone **11** or **12**.

3-(Dimethylamino)-1-(4-(hexyloxy)phenyl)propan-1-one 9. Yield 92% ^1H NMR (400 MHz, CDCl_3) δ 7.93 (d, 2H, $J = 8.9$ Hz), 6.91 (d, 2H, $J = 8.9$ Hz), 4.01 (t, 2H, $J = 6.6$ Hz), 3.11 (m, 2H), 2.76 (m, 2H), 2.29 (s, 6H), 1.79 (m, 2H), 1.45 (m, 2H), 1.34 (m, 4H), 0.91 (t, 3H, $J = 6.9$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 197.58, 163.12, 130.30, 129.75, 114.17, 68.24, 54.57, 45.46, 36.46, 31.50, 29.04, 25.62, 22.55, 13.98; MS (ESI) m/z 278.4 $[\text{M}+\text{H}]^+$.

3-(Dimethylamino)-1-(2-(hexyloxy)-4-methylphenyl)propan-1-one 11. Yield 89% ^1H NMR (400 MHz, CDCl_3) δ 7.63 (d, 1H, $J = 7.9$ Hz), 6.76 (t, 1H, $J = 6.3$ Hz), 6.73 (m, 1H), 4.02 (t, 2H, $J = 6.2$), 3.19 (m, 2H), 2.70 (m, 2H), 2.35 (s, 3H), 2.26 (m, 6H), 1.84 (m, 2H), 1.47 (m, 2H), 1.34 (m, 4H), 0.89 (t, 3H, $J = 7.0$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 220.10, 177.84, 163.94, 150.03, 144.96, 140.75, 132.35, 87.93, 73.91, 64.86, 61.53, 51.01, 48.72, 45.41, 42.05, 41.30, 33.48; MS (ESI) m/z 292.2 $[\text{M}+\text{H}]^+$.

3-(Dimethylamino)-1-(4-(hexyloxy)-3-methylphenyl)propan-1-one 12{1}. Yield 100%; ¹H NMR (400 MHz, CDCl₃) δ 7.80 (m, 2H), 6.82 (d, 1H, *J* = 8.5 Hz), 4.02 (t, 2H, *J* = 6.4 Hz), 3.11 (m, 2H), 2.76 (m, 2H), 2.30 (s, 6H), 2.24 (s, 3H), 1.82 (m, 2H), 1.46 (m, 2H), 1.36 (m, 4H), 0.90 (t, 3H, *J* = 7.0 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 197.87, 161.35, 130.64, 129.19, 128.11, 126.90, 109.93, 68.17, 54.66, 45.44, 36.41, 31.49, 29.08, 25.71, 22.55, 16.26, 13.97; MS (ESI) *m/z* 292.4 [M+H]⁺.

3-(Dimethylamino)-1-(4-(hexyloxy)-2-methylphenyl)propan-1-one 12{2}. Yield 98%; ¹H NMR (400 MHz, CDCl₃) δ 7.72 (m, 1H), 6.74 (m, 2H), 3.99 (t, 2H, *J* = 6.6 Hz), 3.07 (t, 2H, *J* = 7.4 Hz), 2.72 (m, 2H), 2.53 (s, 3H), 2.28 (s, 6H), 1.78 (m, 2H), 1.45 (d, 2H, *J* = 7.9 Hz), 1.34 (m, 5H), 0.91 (t, 3H, *J* = 6.9 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 220.17, 180.92, 161.52, 151.02, 149.18, 137.52, 130.47, 87.50, 74.27, 64.94, 58.45, 51.00, 48.56, 45.12, 42.04, 41.86, 33.48; MS (ESI) *m/z* 292.2 [M+H]⁺.

3-(Dimethylamino)-1-(4-(hexyloxy)-2-methoxyphenyl)propan-1-one 12{4}. Yield 90%; ¹H NMR (400 MHz, CDCl₃) δ 7.76 (t, 1H, *J* = 7.6 Hz), 6.47 (dd, 1H, *J* = 2.2, 8.8 Hz), 6.41 (d, 1H, *J* = 2.2 Hz), 3.97 (q, 2H, *J* = 6.9 Hz), 3.86 (s, 3H), 3.20 (t, 2H, *J* = 7.4 Hz), 2.79 (m, 2H), 2.33 (s, 6H), 1.75 (m, 2H), 1.42 (m, 2H), 1.30 (m, 4H), 0.87 (t, 3H, *J* = 7.0 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 198.17, 164.14, 160.81, 132.59, 120.39, 105.65, 98.60, 68.22, 55.39, 54.23, 44.94, 41.09, 31.42, 28.98, 25.54, 22.46, 13.90; MS (ESI) *m/z* 308.4 [M+H]⁺.

3-(Dimethylamino)-1-(4-(hexyloxy)-3-(methylthio)phenyl)propan-1-one 12{5}. Yield 93%; ¹H NMR (400 MHz, CDCl₃) δ 7.73 (m, 2H), 6.80 (d, 1H, *J* = 8.5 Hz), 4.07 (t, 2H, *J* = 6.5 Hz), 3.09 (t, 2H, *J* = 7.4 Hz), 2.74 (m, 2H), 2.43 (d, 3H, *J* = 3.6 Hz), 2.27 (m, 6H), 1.83 (m, 2H), 1.48 (m, 2H),

1.34 (m, 4H), 0.88 (t, 3H, $J = 7.0$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 197.46, 159.32, 130.05, 128.46, 126.78, 125.16, 109.68, 68.93, 54.58, 45.45, 36.44, 31.43, 28.89, 25.58, 22.49, 14.28, 13.95; MS (ESI) m/z 324.5 $[\text{M}+\text{H}]^+$.

1-(3-*tert*-Butyl-4-(hexyloxy)phenyl)-3-(dimethylamino)propan-1-one 12{8}. Yield 98%; ^1H NMR (400 MHz, CDCl_3) δ 7.96 (d, 1H, $J = 2.2$ Hz), 7.82 (dd, 1H, $J = 2.3, 8.6$ Hz), 6.87 (d, 1H, $J = 8.6$ Hz), 4.05 (t, 2H, $J = 6.5$ Hz), 3.74 (t, 1H, $J = 6.7$ Hz), 3.11 (m, 2H), 2.75 (m, 2H), 2.30 (s, 6H), 1.87 (m, 2H), 1.52 (m, 2H), 1.37 (m, 13H), 0.91 (t, 3H, $J = 7.1$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 198.12, 161.98, 138.06, 129.10, 128.23, 127.00, 111.04, 68.20, 54.74, 45.50, 36.47, 34.98, 31.45, 29.57, 29.18, 25.94, 22.51, 13.96; MS (ESI) m/z 334.5 $[\text{M}+\text{H}]^+$.

1-(3-Fluoro-4-(hexyloxy)phenyl)-3-(dimethylamino)propan-1-one 12{9} ^1H NMR (400 MHz, CDCl_3) δ 7.75 – 7.67 (m, 2H), 6.97 (t, $J = 8.3$, 1H), 4.10 (T, $J = 6.7$, 2H), 3.10 (t, $J = 7.4$, 2H), 2.77 (t, $J = 7.3$, 2H), 2.31 (s, 6H), 1.91 – 1.75 (m, 2H), 1.47 (M, 2H), 1.34 (M, $J = 3.6, 7.4$, 6H), 0.90 (t, $J = 7.2$, 4H). NMR (101 MHz, CDCl_3) δ 196.63, 196.61, 153.31, 151.54, 151.43, 150.84, 129.88, 129.83, 125.26, 125.22, 115.77, 115.58, 113.21, 113.20, 69.33, 67.96, 54.29, 45.32, 36.33, 31.42, 31.41, 31.35, 28.89, 28.59, 25.47, 25.32, 22.49, 22.45, 13.94; MS (ESI) m/z 296.4 $[\text{M}+\text{H}]^+$.

1-(3-Chloro-4-(hexyloxy)phenyl)-3-(dimethylamino)propan-1-one 12{10}. Yield 99%; ^1H NMR (400 MHz, CDCl_3) δ 7.98 (d, 1H, $J = 2.2$ Hz), 7.84 (dd, 1H, $J = 2.2, 8.6$ Hz), 6.93 (dd, 1H, $J = 3.1, 8.6$ Hz), 4.08 (m, 2H), 3.07 (m, 2H), 2.74 (m, 2H), 2.29 (s, 6H), 1.86 (m, 2H), 1.49 (m, 2H), 1.34 (m, 4H), 0.91 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 216.15, 177.88, 149.85, 149.64, 147.86,

142.63, 131.55, 96.81, 96.49, 96.17, 88.81, 73.87, 64.94, 55.96, 50.91, 48.32, 45.01, 42.00, 33.45;

MS (ESI) m/z 312.9 [M+H]⁺.

1-(2-Chloro-4-(hexyloxy)phenyl)-3-(dimethylamino)propan-1-one 12{11}. Yield 100%; ¹H NMR (400 MHz, CDCl₃) δ 7.59 (d, 1H, J = 8.7 Hz), 6.92 (d, 1H, J = 2.4 Hz), 6.82 (dd, 1H, J = 2.5, 8.7 Hz), 3.98 (t, 2H, J = 6.5 Hz), 3.16 (t, 2H, J = 7.3 Hz), 2.74 (t, 2H, J = 7.3 Hz), 2.28 (s, 6H), 1.78 (m, 2H), 1.45 (m, 2H), 1.34 (m, 4H), 0.91 (t, 3H, J = 6.7 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 199.99, 161.73, 133.29, 131.59, 130.57, 116.46, 113.18, 68.57, 54.43, 45.32, 40.70, 31.47, 28.93, 25.57, 22.54, 13.98; MS (ESI) m/z 312.9 [M+H]⁺.

1-(3-Bromo-4-(hexyloxy)phenyl)-3-(dimethylamino)propan-1-one 12{12}. Yield 100%; ¹H NMR (400 MHz, CDCl₃) δ 8.13 (d, 1H, J = 2.1 Hz), 7.86 (dd, 1H, J = 2.1, 8.6 Hz), 6.87 (d, 1H, J = 8.7 Hz), 4.05 (t, 2H, J = 6.5 Hz), 3.06 (t, 2H, J = 7.3 Hz), 2.73 (t, 2H, J = 7.3 Hz), 2.27 (s, 6H), 1.83 (m, 2H), 1.48 (m, 2H), 1.33 (m, 4H), 0.88 (t, 3H, J = 7.0 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 196.40, 159.15, 133.46, 130.52, 129.06, 112.25, 111.82, 69.33, 54.29, 45.35, 36.35, 31.35, 28.76, 25.48, 22.45, 13.91; MS (ESI) m/z 357.3 [M+H]⁺.

1-(2-Bromo-4-(hexyloxy)phenyl)-3-(dimethylamino)propan-1-one 12{13}. Yield 97%; ¹H NMR (400 MHz, CDCl₃) δ 7.50 (d, 1H, J = 8.7 Hz), 7.13 (d, 1H, J = 2.4 Hz), 6.86 (dd, 1H, J = 2.5, 8.6 Hz), 3.97 (m, 2H), 3.13 (m, 2H), 2.72 (t, 2H, J = 7.3 Hz), 2.26 (s, 6H), 1.78 (m, 2H), 1.44 (m, 2H), 1.33 (m, 4H), 0.90 (t, 3H, J = 7.0 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 200.94, 161.32, 132.65, 131.02, 120.77, 119.88, 113.52, 68.56, 54.45, 45.36, 40.37, 31.47, 28.94, 25.57, 22.54, 13.98; MS (ESI) m/z 357.2 [M+H]⁺.

3-(Dimethylamino)-1-(4-(hexyloxy)-3-iodophenyl)propan-1-one 12{14}. Yield 100%; ^1H NMR (400 MHz, CDCl_3) δ 8.38 (d, 1H, $J = 2.2$ Hz), 7.92 (dd, 1H, $J = 2.2, 8.6$ Hz), 6.79 (d, 1H, $J = 8.7$ Hz), 4.07 (t, 2H, $J = 6.4$ Hz), 3.07 (t, 2H, $J = 7.4$ Hz), 2.73 (t, 2H, $J = 7.3$ Hz), 2.28 (s, 6H), 1.85 (m, 3H), 1.51 (m, 2H), 1.36 (m, 4H), 0.91 (t, 3H, $J = 7.0$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 196.41, 161.26, 139.78, 131.28, 130.12, 110.78, 86.51, 69.49, 54.41, 45.47, 36.49, 31.38, 28.82, 25.63, 22.51, 13.97; MS (ESI) m/z 404.3 $[\text{M}+\text{H}]^+$.

3-(Dimethylamino)-1-(4-(hexyloxy)-2-iodophenyl)propan-1-one 12{15}. Yield 92%; ^1H NMR (400 MHz, CDCl_3) δ 7.49 (dd, 2H, $J = 5.6, 12.5$ Hz), 6.89 (dd, 1H, $J = 2.5, 8.6$ Hz), 3.96 (t, 2H, $J = 6.5$ Hz), 3.08 (t, 2H, $J = 7.4$ Hz), 2.73 (t, 2H, $J = 7.3$ Hz), 2.27 (m, 6H), 1.77 (m, 2H), 1.44 (m, 2H), 1.34 (m, 4H), 0.91 (t, 3H, $J = 6.6$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 200.72, 161.03, 134.52, 130.21, 127.40, 113.90, 92.89, 68.50, 54.48, 45.38, 39.31, 31.46, 28.95, 25.56, 22.54, 13.98; MS (ESI) m/z 404.3 $[\text{M}+\text{H}]^+$.

3-(Dimethylamino)-1-(4-(hexyloxy)-3-(methylsulfonyl)phenyl)propan-1-one 12{16}. Yield 95%; ^1H NMR (400 MHz, CDCl_3) δ 8.51 (d, 1H, $J = 2.2$ Hz), 8.18 (dd, 1H, $J = 2.3, 8.8$ Hz), 7.05 (d, 1H, $J = 8.8$ Hz), 4.17 (t, 2H, $J = 6.6$ Hz), 3.18 (s, 3H), 3.13 (t, 2H, $J = 7.2$ Hz), 2.78 (t, 2H, $J = 7.1$ Hz), 2.29 (m, 6H), 1.83 (m, 3H), 1.45 (m, 2H), 1.38 (m, 4H), 0.86 (t, 3H, $J = 7.1$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 196.13, 160.19, 135.43, 130.21, 129.45, 128.41, 113.02, 69.99, 53.98, 45.21, 42.90, 36.19, 31.32, 28.77, 25.50, 22.43, 13.92; MS (ESI) m/z 356.4 $[\text{M}+\text{H}]^+$.

3-(Dimethylamino)-1-(4-(hexyloxy)-2,6-dimethylphenyl)propan-1-one 12{22}. Yield 93%; ^1H NMR (400 MHz, CDCl_3) δ 6.54 (s, 2H), 3.92 (t, 2H, $J = 6.5$ Hz), 2.88 (t, 2H, $J = 7.5$ Hz), 2.71 (t, 2H, $J = 7.0$ Hz), 2.25 (s, 6H), 2.21 (s, 6H), 1.75 (m, 2H), 1.44 (m, 2H), 1.33 (m, 4H), 0.90 (t, 3H, $J = 7.0$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 209.16, 159.04, 134.90, 134.66, 113.72, 67.85, 53.88, 45.42, 43.35, 31.54, 29.18, 25.68, 22.58, 19.60, 14.01; MS (ESI) m/z 306.5 $[\text{M}+\text{H}]^+$.

3-(Dimethylamino)-1-(6-(hexyloxy)biphenyl-3-yl)propan-1-one 12{27}. ^1H NMR (400 MHz, CDCl_3) δ 7.95 (m, 2H), 7.53 (m, 2H), 7.41 (m, 2H), 7.34 (m, 1H), 6.99 (d, 1H, $J = 8.2$ Hz), 4.04 (t, 2H, $J = 6.5$ Hz), 3.15 (m, 2H), 2.78 (m, 2H), 2.28 (s, 6H), 1.74 (m, 2H), 1.40 (m, 2H), 1.29 (m, 4H), 0.89 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 197.61, 159.95, 137.56, 131.16, 130.69, 129.72, 129.49, 129.35, 127.89, 127.18, 111.44, 68.55, 54.51, 45.40, 36.44, 31.31, 28.83, 25.59, 22.48, 13.90; MS (ESI) m/z 354.5 $[\text{M}+\text{H}]^+$.

1-(3-Benzyl-4-(hexyloxy)phenyl)-3-(dimethylamino)propan-1-one 12{28} ^1H NMR (400 MHz, CDCl_3) δ 7.87 (dd, 1H, $J = 2.2, 8.5$ Hz), 7.80 (d, 1H, $J = 2.2$ Hz), 7.24 (m, 5H), 6.88 (d, 1H, $J = 8.6$ Hz), 4.02 (m, 4H), 3.09 (m, 2H), 2.75 (m, 2H), 2.30 (s, 6H), 1.79 (m, 2H), 1.43 (m, 2H), 1.33 (m, 4H), 0.92 (t, 3H, $J = 6.7$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 197.81, 160.91, 140.36, 130.60, 129.89, 129.40, 128.79, 128.68, 128.25, 125.93, 110.45, 68.24, 54.65, 45.44, 36.44, 36.25, 31.48, 29.05, 25.66, 22.54, 13.99; MS (ESI) m/z 368.5 $[\text{M}+\text{H}]^+$.

General procedure for 22 and 24: To a solution phenol **21{3}** (1.0 eq.) in DMF was added K_2CO_2 (2.0 eq.) and n-hexylbromide (1.5 eq.), and then stirred at 85 °C for overnight. The reaction mixture

was poured to water and extracted with Et₂O. The combined organic layer were washed with brine and dried over MgSO₄ and concentrated *in vacuo* to yield crude compound **9**. Most of products were used for next step without any purification. **1-(4-(Hexyloxy)-3-methoxyphenyl)ethanone 22{3}**. ¹H NMR (400 MHz, CDCl₃) δ 7.54 (m, 2H), 6.87 (d, 1H, *J* = 8.3 Hz), 4.07 (m, 2H), 3.92 (s, 3H), 2.56 (s, 3H), 1.87 (m, 2H), 1.47 (m, 2H), 1.35 (m, 4H), 0.90 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 196.78, 152.97, 149.22, 130.21, 123.21, 111.02, 110.44, 69.05, 56.03, 31.52, 28.91, 26.17, 25.56, 22.54, 13.98.

Synthesis of compound 22{6}: To a solution of compound **21{7, R=3-F}** in DMF was added NaSMe and stirred at rt for 1 h. The reaction mixture was poured into water and extracted with Et₂O. The combined organic layer was washed with brine, dried over with MgSO₄. After concentration under vacuum, the crude mixture was purified on normal phase column chromatography (SP1, Biotage) to yield the desired product. **1-(4-(Hexyloxy)-2-(methylthio)phenyl)ethanone 22{6}**. ¹H NMR (400 MHz, CDCl₃) δ 7.83 (d, 1H, *J* = 8.7 Hz), 6.77 (d, 1H, *J* = 2.4 Hz), 6.64 (dd, 1H, *J* = 2.4, 8.7 Hz), 4.02 (t, 2H, *J* = 6.6 Hz), 2.55 (s, 3H), 2.39 (s, 3H), 1.80 (m, 2H), 1.45 (m, 2H), 1.34 (m, 4H), 0.91 (t, 3H, *J* = 8.0 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 196.99, 162.27, 145.93, 133.74, 126.82, 111.08, 108.25, 68.25, 31.52, 29.07, 27.62, 25.64, 22.56, 15.78, 14.00.

1-(2-Fluoro-4-(hexyloxy)phenyl)ethanone 22{7}. ¹H NMR (400 MHz, CDCl₃) δ 7.86 (t, 1H, *J* = 8.8 Hz), 6.72 (dd, 1H, *J* = 2.4, 8.9 Hz), 6.58 (m, 1H), 3.98 (t, 2H, *J* = 6.6 Hz), 2.57 (d, 3H, *J* = 5.2 Hz), 1.78 (m, 2H), 1.45 (m, 2H), 1.33 (m, 4H), 0.90 (t, 3H, *J* = 8.0 Hz); ¹³C NMR (100 MHz,

CDCl₃) δ 194.42 (d, $J = 2.0$ Hz), 165.10, 164.44 (d, $J = 5.9$ Hz), 163.84 (d, $J = 127.55$ Hz), 131.95 (d, $J = 2.2$ Hz), 118.28 (d, $J = 7.5$ Hz), 111.04 (d, $J = 1.2$ Hz), 101.95 (d, $J = 13.8$ Hz), 68.71, 31.31 (d, $J = 13.6$ Hz), 28.87, 25.54, 22.52, 13.95.

General procedure for oxidation of thioether to sulfonyl compound- Synthesis of compound

22{17} To a solution of **22{6}** in DCM was added *m*CPBA (2.2 eq) at 0 °C and stirred for 1 h. The reaction mixture was poured to water and extracted with DCM. The combined organic layer was washed with NaHCO₃ and brine, dried over MgSO₄, and concentrated in vacuo to yield the corresponding sulfonyl compound. **1-(4-(Hexyloxy)-2-(methylsulfonyl)phenyl)ethanone 22{17}**.

¹H NMR (400 MHz, CDCl₃) δ 7.60 (d, 1H, $J = 2.6$ Hz), 7.47 (d, 1H, $J = 8.5$ Hz), 7.12 (dd, 1H, $J = 2.6, 8.5$ Hz), 4.04 (t, 2H, $J = 6.5$ Hz), 3.33 (s, 3H), 2.60 (s, 3H), 1.80 (m, 2H), 1.45 (m, 2H), 1.34 (m, 4H), 0.91 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 201.84, 160.46, 140.08, 133.41, 129.07, 118.79, 115.90, 68.86, 45.92, 31.42, 30.47, 28.88, 25.53, 22.52, 13.96.

1-(4-(Hexyloxy)-3-(trifluoromethyl)phenyl)ethanone 22{18}. ¹H NMR (400 MHz, CDCl₃) δ 8.17 (d, 1H, $J = 2.2$ Hz), 8.10 (dd, 1H, $J = 2.2, 8.7$ Hz), 7.02 (d, 1H, $J = 8.7$ Hz), 4.11 (t, 2H, $J = 6.4$ Hz), 2.57 (s, 3H), 1.83 (m, 2H), 1.48 (m, 2H), 1.33 (m, 4H), 0.90 (t, 3H, $J = 8.0$ Hz).

1-(4-(Hexyloxy)-2-(trifluoromethyl)phenyl)ethanone 22{19}. ¹H NMR (400 MHz, CDCl₃) δ 7.51 (d, 1H, $J = 8.6$ Hz), 7.21 (d, 1H, $J = 2.5$ Hz), 7.03 (dd, 1H, $J = 2.5, 8.6$ Hz), 4.01 (t, 2H, $J = 6.5$ Hz), 2.55 (s, 3H), 1.79 (m, 2H), 1.45 (d, 2H), 1.34 (m, 4H), 0.91 (t, 3H, $J = 8.0$ Hz).

1-(4-(Hexyloxy)-3-nitrophenyl)ethanone 22{20}. ¹H NMR (400 MHz, CDCl₃) δ 8.40 (d, 1H, $J = 2.2$ Hz), 8.13 (m, 1H), 7.12 (d, 1H, $J = 8.9$ Hz), 4.17 (t, 2H, $J = 6.5$ Hz), 2.59 (s, 3H), 1.85 (m, 2H),

1.49 (m, 2H), 1.34 (m, 4H), 0.90 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 194.80, 155.80, 139.40, 133.77, 129.26, 126.11, 113.96, 70.15, 31.33, 28.70, 26.28, 25.39, 22.46, 13.93.

2-(Hexyloxy)-1,3-dimethylbenzene 22{21}. ^1H NMR (400 MHz, CDCl_3) δ 7.63 (s, 2H), 3.79 (t, 2H, $J = 6.6$ Hz), 2.54 (s, 3H), 2.31 (s, 6H), 1.81 (m, 2H), 1.50 (m, 2H), 1.36 (m, 4H), 0.92 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 197.64, 160.49, 132.66, 131.20, 129.35, 72.47, 31.69, 30.35, 26.48, 25.73, 22.60, 16.45, 14.02.

1-(4-(Hexyloxy)-2-isopropyl-5-methylphenyl)ethanone 22{23}. ^1H NMR (400 MHz,) δ 7.42 (s, 1H), 6.82 (s, 1H), 4.02 (t, 2H, $J = 6.4$ Hz), 3.75 (m, 1H), 2.54 (s, 3H), 2.21 (s, 3H), 1.81 (m, 2H), 1.50 (m, 2H), 1.35 (m, 4H), 1.22 (d, 6H, $J = 6.8$ Hz), 0.92 (t, 3H, $J = 7.0$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 201.27, 159.74, 149.39, 131.88, 129.52, 123.44, 108.42, 67.90, 31.53, 30.11, 29.18, 28.97, 25.76, 24.13, 22.58, 15.77, 13.99.

1-(2,5-Dichloro-4-(hexyloxy)phenyl)ethanone 22{25}. ^1H NMR (400 MHz,) δ 7.74 (s, 1H), 6.92 (s, 1H), 4.06 (t, 2H, $J = 6.5$ Hz), 2.63 (m, 3H), 1.85 (m, 2H), 1.49 (m, 2H), 1.35 (m, 4H), 0.91 (t, 3H, $J = 7.0$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 196.99, 157.11, 131.95, 131.87, 130.54, 121.71, 114.79, 69.72, 31.38, 30.57, 28.73, 25.48, 22.51, 13.96.

General procedure for Mannich reaction: A solution of compound **24** (50 mg, 0.23 mmol, 1 equiv.), dimethylamine hydrochloride (37 mg, 0.45 mmol, 2 equiv.), paraformaldehyde (15 mg, 0.45 mmol, 2 equiv.), and conc-HCl (cat.) in H_2O /acetonitrile (1/9) was heated at 120 °C in MW for 2 h. The reaction mixture was concentrated *in vacuo*, and purified on normal phase column

chromatography (SP1, Biotage) to yield the desired product **10. 3-(Dimethylamino)-1-(3-(hexyloxy)phenyl)propan-1-one 10**. Yield 79% ^1H NMR (400 MHz, CDCl_3) δ 7.52 (d, 1H, $J = 7.7$ Hz), 7.47 (m, 1H), 7.35 (t, 1H, $J = 7.9$ Hz), 7.09 (m, 1H), 3.99 (t, 2H, $J = 6.6$ Hz), 3.15 (t, 2H, $J = 7.4$ Hz), 2.78 (t, 2H, $J = 7.3$ Hz), 2.31 (s, 6H), 1.79 (m, 2H), 1.46 (m, 2H), 1.34 (m, 4H), 0.90 (t, 3H, $J = 7.0$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 198.86, 159.40, 138.19, 129.53, 120.45, 120.01, 113.00, 68.23, 54.36, 45.41, 36.89, 31.53, 29.13, 25.67, 22.57, 14.00; MS (ESI) m/z 278.3 $[\text{M}+\text{H}]^+$.

3-(Dimethylamino)-1-(4-(hexyloxy)-3-methoxyphenyl)propan-1-one 12{3}. Yield 83% ^1H NMR (400 MHz, CDCl_3) δ 7.56 (dd, 1H, $J = 1.9, 8.4$ Hz), 7.49 (d, 1H, $J = 1.9$ Hz), 6.85 (d, 1H, $J = 8.5$ Hz), 4.05 (t, 2H, $J = 6.9$ Hz), 3.89 (d, 3H, $J = 6.9$ Hz), 3.19 (t, 2H, $J = 7.3$ Hz), 2.87 (t, 2H, $J = 7.3$ Hz), 2.37 (s, 6H), 1.84 (m, 2H), 1.43 (m, 2H), 1.32 (m, 4H), 0.87 (t, 3H, $J = 7.0$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 196.96, 153.08, 149.22, 129.50, 122.76, 111.05, 110.40, 68.99, 55.97, 54.33, 45.02, 35.72, 31.44, 28.83, 25.48, 22.46, 13.91; MS (ESI) m/z 308.4 $[\text{M}+\text{H}]^+$.

3-(Dimethylamino)-1-(4-(hexyloxy)-2-(methylthio)phenyl)propan-1-one 12{6}. Yield 65% ^1H NMR (400 MHz, CDCl_3) δ 7.90 (d, 1H, $J = 8.8$ Hz), 6.75 (d, 1H, $J = 2.2$ Hz), 6.65 (m, 1H), 4.01 (t, 2H, $J = 6.5$ Hz), 3.40 (s, 2H), 3.17 (s, 2H), 2.53 (m, 6H), 2.38 (s, 3H), 1.78 (m, 2H), 1.45 (m, 2H), 1.33 (m, 4H), 0.89 (t, 3H, $J = 7.0$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 195.61, 162.69, 146.32, 133.37, 125.62, 111.39, 108.47, 68.33, 53.60, 44.21, 35.59, 31.48, 29.00, 25.59, 22.52, 15.75, 13.97; MS (ESI) m/z 324.5 $[\text{M}+\text{H}]^+$.

Synthesis of compound 12{7}: A solution of compound **22{7}** and dimethylamine hydrochloride (3eq.) in DMF was heated at 110 °C in MW for 1h. The reaction mixture was poured into water and

extracted with Et₂O. The combined organic layer was washed with brine, dried over with MgSO₄.

After concentration under vacuum, the crude mixture was purified on normal phase column

chromatography (SP1, Biotage) to yield the desired product. **3-(Dimethylamino)-1-(2-**

(dimethylamino)-4-(hexyloxy)phenyl)propan-1-one 12{7}. ¹H NMR (400 MHz, CDCl₃) δ 7.43 (d,

1H, *J* = 8.5 Hz), 6.45 (m, 2H), 3.98 (m, 2H), 3.17 (m, 2H), 2.77 (s, 7H), 2.66 (m, 2H), 2.27 (s, 6H),

1.77 (m, 2H), 1.40 (m, 7H), 0.90 (t, 3H, *J* = 6.6 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 203.03, 162.36,

154.11, 132.01, 124.85, 105.36, 103.87, 68.01, 55.41, 45.34, 44.44, 39.03, 31.54, 29.16, 25.68,

22.56, 14.00.

3-(Dimethylamino)-1-(4-(hexyloxy)-2-(methylsulfonyl)phenyl)propan-1-one 12{17}. Yield 42%

¹H NMR (400 MHz, CDCl₃) δ 7.57 (d, 1H, *J* = 2.5 Hz), 7.46 (d, 1H, *J* = 8.5 Hz), 7.11 (dd, 1H, *J* =

2.5, 8.5 Hz), 4.03 (t, 2H, *J* = 6.5 Hz), 3.26 (m, 3H), 3.05 (t, 2H, *J* = 7.3 Hz), 2.73 (t, 1H, *J* = 7.2 Hz),

2.25 (m, 6H), 1.79 (m, 2H), 1.45 (s, 2H), 1.33 (m, 4H), 0.89 (t, 3H, *J* = 7.0 Hz); ¹³C NMR (100

MHz, CDCl₃) δ 203.54, 160.34, 139.90, 133.45, 128.86, 118.92, 115.71, 68.85, 53.80, 46.02, 45.41,

41.50, 31.42, 28.89, 25.54, 22.52, 13.96; MS (ESI) *m/z* 356.4 [M+H]⁺.

3-(Dimethylamino)-1-(4-(hexyloxy)-3-(trifluoromethyl)phenyl)propan-1-one 12{18}. Yield 8%;

¹H NMR (400 MHz, CDCl₃) δ 7.43 (d, 1H, *J* = 8.6 Hz), 7.14 (d, 1H, *J* = 2.4 Hz), 6.97 (dd, 1H, *J* =

2.5, 8.6 Hz), 3.95 (t, 2H, *J* = 6.5 Hz), 2.95 (t, 2H, *J* = 7.3 Hz), 2.63 (t, 2H, *J* = 7.3 Hz), 2.19 (s, 6H),

1.73 (m, 2H), 1.40 (s, 2H), 1.28 (m, 5H), 0.84 (t, 3H, *J* = 6.9 Hz); MS (ESI) *m/z* 346.3 [M+H]⁺.

3-(Dimethylamino)-1-(4-(hexyloxy)-2-(trifluoromethyl)phenyl)propan-1-one 12{19}. Yield

20%; ¹H NMR (400 MHz, CDCl₃) δ 8.13 (s, 1H), 8.05 (d, 1H, *J* = 8.7 Hz), 6.97 (t, 1H, *J* = 9.5 Hz),

4.05 (t, 2H, $J = 6.3$ Hz), 3.08 (t, 2H, $J = 7.3$ Hz), 2.74 (t, 3H, $J = 7.3$ Hz), 2.26 (s, 6H), 1.77 (m, 2H), 1.43 (d, 2H, $J = 7.1$ Hz), 1.28 (m, 4H), 0.83 (t, 3H, $J = 6.9$ Hz); MS (ESI) m/z 346.4 $[M+H]^+$.

3-(Dimethylamino)-1-(4-(hexyloxy)-3-nitrophenyl)propan-1-one 12{20}. Yield 63% ^1H NMR (400 MHz, CDCl_3) δ 8.41 (d, 1H, $J = 2.3$ Hz), 8.12 (m, 1H), 7.12 (t, 1H, $J = 10.0$ Hz), 4.16 (t, 2H, $J = 6.4$ Hz), 3.13 (t, 2H, $J = 7.2$ Hz), 2.79 (t, 2H, $J = 7.2$ Hz), 2.31 (s, 6H), 1.84 (m, 2H), 1.47 (s, 2H), 1.33 (m, 4H), 0.89 (t, 3H, $J = 6.7$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 195.71, 155.81, 139.48, 133.66, 128.95, 125.82, 113.99, 70.15, 54.08, 45.35, 36.41, 31.33, 28.70, 25.40, 22.47, 13.94; MS (ESI) m/z 323.4 $[M+H]^+$.


3-(Dimethylamino)-1-(4-(hexyloxy)-3,5-dimethylphenyl)propan-1-one 12{21}. Yield 47%; ^1H NMR (400 MHz, CDCl_3) δ 7.57 (s, 1H), 3.72 (t, 1H, $J = 6.6$ Hz), 3.02 (t, 1H, $J = 7.4$ Hz), 2.66 (m, 1H), 2.24 (s, 3H), 2.22 (s, 3H), 1.74 (m, 1H), 1.43 (m, 1H), 1.28 (m, 2H), 0.85 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 195.62, 161.16, 131.54, 129.66, 129.19, 72.45, 53.03, 43.64, 34.16, 31.59, 30.26, 25.63, 22.52, 16.38, 13.95; MS (ESI) m/z 306.5 $[M+H]^+$.

3-(Dimethylamino)-1-(4-(hexyloxy)-2-isopropyl-5-methylphenyl)propan-1-one 12{23}. Yield 80%; ^1H NMR (400 MHz, CDCl_3) δ 7.44 (s, 1H), 6.79 (s, 1H), 3.99 (t, 2H, $J = 6.4$ Hz), 3.61 (m, 1H), 3.35 (t, 2H, $J = 7.2$ Hz), 3.14 (t, 2H, $J = 7.1$ Hz), 2.58 (s, 6H), 2.15 (s, 3H), 1.78 (m, 2H), 1.46 (m, 2H), 1.31 (m, 4H), 1.18 (d, 6H, $J = 6.8$ Hz), 0.88 (t, 3H, $J = 7.0$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 199.49, 160.16, 149.88, 131.41, 128.01, 123.77, 108.45, 67.83, 53.68, 44.05, 37.69, 31.41, 31.40, 29.02, 25.63, 24.02, 22.46, 15.64, 15.63, 13.88; MS (ESI) m/z 334.5 $[M+H]^+$.

1-(2,3-dichloro-4-(hexyloxy)phenyl)-3-(dimethylamino)propan-1-one 12{24} ^1H NMR (400 MHz, CDCl_3) δ 7.44 (d, $J = 8.7$, 2H), 6.87 (d, $J = 8.7$, 2H), 4.08 (t, $J = 6.5$, 4H), 3.20 – 3.09 (m, 4H), 2.73 (t, $J = 7.3$, 4H), 2.27 (s, 12H), 1.93 – 1.80 (m, 4H), 1.59 – 1.42 (m, 4H), 1.43 – 1.30 (m, 8H), 0.99 – 0.82 (m, 6H); ^{13}C NMR (101 MHz, CDCl_3) δ 200.65, 157.64, 136.07, 132.77, 128.00, 123.24, 110.38, 69.75, 54.41, 45.35, 41.05, 31.45, 28.87, 25.57, 22.57, 14.02; MS (ESI) m/z 347.3 $[\text{M}+\text{H}]^+$.

1-(2,5-Dichloro-4-(hexyloxy)phenyl)-3-(dimethylamino)propan-1-on 12{25}. Yield 32%; ^1H NMR (400 MHz, CDCl_3) δ 7.59 (s, 1H), 6.84 (s, 1H), 3.98 (t, 2H, $J = 6.5$ Hz), 3.09 (t, 2H, $J = 7.2$ Hz), 2.68 (t, 2H, $J = 7.2$ Hz), 2.22 (s, 6H), 1.78 (m, 2H), 1.42 (s, 2H), 1.27 (m, 4H), 0.84 (t, 3H, $J = 7.1$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 198.78, 156.92, 131.45, 131.31, 130.71, 121.75, 114.73, 69.71, 54.23, 45.24, 40.62, 31.38, 28.73, 25.48, 22.51, 13.96; MS (ESI) m/z 347.3 $[\text{M}+\text{H}]^+$.

1-(2,6-dichloro-4-(hexyloxy)phenyl)-3-(dimethylamino)propan-1-one 12{26} ^1H NMR (400 MHz, CDCl_3) δ 6.75 (s, 2H), 3.86 (t, $J = 6.5$, 2H), 2.94 (t, $J = 7.4$, 2H), 2.68 (t, $J = 7.4$, 2H), 2.20 (s, 6H), 1.72 – 1.58 (m, 2H), 1.43 – 1.31 (m, 2H), 1.31 – 1.20 (m, 4H), 0.87 (t, $J = 7.0$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 201.28, 159.93, 131.95, 131.12, 114.56, 68.87, 53.22, 45.35, 42.36, 31.46, 28.88, 25.56, 22.57, 14.02; MS (ESI) m/z 346.3 $[\text{M}+\text{H}]^+$.



Reagent and condition. (a) Hexyl bromide, K_2CO_3 , DMF, 80-90 °C, 12 h; (b) 2-Chloropropyl chloride, AlCl_3 , DCM, 0 °C; (c) 1 M $\text{Me}_2\text{NH}/\text{THF}$, THF, rt, 30 min; (d) paraformaldehyde, $\text{Me}_2\text{NH}\cdot\text{HCl}$, $c\text{-HCl}$, $\text{H}_2\text{O}/\text{MeCN}$ (1/9, v/v), MW, 120 °C, 2 h

1-(Hexyloxy)naphthalene 24}\{1\}. ^1H NMR (400 MHz, CDCl_3) δ 8.30 (dd, 1H, $J = 3.0, 6.7$ Hz), 7.80 (dd, 1H, $J = 3.1, 6.3$ Hz), 7.48 (m, 2H), 7.39 (m, 2H), 6.81 (dd, 1H, $J = 1.1, 7.3$ Hz), 4.14 (t, 2H, $J = 6.4$ Hz), 1.94 (m, 2H), 1.58 (m, 2H), 1.41 (m, 4H), 0.93 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 154.90, 134.48, 127.38, 126.27, 125.89, 125.75, 125.00, 122.08, 119.89, 104.51, 68.13, 31.63, 29.28, 25.95, 22.63, 14.04.

4-(Hexyloxy)biphenyl 24}\{2\}. ^1H NMR (400 MHz, CDCl_3) δ 7.46 (m, 4H), 7.34 (m, 2H), 7.21 (m, 1H), 6.89 (m, 2H), 3.92 (t, 2H, $J = 6.6$ Hz), 1.73 (m, 2H), 1.41 (m, 2H), 1.28 (m, 4H), 0.84 (t, 3H, $J = 7.0$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 158.74, 140.91, 133.54, 128.70, 128.10, 126.72, 126.59, 114.78, 68.11, 31.61, 29.28, 25.76, 22.63, 14.05.

1-(4-(hexyloxy)phenyl)ethanone 24{3}. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.38 (s, 1H), 7.99 (dd, 1H, $J = 1.8, 8.6$ Hz), 7.84 (d, 1H, $J = 8.9$ Hz), 7.74 (d, 1H, $J = 8.6$ Hz), 7.20 (dd, 1H, $J = 2.5, 8.9$ Hz), 7.14 (d, 1H, $J = 2.4$ Hz), 4.10 (t, 2H, $J = 6.6$ Hz), 2.70 (s, 3H), 1.86 (m, 2H), 1.50 (m, 2H), 1.38 (m, 4H), 0.92 (t, 3H, $J = 7.1$ Hz).

3-Chloro-1-(4-(hexyloxy)naphthalen-1-yl)propan-1-one 25{1}. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.97 (d, 1H, $J = 8.4$ Hz), 8.35 (d, 1H, $J = 8.4$ Hz), 7.98 (dd, 1H, $J = 3.8, 8.2$ Hz), 7.63 (dd, 1H, $J = 6.9, 8.6$ Hz), 7.54 (d, 1H, $J = 8.3$ Hz), 6.78 (d, 1H, $J = 8.3$ Hz), 4.20 (m, 2H), 3.99 (m, 2H), 3.52 (m, 2H), 1.96 (m, 2H), 1.58 (m, 2H), 1.40 (m, 4H), 0.94 (m, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 198.29, 159.08, 132.05, 131.50, 128.84, 126.31, 125.93, 125.91, 125.84, 122.24, 102.64, 68.59, 43.28, 39.65, 31.54, 29.02, 25.85, 22.58, 14.01.

3-Chloro-1-(4'-(hexyloxy)biphenyl-4-yl)propan-1-one 25{2}. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.00 (d, 2H, $J = 8.5$ Hz), 7.66 (d, 2H, $J = 8.5$ Hz), 7.56 (d, 2H, $J = 8.8$ Hz), 6.99 (d, 2H, $J = 8.8$ Hz), 3.97 (m, 4H), 3.48 (t, 2H, $J = 4.8$ Hz), 1.81 (m, 2H), 1.48 (m, 2H), 1.36 (m, 4H), 0.91 (m, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 196.20, 159.61, 145.89, 134.39, 131.76, 128.66, 128.32, 126.67, 114.97, 68.15, 41.24, 38.80, 31.57, 29.19, 25.70, 22.59, 14.02.


3-(Dimethylamino)-1-(4-(hexyloxy)naphthalen-1-yl)propan-1-one 13{1}. Yield 94%; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.89 (m, 1H), 8.34 (dd, 1H, $J = 0.6, 8.4$ Hz), 7.98 (d, 1H, $J = 8.2$ Hz), 7.60 (m, 1H), 7.51 (m, 1H), 6.76 (d, 1H, $J = 8.2$ Hz), 4.18 (t, 2H, $J = 6.4$ Hz), 3.23 (t, 2H, $J = 7.4$ Hz), 2.83 (m, 2H), 2.29 (s, 6H), 1.94 (m, 2H), 1.56 (m, 2H), 1.39 (m, 4H), 0.93 (t, 3H, $J = 7.0$ Hz); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 201.11, 158.54, 132.01, 130.83, 128.49, 127.12, 125.98, 125.88, 125.63,

122.13, 102.63, 68.46, 55.00, 45.34, 39.25, 31.51, 29.01, 25.83, 22.55, 13.98; MS (ESI) m/z 328.5 [M+H]⁺.

3-(Dimethylamino)-1-(4'-(hexyloxy)biphenyl-4-yl)propan-1-one 13{2}. Yield 100%; ¹H NMR (400 MHz, CDCl₃) δ 8.00 (d, 2H, J = 8.3 Hz), 7.63 (d, 2H, J = 8.3 Hz), 7.56 (dd, 2H, J = 4.9, 6.8 Hz), 6.98 (dd, 2H, J = 4.9, 6.8 Hz), 3.99 (t, 2H, J = 6.6 Hz), 3.18 (t, 2H, J = 7.4 Hz), 2.79 (t, 2H, J = 7.4 Hz), 2.31 (m, 6H), 1.80 (m, 2H), 1.45 (m, 2H), 1.33 (m, 4H), 0.91 (t, 3H, J = 7.0 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 198.51, 159.45, 145.35, 134.89, 131.87, 128.62, 128.23, 126.52, 114.89, 68.07, 54.41, 45.44, 36.80, 31.52, 29.16, 25.66, 22.55, 13.98; MS (ESI) m/z 354.5 [M+H]⁺.

3-(Dimethylamino)-1-(6-(hexyloxy)naphthalen-2-yl)propan-1-one 13{3}. Yield 61%; ¹H NMR (400 MHz, CDCl₃) δ 8.39 (s, 1H), 7.98 (dd, 1H, J = 1.7, 8.6 Hz), 7.83 (d, 1H, J = 9.0 Hz), 7.71 (dd, 1H, J = 7.2, 15.0 Hz), 7.19 (dd, 1H, J = 2.5, 8.9 Hz), 7.12 (d, 1H, J = 2.3 Hz), 4.08 (t, 2H, J = 6.6 Hz), 3.29 (t, 2H, J = 7.4 Hz), 2.86 (t, 2H, J = 7.3 Hz), 2.34 (d, 6H, J = 16.4 Hz), 1.84 (m, 2H), 1.48 (m, 2H), 1.35 (m, 4H), 0.91 (t, 3H, J = 7.1 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 198.39, 159.30, 137.33, 132.01, 131.04, 129.62, 127.64, 127.04, 124.41, 119.98, 106.37, 68.14, 54.45, 45.30, 36.47, 31.52, 29.05, 25.69, 22.54, 13.98; MS (ESI) m/z 328.5 [M+H]⁺.

Scheme 4. Synthesis of α -substituted β -aminoketone ^a



^aReagent and condition. (a) *n*HexBr, K₂CO₃, DMF, 85 °C; (b) paraformaldehyde, Me₂NH•HCl, *c*-HCl, H₂O/MeCN (1/9, v/v), MW, 120 °C, 2 h;

1-(4-(Hexyloxy)phenyl)propan-1-one 27{1}. Yield 90%; ¹H NMR (400 MHz, CDCl₃) δ 7.86 (d, 2H, *J* = 8.8 Hz), 6.84 (d, 2H, *J* = 8.9 Hz), 3.94 (t, 2H, *J* = 6.6 Hz), 2.87 (t, 2H, *J* = 7.3 Hz), 1.72 (m, 2H), 1.38 (m, 2H), 1.27 (m, 4H), 1.14 (t, 3H, *J* = 7.3 Hz), 0.84 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 199.49, 162.94, 130.19, 129.80, 114.12, 68.23, 31.54, 31.38, 29.08, 25.66, 22.58, 14.01, 8.47.

1-(4-(Hexyloxy)phenyl)-3-methylbutan-1-one 27{2}. Yield 75%; ¹H NMR (400 MHz, CDCl₃) δ 7.83 (d, 2H, *J* = 8.9 Hz), 6.82 (d, 2H, *J* = 8.9 Hz), 3.92 (t, 2H, *J* = 6.6 Hz), 2.68 (d, 2H, *J* = 6.9 Hz), 2.18 (m, 1H), 1.70 (m, 2H), 1.36 (m, 2H), 1.25 (m, 4H), 0.89 (d, 6H, *J* = 6.6 Hz), 0.81 (t, 3H, *J* = 7.1 Hz) 218.38, 182.41, 149.83, 149.75, 133.56, 87.70, 66.65, 51.00, 48.54, 45.12, 44.88, 42.27, 42.04, 33.48.

1-(4-(Hexyloxy)phenyl)-2-phenylethanone 27{3}. Yield 93% ¹H NMR (400 MHz, CDCl₃) δ 7.90 (d, 2H, *J* = 8.9 Hz), 7.19 (m, 5H), 6.82 (d, 2H, *J* = 8.9 Hz), 4.14 (s, 2H), 3.92 (t, 2H, *J* = 6.6 Hz), 1.71 (m, 2H), 1.36 (m, 2H), 1.26 (m, 4H), 0.83 (t, 3H, *J* = 7.0 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 215.72, 182.65, 154.51, 150.41, 148.86, 148.09, 146.22, 133.71, 87.74, 64.71, 51.00, 48.52, 45.12, 42.06, 33.50.

5-(Hexyloxy)-2,3-dihydro-1H-inden-1-one 27{4}. Yield 91%; ^1H NMR (400 MHz,) δ 7.67 (d, 1H, $J = 9.1$ Hz), 6.89 (m, 2H), 4.02 (t, 2H, $J = 6.6$ Hz), 3.07 (m, 2H), 2.66 (m, 2H), 1.81 (m, 2H), 1.47 (s, 2H), 1.35 (m, 4H), 0.91 (t, 3H, $J = 7.0$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 205.25, 164.85, 158.11, 130.17, 125.29, 115.61, 110.23, 77.31, 77.00, 76.68, 68.44, 36.41, 31.49, 29.02, 25.84, 25.63, 22.56, 13.99.

6-(Hexyloxy)-3,4-dihydronaphthalen-1(2H)-one 27{5}. Yield 100%; ^1H NMR (400 MHz, CDCl_3) δ 8.02 (d, 1H, $J = 8.7$ Hz), 6.83 (dd, 1H, $J = 2.4, 8.7$ Hz), 6.71 (d, 1H, $J = 2.1$ Hz), 4.02 (t, 2H, $J = 6.5$ Hz), 2.93 (t, 2H, $J = 6.1$ Hz), 2.62 (m, 2H), 2.13 (m, 2H), 1.81 (m, 2H), 1.48 (m, 2H), 1.37 (m, 5H), 0.93 (t, 3H, $J = 7.0$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 216.69, 182.65, 166.37, 149.07, 145.57, 132.87, 132.59, 87.64, 58.37, 50.98, 49.63, 48.53, 45.11, 42.86, 42.04, 33.48.

7-(Hexyloxy)chroman-4-one 27{6}. Yield 89%; ^1H NMR (400 MHz, CDCl_3) δ 7.80 (d, 1H, $J = 8.8$ Hz), 6.54 (dd, 1H, $J = 2.4, 8.8$ Hz), 6.36 (d, 1H, $J = 2.4$ Hz), 4.48 (m, 2H), 3.95 (t, 2H, $J = 6.6$ Hz), 2.72 (m, 2H), 1.75 (m, 2H), 1.42 (m, 2H), 1.31 (m, 4H), 0.88 (t, 3H, $J = 7.0$ Hz).

3-(Dimethylamino)-1-(4-(hexyloxy)phenyl)-2-methylpropan-1-one 14{1}. Yield 72%; ^1H NMR (400 MHz, CDCl_3) δ 7.89 (d, 2H, $J = 8.8$ Hz), 6.85 (d, 2H, $J = 8.8$ Hz), 3.94 (t, 2H, $J = 6.5$ Hz), 3.59 (m, 1H), 2.72 (dd, 1H, $J = 7.3, 12.3$ Hz), 2.29 (m, 1H), 2.16 (m, 6H), 1.73 (m, 2H), 1.38 (dd, 2H, $J = 7.1, 14.8$ Hz), 1.27 (m, 4H), 1.12 (d, 3H, $J = 7.0$ Hz), 0.84 (t, 3H, $J = 6.9$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 221.31, 182.56, 150.04, 148.75, 133.70, 87.70, 82.27, 65.36, 58.12, 50.98, 48.52, 45.11, 42.03, 36.26, 33.47; MS (ESI) m/z 292.8 $[\text{M}+\text{H}]^+$.

2-((Dimethylamino)methyl)-1-(4-(hexyloxy)phenyl)-3-methylbutan-1-one 14{2}. Yield 50%; ¹H NMR (400 MHz, CDCl₃) δ 7.89 (d, 2H, *J* = 8.9 Hz), 6.84 (d, 2H, *J* = 8.9 Hz), 3.93 (t, 2H, *J* = 6.6 Hz), 3.38 (m, 1H), 2.88 (m, 1H), 2.29 (m, 1H), 2.07 (s, 6H), 1.90 (m, 1H), 1.72 (m, 2H), 1.39 (m, 2H), 1.27 (m, 4H), 0.85 (m, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 221.28, 182.38, 150.54, 149.96, 133.60, 87.65, 78.84, 69.32, 65.46, 50.98, 49.93, 48.53, 45.11, 42.03, 40.48, 39.38, 33.46; MS (ESI) *m/z* 320.5 [M+H]⁺.

3-(Dimethylamino)-1-(4-(hexyloxy)phenyl)-2-phenylpropan-1-one 14{3}. Yield 74%; ¹H NMR (400 MHz, CDCl₃) δ 7.88 (m, 2H), 7.25 (m, 2H), 7.19 (t, 2H, *J* = 7.7 Hz), 7.10 (t, 1H, *J* = 7.2 Hz), 6.77 (d, 2H, *J* = 8.8 Hz), 4.72 (dd, 1H, *J* = 4.7, 8.8 Hz), 3.88 (m, 2H), 3.28 (dd, 1H, *J* = 8.9, 12.4 Hz), 2.48 (dd, 1H, *J* = 4.7, 12.4 Hz), 2.15 (s, 6H), 1.67 (m, 2H), 1.33 (m, 2H), 1.22 (m, 4H), 0.81 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 216.76, 182.50, 158.09, 150.45, 149.06, 148.36, 147.61, 146.54, 133.63, 87.66, 82.60, 70.85, 65.40, 50.97, 48.49, 45.09, 42.03, 33.48; MS (ESI) *m/z* 354.5 [M+H]⁺.


2-((Dimethylamino)methyl)-5-(hexyloxy)-2,3-dihydro-1*H*-inden-1-one 14{4}. Yield 72%; ¹H NMR (400 MHz, CDCl₃) δ 7.65 (m, 1H), 6.87 (m, 2H), 4.01 (t, 2H, *J* = 6.6 Hz), 3.25 (dd, 1H, *J* = 7.7, 17.5 Hz), 3.01 (dd, 1H, *J* = 3.3, 17.5 Hz), 2.84 (m, 1H), 2.80 (s, 1H), 2.42 (dd, 1H, *J* = 10.5, 12.1 Hz), 2.28 (s, 6H), 1.79 (m, 2H), 1.47 (d, 2H, *J* = 7.0 Hz), 1.33 (m, 4H), 0.90 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 205.69, 165.03, 157.01, 129.57, 125.46, 115.65, 110.17, 68.41, 61.35, 46.57, 45.64, 32.16, 31.89, 31.46, 28.99, 25.60, 22.52, 22.51, 13.96; MS (ESI) *m/z* 290.3 [M+H]⁺.

2-((Dimethylamino)methyl)-6-(hexyloxy)-3,4-dihydronaphthalen-1(2H)-one 14{5}. Yield 43%;

^1H NMR (400 MHz, CDCl_3) δ 7.90 (d, 1H, $J = 8.8$ Hz), 6.73 (dd, 1H, $J = 2.5, 8.8$ Hz), 6.61 (d, 1H, $J = 2.3$ Hz), 3.93 (t, 2H, $J = 6.6$ Hz), 2.94 (m, 3H), 2.69 (m, 1H), 2.60 (m, 1H), 2.39 (m, 7H), 1.90 (m, 1H), 1.72 (m, 2H), 1.39 (m, 2H), 1.27 (m, 4H), 0.84 (t, 3H, $J = 7.0$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 197.50, 163.37, 146.58, 129.89, 125.58, 113.71, 112.98, 68.25, 58.95, 45.27, 31.53, 29.07, 28.74, 27.72, 25.66, 22.59, 14.03; MS (ESI) m/z 304.4 $[\text{M}+\text{H}]^+$.

3-((Dimethylamino)methyl)-7-(hexyloxy)chroman-4-one 14{6}. Yield 83%; ^1H NMR (400 MHz, CDCl_3) δ 7.80 (d, 1H, $J = 8.8$ Hz), 6.55 (dd, 1H, $J = 2.4, 8.8$ Hz), 6.38 (d, 1H, $J = 2.3$ Hz), 4.56 (dd, 1H, $J = 4.4, 11.3$ Hz), 4.36 (dd, 1H, $J = 8.1, 11.3$ Hz), 3.97 (t, 2H, $J = 6.5$ Hz), 2.79 (m, 1H), 2.65 (dd, 1H, $J = 5.0, 12.6$ Hz), 2.56 (m, 1H), 2.26 (s, 6H), 1.77 (m, 2H), 1.44 (m, 2H), 1.33 (m, 4H), 0.90 (t, 3H, $J = 6.6$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 192.25, 165.52, 163.54, 128.94, 114.39, 110.32, 101.00, 69.75, 68.42, 56.12, 45.66, 44.08, 31.47, 28.92, 25.59, 22.54, 13.98; MS (ESI) m/z 306.4 $[\text{M}+\text{H}]^+$.

Scheme 5. Synthesis of the different amino Mannich base^a



^aReagent and condition. (a) $\text{R}_1\text{R}_2\text{NH}$, DBU, THF, rt, 1-2 h

General procedure for 15: To a solution compound **18** in THF was added the corresponding amine (2 equiv.) in the presence of DBU (2 equiv.) and stirred at rt for 2 h. The reaction mixture

was concentrated in vacuo and purified on normal phase column chromatography (SP1, Biotage) to yield the desired product. **3-(Dibutylamino)-1-(4-(hexyloxy)phenyl)propan-1-one 15{1}**. Yield 45%; ^1H NMR (400 MHz, CDCl_3) δ 7.87 (t, 2H, $J = 9.3$ Hz), 6.86 (t, 2H, $J = 9.6$ Hz), 3.95 (m, 2H), 3.01 (m, 2H), 2.84 (m, 2H), 2.38 (m, 4H), 1.73 (m, 2H), 1.37 (m, 6H), 1.24 (m, 8H), 0.84 (m, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ 217.88, 182.53, 149.79, 149.38, 133.62, 87.71, 73.31, 68.80, 55.35, 50.99, 48.61, 48.52, 45.11, 42.04, 40.17, 40.16, 33.52, 33.47; MS (ESI) m/z 362.6 $[\text{M}+\text{H}]^+$.

1-(4-(Hexyloxy)phenyl)-3-(piperidin-1-yl)propan-1-one 15{2}. Yield 83%; ^1H NMR (400 MHz, CDCl_3) δ 7.86 (d, 2H, $J = 8.9$ Hz), 6.86 (m, 2H), 3.95 (m, 2H), 3.09 (m, 2H), 2.72 (m, 2H), 2.40 (s, 4H), 1.72 (m, 2H), 1.54 (m, 4H), 1.39 (m, 4H), 1.27 (m, 4H), 0.83 (t, 3H, $J = 7.0$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 217.30, 182.57, 149.77, 149.25, 133.63, 87.71, 74.04, 73.56, 55.34, 50.98, 48.51, 45.34, 45.10, 43.68, 42.03, 33.46; MS (ESI) m/z 318.5 $[\text{M}+\text{H}]^+$.

1-(4-(Hexyloxy)phenyl)-3-(pyrrolidin-1-yl)propan-1-one 15{3}. Yield 63%; ^1H NMR (400 MHz, CDCl_3) δ 7.98 – 7.77 (m, 2H), 6.86 – 6.65 (m, 2H), 4.07 – 3.77 (m, 2H), 3.15 (t, $J = 7.6$, 2H), 2.98 – 2.83 (m, 2H), 2.58 (s, 4H), 1.88 – 1.67 (m, 6H), 1.47 – 1.35 (m, 2H), 1.35 – 1.09 (m, 4H), 0.98 – 0.73 (m, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 197.28, 163.21, 130.36, 129.60, 114.22, 68.27, 54.23, 51.10, 37.41, 31.53, 29.06, 25.65, 23.49, 22.58, 14.02; MS (ESI) m/z 304.4 $[\text{M}+\text{H}]^+$.

1-(4-(Hexyloxy)phenyl)-3-(2-methylaziridin-1-yl)propan-1-one 15{4}. Yield 69%; ^1H NMR (400 MHz, CDCl_3) δ 7.86 (m, 2H), 6.84 (m, 2H), 3.94 (t, 2H, $J = 6.6$ Hz), 3.12 (m, 2H), 2.58 (m, 2H),

1.72 (m, 2H), 1.37 (m, 4H), 1.27 (m, 4H), 1.21 (d, 1H, $J = 6.3$ Hz), 1.06 (d, 3H, $J = 5.3$ Hz), 0.84 (m, 3H) ; ^{13}C NMR (100 MHz, CDCl_3) δ 217.13, 182.61, 149.83, 149.33, 133.63, 87.71, 75.78, 58.04, 54.33, 50.98, 48.51, 45.09, 42.02, 37.78, 33.46; MS (ESI) m/z 290.4 $[\text{M}+\text{H}]^+$.

1-(4-(Hexyloxy)phenyl)-3-(4-methylpiperazin-1-yl)propan-1-one 15{5}. Yield 84%; ^1H NMR (400 MHz, CDCl_3) δ 7.92 (d, 2H, $J = 8.9$ Hz), 6.91 (d, 2H, $J = 8.9$ Hz), 4.01 (t, 2H, $J = 6.6$ Hz), 3.13 (t, 2H, $J = 7.5$ Hz), 2.84 (m, 2H), 2.53 (m, 8H), 2.29 (s, 3H), 1.79 (m, 2H), 1.46 (s, 2H), 1.34 (m, 4H), 0.91 (t, 3H, $J = 7.0$ Hz) ; ^{13}C NMR (100 MHz, CDCl_3) δ 217.00, 182.59, 149.73, 149.20, 133.64, 87.71, 74.47, 72.76, 72.55, 65.42, 55.22, 50.97, 48.50, 45.09, 42.02, 33.46; MS (ESI) m/z 3333.5 $[\text{M}+\text{H}]^+$.

1-(4-(Hexyloxy)phenyl)-3-(4-phenylpiperazin-1-yl)propan-1-one 15{6}. Yield 76%; ^1H NMR (400 MHz, CDCl_3) δ 7.86 (m, 2H), 7.19 (m, 2H), 6.85 (m, 4H), 6.78 (t, 1H, $J = 7.3$ Hz), 3.94 (t, 2H, $J = 6.5$ Hz), 3.14 (m, 6H), 2.84 (t, 2H, $J = 7.4$ Hz), 2.63 (m, 4H), 1.73 (m, 2H), 1.39 (m, 2H), 1.26 (m, 4H), 0.84 (t, 3H, $J = 6.9$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 197.42, 163.16, 151.16, 130.28, 129.67, 129.06, 119.75, 116.06, 114.18, 68.24, 53.30, 53.21, 49.02, 35.71, 31.49, 29.01, 25.60, 22.53, 13.98; MS (ESI) m/z 395.6 $[\text{M}+\text{H}]^+$.

1-(4-(Hexyloxy)phenyl)-3-morpholinopropan-1-one 15{7}. Yield 66%; ^1H NMR (400 MHz, CDCl_3) δ 7.85 (d, 2H, $J = 8.8$ Hz), 6.86 (m, 2H), 3.96 (m, 2H), 3.64 (m, 4H), 3.08 (m, 2H), 2.74 (m, 2H), 2.44 (m, 4H), 1.72 (m, 2H), 1.32 (m, 6H), 0.83 (t, 3H, $J = 6.9$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 216.89, 182.64, 149.74, 149.16, 133.67, 87.73, 86.36, 73.23, 73.16, 55.01, 50.98, 48.50, 45.10, 42.03, 33.47; MS (ESI) m/z 320.4 $[\text{M}+\text{H}]^+$.

1-(4-(Hexyloxy)phenyl)-3-(methyl(phenyl)amino)propan-1-one 15{8}. Yield 63%; ¹H NMR (400 MHz, CDCl₃) δ 7.82 (m, 2H), 7.18 (m, 2H), 6.82 (m, 2H), 6.66 (m, 3H), 3.93 (t, 2H, *J* = 6.6 Hz), 3.75 (m, 2H), 3.10 (m, 2H), 2.89 (s, 3H), 1.72 (m, 2H), 1.38 (m, 2H), 1.26 (m, 4H), 0.84 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 197.96, 163.20, 148.56, 130.28, 129.72, 129.29, 116.43, 116.41, 114.16, 112.32, 112.30, 68.24, 48.16, 38.52, 34.68, 31.49, 29.01, 25.60, 22.53, 13.98; MS (ESI) *m/z* 340.5 [M+H]⁺.


1-(4-(Hexyloxy)phenyl)-3-(phenylamino)propan-1-one 15{9}. Yield 41%; ¹H NMR (400 MHz, CDCl₃) δ 7.83 (m, 2H), 7.11 (t, 2H, *J* = 7.7 Hz), 6.83 (m, 2H), 6.64 (m, 1H), 6.59 (d, 2H, *J* = 8.5 Hz), 3.93 (t, 2H, *J* = 6.6 Hz), 3.52 (t, 2H, *J* = 6.1 Hz), 3.16 (t, 2H, *J* = 6.1 Hz), 1.72 (m, 2H), 1.39 (m, 2H), 1.25 (m, 4H), 0.83 (t, 3H, *J* = 6.9 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 197.76, 163.30, 147.45, 130.29, 129.55, 129.30, 117.79, 114.20, 113.29, 68.27, 39.15, 37.11, 31.50, 29.01, 25.61, 22.55, 13.99; MS (ESI) *m/z* 326.4 [M+H]⁺.

3-(3-Chlorophenylamino)-1-(4-(hexyloxy)phenyl)propan-1-one 15{10}. Yield 34%; ¹H NMR (400 MHz, CDCl₃) δ 7.84 (d, 2H, *J* = 8.9 Hz), 6.98 (t, 1H, *J* = 8.0 Hz), 6.83 (m, 2H), 6.58 (m, 1H), 6.54 (m, 1H), 6.42 (dd, 1H, *J* = 1.9, 7.8 Hz), 4.34 (m, 1H), 3.94 (t, 2H, *J* = 6.6 Hz), 3.49 (t, 2H, *J* = 6.0 Hz), 3.14 (t, 2H, *J* = 6.0 Hz), 1.72 (m, 2H), 1.39 (m, 2H), 1.27 (m, 4H), 0.83 (t, 3H, *J* = 6.9 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 217.03, 182.88, 168.38, 154.55, 151.46, 149.84, 149.78, 149.70, 148.95, 136.80, 133.74, 133.65, 133.43, 131.97, 130.97, 87.79, 58.22, 56.41, 50.99, 48.50, 45.10, 42.04, 33.48; MS (ESI) *m/z* 360.9 [M+H]⁺.

1-(4-(Hexyloxy)phenyl)-3-(1*H*-imidazol-1-yl)propan-1-one 15{11}. Yield 54%; ¹H NMR (400 MHz, CDCl₃) δ 7.86 (m, 2H), 7.64 (s, 1H), 7.00 (m, 2H), 6.89 (m, 2H), 4.41 (t, 2H, *J* = 6.5 Hz), 3.99 (t, 2H, *J* = 6.6 Hz), 3.37 (t, 2H, *J* = 6.6 Hz), 1.77 (m, 2H), 1.43 (m, 2H), 1.30 (m, 4H), 0.88 (t, 3H, *J* = 7.0 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 194.92, 163.59, 130.24, 128.99, 114.35, 68.33, 41.73, 39.40, 31.46, 28.97, 25.57, 22.51, 13.94; MS (ESI) *m/z* 301.4 [M+H]⁺.

1-(3-(4-(Hexyloxy)phenyl)-3-oxopropyl)pyrrolidine-2,5-dione 15{12}. Yield 65%; ¹H NMR (400 MHz, CDCl₃) δ 7.81 (d, 2H, *J* = 8.8 Hz), 6.83 (d, 2H, *J* = 8.8 Hz), 3.94 (t, 2H, *J* = 6.6 Hz), 3.86 (t, 2H, *J* = 7.4 Hz), 3.18 (m, 2H), 2.65 (s, 6H), 1.72 (m, 2H), 1.39 (m, 2H), 1.26 (m, 4H), 0.83 (t, 3H, *J* = 7.0 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 215.21, 196.51, 182.80, 149.73, 148.70, 133.71, 87.75, 54.90, 54.05, 50.97, 48.49, 47.64, 45.09, 42.02, 33.47; MS (ESI) *m/z* 332.4 [M+H]⁺.

Scheme 6. Synthesis of hydrophobic side chain modified β -aminophenylketones.



Reagent and condition. (a) EtOEtBr, K₂CO₃, DMF, 80-90 °C, 12 h; (b) *n*EtI, K₂CO₃, DMF; (c) *n*HexBr, K₂CO₃, DMF, 80-90 °C, 12 h; (d) 3-chloropropionic chloride, AlCl₃, DCM, 0 °C, 1 h; (e) *m*CPBA, DCM, 0 °C, 1 h; (f) 2 M Me₂NH/THF, THF, rt, 1 h; (g) C₆H₁₃NH₂, DIC, DMAP, DCM, rt; (h) paraformaldehyde, Me₂NH•HCl, *c*-HCl, H₂O/MeCN (1/9, v/v), MW, 120 °C, 2 h; (i) RX (*n*C₅H₁₂COCl, *n*C₅H₁₂SO₂Cl, *n*BuNCO), TEA, DCM, rt.

Synthesis of compound 29{1}: To a solution phenol **2** (0.5 g, 5.3 mmol) in DMF was added K_2CO_2 (1.38 g, 10.6 mmol) and ethoxyethylbromide (0.874 mL, 8.0 mmol), and then stirred at 85 °C for overnight. The reaction mixture was poured to water and extracted with Et_2O . The combined organic layer were washed with brine and dried over $MgSO_4$ and concentrated in vacuo to yield crude compound **29{1}**. **(2-Ethoxyethoxy)benzene 29{1}**. 1H NMR (400 MHz, $CDCl_3$) δ 7.28 (m, 2H), 6.94 (m, 3H), 4.13 (m, 2H), 3.80 (m, 2H), 3.61 (m, 2H), 1.26 (m, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 158.81, 129.37, 120.81, 114.64, 68.96, 67.34, 66.83, 15.15.

4-Benzyl-1-ethylpiperidine 29{2}. 1H NMR (400 MHz,) δ 7.27 – 7.15 (m, 2H), 7.15 – 6.99 (m, 3H), 2.84 (d, $J = 11.7$, 2H), 2.45 (d, $J = 7.1$, 2H), 2.29 (q, $J = 7.2$, 2H), 1.74 (t, $J = 11.7$, 2H), 1.56 (d, $J = 13.0$, 2H), 1.50 – 1.34 (m, 1H), 1.33 – 1.13 (m, 2H), 1.06 – 0.87 (m, 3H); NMR (101 MHz,) δ 140.73, 129.10, 128.10, 125.71, 53.50, 52.59, 43.22, 38.00, 32.16, 12.13.

Synthesis of compound 29{3}: To a solution amine **28{3}** (0.50g, 2.45 mmol) in DCM were added n-propyl bromide (0.262 mL, 2.69 mmol), and TEA (0.443 mL, 3.19 mmol) and then stirred at rt for 3h. The reaction mixture was washed with water and brine, and dried over $MgSO_4$. After concentration under vacuum, the crude mixture was purified on normal phase column chromatography (SP1, Biotage) to yield the desired product. **1-(4-(4-Propylpiperazin-1-yl)phenyl)ethanone 29{3}**. Yield 87%; 1H NMR (400 MHz, $CDCl_3$) δ 7.83 (d, 2H, $J = 9.0$ Hz),

6.82 (d, 2H, $J = 9.1$ Hz), 3.33 (m, 4H), 2.54 (m, 4H), 2.47 (s, 3H), 2.32 (m, 2H), 1.51 (m, 2H), 0.90 (t, 3H, $J = 7.4$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 196.30, 154.06, 130.23, 127.37, 113.17, 60.46, 52.75, 47.18, 25.99, 19.88, 11.82.

Synthesis of compound 29{4}: To a solution thiophenol **28{4}** (2.0 g, 18.2 mmol) in DMF was added K_2CO_2 (3.26 g, 23.6 mmol) and *n*-hexylbromide (2.95 mL, 23.6 mmol) and then stirred at 85 °C for overnight. The reaction mixture was poured to water and extracted with Et_2O . The combined organic layer were washed with brine and dried over MgSO_4 and concentrated in vacuo to yield crude compound **29{4}**. **Hexyl(phenyl)sulfane 29{4}** ^1H NMR (400 MHz, CDCl_3) δ 7.33 (m, 4H), 7.19 (m, 1H), 2.95 (m, 2H), 1.68 (m, 2H), 1.46 (m, 2H), 1.33 (m, 4H), 0.92 (t, 3H, $J = 7.0$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 137.04, 128.82, 128.78, 125.60, 33.58, 31.35, 29.11, 28.52, 22.52, 14.00.

Synthesis of compound 29{6}: To a solution phenol **28{6}** (0.5 g, 3.05 mmol) in DCM were added *n*-hexylamine (0.52 mL, 3.96 mmol), DIC (0.613 mL, 3.96 mmol), and DMAP (cat.) and then stirred at rt for 3h. The reaction mixture was washed with water and brine, and dried over MgSO_4 . After concentration under vacuum, the crude mixture was purified on normal phase column chromatography (SP1, Biotage) to yield the desired product **29{6}**. **4-Acetyl-*N*-hexylbenzamide 29{6}**. Yield 57%; ^1H NMR (400 MHz, CDCl_3) δ 7.94 (d, 2H, $J = 8.3$ Hz), 7.81 (d, 2H, $J = 8.3$ Hz), 6.48 (s, 1H), 3.42 (m, 2H), 2.59 (s, 3H), 1.58 (m, 2H), 1.29 (m, 7H), 0.85 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 197.43, 166.49, 138.91, 138.74, 128.38, 127.15, 40.24, 31.42, 29.48, 26.72, 26.60, 22.48, 13.94.

Synthesis of compound 29{7}: To a solution phenol **28{7}** (0.5 g, 3.70 mmol) in DCM were added n-pentanoic acid (0.60 mL, 4.81 mmol), DIC (0.745 mL, 4.81 mmol), and DMAP (cat.) and then stirred at rt for 3h. The reaction mixture was washed with water and brine, and dried over MgSO₄. After concentration under vacuum, the crude mixture was purified on normal phase column chromatography (SP1, Biotage) to yield the desired product **29{7}**. *N*-(4-Acetylphenyl)hexanamide **29{7}**. Yield 59%; ¹H NMR (400 MHz, CDCl₃) δ 7.92 (m, 2H), 7.71 (s, 1H), 7.64 (d, 2H, *J* = 8.7 Hz), 2.59 (s, 3H), 2.39 (m, 2H), 1.73 (m, 2H), 1.34 (m, 4H), 0.89 (t, 3H, *J* = 7.1 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 197.05, 171.84, 142.45, 132.66, 129.70, 118.81, 37.79, 31.35, 31.34, 26.41, 25.11, 22.37, 22.36, 13.87, 13.86.

Synthesis of compound 29{8}: To a solution phenol **28{8}** (0.20 g, 1.48 mmol) in DCM were added n-pentane sulfonyl chloride (0.26 mL, 1.78 mmol), and TEA (0.31 mL, 2.22 mmol) and then stirred at rt for 3h. The reaction mixture was washed with water and brine, and dried over MgSO₄. After concentration under vacuum, the crude mixture was purified on normal phase column chromatography (SP1, Biotage) to yield the desired product **29{8}**. *N*-(4-Acetylphenyl)pentane-1-sulfonamide **29{8}**. Yield 45%; ¹H NMR (400 MHz, CDCl₃) δ 7.95 (m, 2H), 7.47 (s, 1H), 7.28 (m, 2H), 3.17 (m, 2H), 2.61 (s, 3H), 1.82 (m, 2H), 1.32 (m, 4H), 0.85 (t, 3H, *J* = 7.2 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 196.89, 141.64, 133.03, 130.29, 117.98, 52.19, 30.09, 26.41, 23.07, 22.01, 13.59.

Synthesis of compound 29{9}: To a solution amine **28{9}** (0.50 g, 3.70 mmol) in DCM was added n-butane isocyanate (0.50 mL, 4.44 mmol) and then stirred at rt for 3h. The reaction mixture was washed with water and brine, and dried over MgSO₄. After concentration under vacuum, the

crude mixture was purified on normal phase column chromatography (SP1, Biotage) to yield the desired product. **1-(4-Acetylphenyl)-3-butylurea 29{9}**. Yield 24%; ^1H NMR (400 MHz, CDCl_3) δ 8.10 (s, 1H), 7.76 (d, 2H, $J = 8.7$ Hz), 7.35 (d, 2H, $J = 8.7$ Hz), 5.86 (t, 1H, $J = 5.4$ Hz), 3.15 (m, 2H), 2.46 (s, 3H), 1.40 (m, 3H), 1.24 (m, 3H), 0.81 (t, 3H, $J = 7.3$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 217.14, 175.25, 164.06, 150.29, 149.38, 137.19, 59.35, 51.58, 45.84, 39.50, 33.20.

3-Chloro-1-(4-(2-ethoxyethoxy)phenyl)propan-1-one 30{1}. ^1H NMR (400 MHz, CDCl_3) δ 7.92 (m, 2H), 6.96 (m, 2H), 4.18 (d, 2H, $J = 5.4$ Hz), 3.90 (t, 2H, $J = 6.9$ Hz), 3.81 (d, 2H, $J = 5.4$ Hz), 3.60 (m, 2H), 3.40 (t, 2H, $J = 6.9$ Hz), 1.24 (t, 3H, $J = 7.0$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 195.19, 163.10, 130.28, 129.56, 114.45, 68.64, 67.70, 66.92, 40.89, 38.93, 15.09.

3-Chloro-1-(4-((1-ethylpiperidin-4-yl)methyl)phenyl)propan-1-one 30{2}. ^1H NMR (400 MHz,) δ 7.85 (d, $J = 8.4$, 2H), 7.28 (d, 2H), 3.87 (t, $J = 6.7$, 2H), 3.51 (d, $J = 11.9$, 2H), 3.46 – 3.30 (m, 2H), 3.10 – 2.96 (m, 2H), 2.66 (d, $J = 6.9$, 2H), 2.63 – 2.44 (m, 2H), 2.16 – 1.95 (m, 2H), 1.80 (d, $J = 11.8$, 3H), 1.41 (t, $J = 7.3$, 3H).

3-Chloro-1-(4-(hexylthio)phenyl)propan-1-one 30{4}. ^1H NMR (400 MHz, CDCl_3) δ 7.68 (d, 2H, $J = 8.5$ Hz), 7.13 (d, 2H, $J = 8.6$ Hz), 3.74 (t, 2H, $J = 6.9$ Hz), 3.24 (t, 2H, $J = 6.8$ Hz), 2.82 (m, 2H), 1.53 (m, 2H), 1.29 (s, 2H), 1.14 (m, 4H), 0.72 (t, 3H, $J = 6.8$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 195.66, 145.81, 132.81, 128.43, 126.20, 41.03, 38.78, 31.87, 31.30, 28.65, 28.55, 22.49, 13.98.

3-Chloro-1-(4-(hexylsulfonyl)phenyl)propan-1-on 30{5}. **Beta-chloro/enone =1:0.3** ^1H NMR (400 MHz, CDCl_3) δ 8.12 (d, 2H, $J = 8.3$ Hz), 8.02 (d, 2H, $J = 8.3$ Hz), 3.93 (t, 2H, $J = 6.6$ Hz),

3.50 (t, 2H, $J = 6.6$ Hz), 3.10 (m, 2H), 1.70 (m, 2H), 1.36 (m, 2H), 1.24 (m, 4H), 0.85 (t, 3H, $J = 6.8$ Hz).

3-(Dimethylamino)-1-(4-(2-ethoxyethoxy)phenyl)propan-1-one 16{1}. Yield 91%; ^1H NMR (400 MHz, CDCl_3) δ 7.91 (m, 2H), 6.93 (m, 2H), 4.15 (dd, 2H, $J = 4.2, 5.5$ Hz), 3.77 (m, 2H), 3.57 (m, 2H), 3.09 (t, 2H, $J = 7.4$ Hz), 2.73 (m, 2H), 2.28 (s, 6H), 1.21 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 197.40, 162.71, 130.19, 130.00, 114.27, 68.61, 67.59, 66.83, 54.39, 45.29, 36.30, 15.05; MS (ESI) m/z 266.4 $[\text{M}+\text{H}]^+$.

3-(Dimethylamino)-1-(4-((1-ethylpiperidin-4-yl)methyl)phenyl)propan-1-one 16{2}. ^1H NMR (400 MHz, CDCl_3) δ 7.87 (d, 2H, $J = 9.1$ Hz), 6.85 (d, 2H, $J = 9.0$ Hz), 3.46 (s, 1H), 3.37 (m, 4H), 3.26 (t, 2H, $J = 7.3$ Hz), 3.02 (t, 2H, $J = 7.3$ Hz), 2.58 (m, 4H), 2.47 (s, 5H), 2.35 (m, 3H), 1.54 (m, 2H), 0.92 (t, 3H, $J = 7.4$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 195.79, 154.31, 130.24, 126.45, 113.27, 60.47, 53.79, 52.72, 47.05, 44.34, 34.82, 19.84, 11.87; MS (ESI) m/z 303.4 $[\text{M}+\text{H}]^+$.

3-(Dimethylamino)-1-(4-(4-propylpiperazin-1-yl)phenyl)propan-1-one 16{3}. Yield 32%; ^1H NMR (400 MHz, CDCl_3) δ 7.87 (d, 2H, $J = 9.1$ Hz), 6.85 (d, 2H, $J = 9.0$ Hz), 3.37 (m, 4H), 3.26 (t, 2H, $J = 7.3$ Hz), 3.02 (t, 2H, $J = 7.3$ Hz), 2.58 (m, 4H), 2.48 (s, 6H), 2.34 (m, 2H), 1.54 (m, 2H), 0.92 (t, 3H, $J = 7.4$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 195.79, 154.31, 130.24, 126.45, 113.27, 60.47, 53.79, 52.72, 47.05, 44.34, 34.82, 19.84, 11.87; MS (ESI) m/z 304.3 $[\text{M}+\text{H}]^+$.

3-(Dimethylamino)-1-(4-(hexylthio)phenyl)propan-1-one 16{4}. Yield 95%; ^1H NMR (400 MHz, CDCl_3) δ 7.75 (m, 2H), 7.22 (d, 2H, $J = 8.3$ Hz), 3.07 (m, 2H), 2.89 (m, 2H), 2.70 (t, 2H, $J =$

7.4), 2.23 (m, 6H), 1.62 (m, 2H), 1.38 (m, 2H), 1.23 (m, 4H), 0.82 (t, 3H, $J = 6.7$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 197.94, 144.99, 133.33, 128.42, 126.20, 54.36, 45.40, 36.55, 31.89, 31.25, 28.64, 28.50, 22.44, 13.93; MS (ESI) m/z 294.5 $[\text{M}+\text{H}]^+$.

3-(Dimethylamino)-1-(4-(hexylsulfonyl)phenyl)propan-1-one 16{5}. Yield 90%; ^1H NMR (400 MHz, CDCl_3) δ 8.11 (d, 2H, $J = 8.7$ Hz), 7.97 (d, 2H, $J = 8.6$ Hz), 3.23 (s, 1H), 3.07 (m, 2H), 2.83 (d, 2H, $J = 6.3$ Hz), 2.34 (s, 6H), 1.66 (m, 2H), 1.33 (m, 2H), 1.22 (s, 4H), 0.82 (t, 3H, $J = 6.9$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 197.44, 142.95, 140.41, 128.76, 128.47, 56.12, 53.62, 53.58, 45.06, 31.04, 27.83, 22.46, 22.18, 13.80; MS (ESI) m/z 326.4 $[\text{M}+\text{H}]^+$.

4-(3-(Dimethylamino)propanoyl)-*N*-hexylbenzamide 16{6}. Yield 27%; ^1H NMR (400 MHz, CDCl_3) δ 7.96 (d, 2H, $J = 8.4$ Hz), 7.82 (d, 2H, $J = 8.3$ Hz), 6.38 (s, 1H), 3.43 (m, 2H), 3.16 (t, 2H, $J = 7.3$ Hz), 2.76 (t, 2H, $J = 7.2$ Hz), 2.27 (s, 6H), 1.60 (m, 2H), 1.33 (m, 6H), 0.88 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 198.36, 166.46, 138.75, 128.18, 127.18, 54.13, 45.39, 40.23, 37.04, 31.43, 29.51, 26.61, 22.49, 13.96; MS (ESI) m/z 305.4 $[\text{M}+\text{H}]^+$.


***N*-(4-(3-(Dimethylamino)propanoyl)phenyl)hexanamide 16{7}**. Yield 25%; ^1H NMR (400 MHz, CDCl_3) δ 8.21 (s, 1H), 7.87 (d, 2H, $J = 8.7$ Hz), 7.63 (d, 2H, $J = 8.7$ Hz), 3.17 (t, 2H, $J = 7.3$ Hz), 2.85 (t, 2H, $J = 7.3$ Hz), 2.34 (m, 8H), 1.69 (m, 2H), 1.30 (m, 4H), 0.86 (t, 3H, $J = 7.1$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 197.13, 172.05, 142.85, 131.94, 129.38, 118.90, 53.82, 44.74, 37.66, 35.72, 31.34, 25.09, 22.35, 13.85; MS (ESI) m/z 291.4 $[\text{M}+\text{H}]^+$.

***N*-(4-(3-(Dimethylamino)propanoyl)phenyl)pentane-1-sulfonamide 16{8}**. Yield 36%; ^1H NMR (400 MHz, CDCl_3) δ 8.75 (s, 1H), 7.81 (d, 2H, $J = 8.7$ Hz), 7.20 (d, 2H, $J = 8.6$ Hz), 3.09 (m, 4H),

2.84 (t, 2H, $J = 7.2$ Hz), 2.36 (s, 6H), 1.73 (m, 2H), 1.23 (m, 4H), 0.79 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 196.20, 142.70, 131.69, 129.93, 118.04, 53.67, 52.23, 44.54, 35.16, 30.13, 23.03, 22.03, 13.63; MS (ESI) m/z 327.4 $[\text{M}+\text{H}]^+$.

1-Butyl-3-(4-(3-(dimethylamino)propanoyl)phenyl)urea 16{9}. Yield 18%; ^1H NMR (400 MHz, CDCl_3) δ 8.49 (s, 1H), 7.70 (m, 2H), 7.43 (m, 2H), 6.15 (s, 1H), 3.20 (m, 2H), 3.11 (t, 2H, $J = 7.1$ Hz), 2.86 (m, 2H), 2.39 (s, 6H), 1.45 (m, 2H), 1.30 (m, 2H), 0.87 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 197.20, 155.74, 145.00, 129.85, 129.51, 117.59, 54.30, 45.04, 39.78, 35.50, 32.10, 20.03, 13.73; MS (ESI) m/z 292.4 $[\text{M}+\text{H}]^+$.

Scheme 7. Synthesis of the second generated compounds



^aReagent and condition. (a) nHexBr, K₂CO₃, DMF, 85 °C; (b) RCH₂C(O)Cl, AlCl₃, DCM, 0 °C, 2 h; (c) *m*CPBA, DCM, 0 °C, 1 h (d) R₂R₃NH, DCM, rt, 1 h

(3-Chlorophenyl)(hexyl)sulfane 32{1}. ¹H NMR (400 MHz, CDCl₃) δ 11.39 (m, 1H), 11.30 (m, 1H), 11.24 (m, 1H), 7.04 (m, 2H), 5.78 (m, 2H), 5.56 (m, 2H), 5.42 (m, 4H), 5.01 (t, 3H, *J* = 6.9 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 139.43, 134.60, 129.75, 127.87, 126.38, 125.55, 33.24, 31.30, 28.87, 28.47, 22.50, 13.98.

(2,3-Dichlorophenyl)(hexyl)sulfane 32{2}. ¹H NMR (400 MHz, CDCl₃) δ 7.34 (m, 1H), 7.22 (m, 2H), 3.02 (m, 2H), 1.80 (m, 2H), 1.57 (m, 2H), 1.41 (m, 4H), 0.99 (t, 3H, *J* = 6.9 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 139.56, 133.42, 130.41, 127.20, 126.46, 124.90, 32.61, 31.33, 28.64, 28.33, 22.49, 13.99.

(2,5-Dichlorophenyl)(hexyl)sulfane 32{3}. ¹H NMR (400 MHz, CDCl₃) δ 7.28 (d, *J* = 8.5, 1H), 7.19 (d, *J* = 2.4, 1H), 7.07 (dd, *J* = 2.4, 8.5, 1H), 2.97 – 2.92 (m, 2H), 1.78 – 1.68 (m, 2H), 1.59 – 1.42 (m, 2H), 1.42 – 1.28 (m, 4H), 0.98 – 0.84 (m, 3H).

(3,5-Dichlorophenyl)(hexyl)sulfane 32{4}. ^1H NMR (400 MHz, CDCl_3) δ 7.13 (s, 2H), 2.92 (m, 2H), 1.66 (m, 2H), 1.43 (m, 2H), 1.30 (m, 4H), 0.89 (t, 3H, $J = 7.0$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 141.26, 135.08, 125.64, 125.33, 32.95, 31.25, 28.63, 28.44, 22.48, 13.97.

(3,5-Dimethylphenyl)(hexyl)sulfane 32{5}. ^1H NMR (400 MHz, CDCl_3) δ 6.95 (s, 2H), 6.79 (s, 1H), 2.90 (m, 2H), 2.28 (m, 6H), 1.64 (m, 2H), 1.43 (m, 2H), 1.30 (m, 4H), 0.89 (t, 3H, $J = 6.5$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 138.36, 136.54, 127.51, 126.45, 33.52, 31.35, 29.14, 28.53, 22.52, 21.21, 14.00.

3-Chloro-1-(2-chloro-4-(hexylthio)phenyl)propan-1-one 33{1}. Yield 70%; ^1H NMR (400 MHz,) δ 7.53 (d, 1H, $J = 8.3$ Hz), 7.26 (d, 1H, $J = 1.9$ Hz), 7.18 (dd, 1H, $J = 1.8, 8.3$ Hz), 3.88 (t, 2H, $J = 6.7$ Hz), 3.45 (t, 2H, $J = 6.6$ Hz), 2.97 (m, 2H), 1.69 (m, 2H), 1.45 (m, 2H), 1.31 (m, 4H), 0.90 (t, 3H, $J = 6.8$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 197.89, 144.86, 133.84, 132.32, 130.18, 127.99, 124.96, 45.22, 38.74, 32.11, 31.25, 28.53, 28.48, 22.47, 13.96.

3-Chloro-1-(2,3-dichloro-4-(hexylthio)phenyl)propan-1-one 33{2}. Yield 64%; ^1H NMR (400 MHz, CDCl_3) δ 7.34 (d, 1H, $J = 8.3$ Hz), 7.07 (d, 1H, $J = 8.4$ Hz), 3.81 (t, 2H, $J = 6.6$ Hz), 3.36 (t, 2H, $J = 6.6$ Hz), 2.90 (m, 2H), 1.68 (m, 2H), 1.42 (m, 2H), 1.26 (m, 4H), 0.84 (t, 3H, $J = 6.9$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 198.18, 144.43, 135.91, 135.61, 131.78, 127.05, 123.15, 45.32, 38.66, 32.19, 31.29, 28.63, 28.04, 22.46, 13.97.

3-Chloro-1-(2,3-dichloro-4-(hexylthio)phenyl)propan-1-one 33{3}. Yield 63%; ^1H NMR (400 MHz, CDCl_3) δ 7.64 (s, 1H), 7.19 (s, 1H), 3.90 (t, $J = 6.6$, 2H), 3.47 (t, $J = 6.6$, 2H), 2.99 (t, $J = 7.4$, 2H), 1.83 – 1.71 (m, 2H), 1.61 – 1.46 (m, 2H), 1.42 – 1.30 (m, 4H), 0.94 (t, $J = 7.0$, 3H).

3-Chloro-1-(2,6-dichloro-4-(hexylthio)phenyl)propan-1-one 33{4}. Yield 55%; ^1H NMR (400 MHz, CDCl_3) δ 7.17 (d, 2H, $J = 8.9$ Hz), 3.87 (t, 2H, $J = 6.8$ Hz), 3.29 (t, 2H, $J = 6.8$ Hz), 2.94 (m, 2H), 1.66 (m, 2H), 1.44 (s, 2H), 1.31 (m, 4H), 0.89 (t, 3H, $J = 6.8$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 198.54, 142.76, 135.01, 130.75, 126.10, 46.36, 37.23, 32.58, 31.22, 28.41, 22.46, 13.96.

3-Chloro-1-(4-(hexylthio)-2,6-dimethylphenyl)propan-1-one 33{5}. Yield 29%; ^1H NMR (400 MHz, CDCl_3) δ 6.84 (d, 2H, $J = 7.3$ Hz), 3.76 (t, 2H, $J = 6.4$ Hz), 3.04 (t, 2H, $J = 6.4$ Hz), 2.80 (m, 2H), 2.10 (s, 6H), 1.53 (m, 2H), 1.32 (m, 2H), 1.19 (m, 4H), 0.78 (t, 3H, $J = 6.9$ Hz).


1-(2-Chloro-4-(hexylsulfonyl)phenyl)prop-2-en-1-one 34{1}. Yield 89%; ^1H NMR (400 MHz, CDCl_3) δ 7.98 (d, 1H, $J = 1.4$ Hz), 7.86 (dd, 1H, $J = 1.7, 7.9$ Hz), 7.55 (d, 1H, $J = 8.0$ Hz), 6.73 (dd, 1H, $J = 10.6, 17.6$ Hz), 6.17 (d, 1H, $J = 10.6$ Hz), 6.10 (d, 1H, $J = 17.6$ Hz), 3.11 (m, 2H), 1.71 (m, 2H), 1.38 (m, 2H), 1.25 (m, 4H), 0.87 (t, 3H, $J = 6.9$ Hz).

1-(2,3-Dichloro-4-(hexylsulfonyl)phenyl)prop-2-en-1-one 34{2}. Yield 70%; ^1H NMR (400 MHz, CDCl_3) δ 8.07 (d, 1H, $J = 8.1$ Hz), 7.36 (t, 1H, $J = 7.4$ Hz), 6.62 (dd, 1H, $J = 10.6, 17.6$ Hz), 6.15 (d, 1H, $J = 10.8$ Hz), 6.01 (d, 1H, $J = 17.6$ Hz), 3.36 (m, 2H), 1.63 (m, 2H), 1.34 (m, 2H), 1.21 (m, 4H), 0.80 (t, 3H, $J = 6.9$ Hz).

3-chloro-1-(2,5-dichloro-4-(hexylsulfonyl)phenyl)propan-1-one 34{3}. Yield 84%; ^1H NMR (400 MHz, CDCl_3) δ 8.12 (s, 1H), 7.57 (s, 1H), 3.82 (t, $J = 6.4$, 2H), 3.41 – 3.28 (m, 4H), 1.65 (dt, $J = 7.7, 15.5$, 2H), 1.39 – 1.30 (m, 2H), 1.22 (dd, 4H), 0.81 (t, $J = 6.9$, 3H).

1-(2,6-Dichloro-4-(hexylsulfonyl)phenyl)prop-2-en-1-one 34{4}. Yield 63%; ^1H NMR (400 MHz, CDCl_3) δ 7.87 (s, 1H), 6.60 (dd, 1H, $J = 10.6, 17.7$ Hz), 6.27 (d, 1H, $J = 10.6$ Hz), 5.98 (d, 1H, $J = 17.7$ Hz), 3.11 (m, 2H), 1.73 (m, 2H), 1.39 (m, 2H), 1.28 (m, 4H), 0.87 (t, 3H, $J = 6.9$ Hz).

1-(4-(Hexylsulfonyl)-2,6-dimethylphenyl)prop-2-en-1-one 34{5}. Yield 75%; ^1H NMR (400 MHz, CDCl_3) δ 7.57 (s, 2H), 6.57 (dd, 1H, $J = 10.5, 17.7$ Hz), 6.19 (d, 1H, $J = 10.5$ Hz), 5.85 (d, 1H, $J = 17.7$ Hz), 3.06 (m, 2H), 2.25 (s, 6H), 1.70 (m, 2H), 0.85 (t, 3H, $J = 6.8$ Hz).



$17\{\text{S}, R_1, R_2R_3\text{NH}\}_7$, $17\{\text{SO}_2, R_1, R_2R_3\text{NH}\}_7$,

$17\{1,1,1\}$

Same with $12\{11\}$

1-(2-Chloro-4-(hexyloxy)phenyl)-3-(2-methylaziridin-1-yl)propan-1-one 17{1,1,2}. Yield 87%; ^1H NMR (400 MHz, CDCl_3) δ 7.64 (d, $J = 8.7$, 1H), 6.93 (d, $J = 2.4$, 1H), 6.82 (dd, $J = 2.4, 8.7$, 1H), 3.99 (t, $J = 6.5$, 2H), 3.24 (t, $J = 7.1$, 2H), 2.71 – 2.52 (m, 2H), 1.84 – 1.71 (m, 2H), 1.52 – 1.41 (m, 4H), 1.40 – 1.30 (m, 4H), 1.15 (t, $J = 6.3$, 3H), 0.91 (t, $J = 6.9$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 199.80, 161.78, 133.48, 131.70, 130.52, 116.58, 113.13, 68.59, 56.14, 42.85, 34.90, 34.87, 31.49, 28.95, 25.59, 22.57, 18.32, 14.02; MS (ESI) m/z 324.4 $[\text{M}+\text{H}]^+$.

1-(2-Chloro-4-(hexyloxy)phenyl)-3-morpholinopropan-1-one 17{1,1,3}. Yield 75%; ^1H NMR (400 MHz, CDCl_3) δ 7.57 (d, $J = 8.7$, 1H), 6.92 (d, $J = 2.4$, 1H), 6.82 (dd, $J = 2.4, 8.7$, 1H), 3.98 (t,

$J = 6.5$, 2H), 3.76 – 3.63 (m, 4H), 3.16 (t, $J = 7.2$, 2H), 2.79 (t, $J = 7.2$, 2H), 2.56 – 2.43 (m, 4H), 1.84 – 1.68 (m, 2H), 1.53 – 1.40 (m, 2H), 1.40 – 1.27 (m, 4H), 0.91 (t, $J = 7.0$, 3H); ^{13}C NMR (101 MHz, C CDCl_3) δ 200.14, 161.72, 133.20, 131.53, 130.65, 116.42, 113.18, 68.60, 66.90, 53.81, 53.53, 39.88, 31.49, 28.96, 25.60, 22.57, 14.02; MS (ESI) m/z 354.4 $[\text{M}+\text{H}]^+$.

4-(3-(2-Chloro-4-(hexyloxy)phenyl)-3-oxopropyl)piperazin-2-one 17{1,1,4}. Yield 100%; ^1H NMR (400 MHz, CDCl_3) δ 7.58 (d, $J = 8.7$, 1H), 6.92 (brs, 2H), 6.82 (dd, $J = 2.3$, 8.7, 1H), 3.98 (t, $J = 6.5$, 2H), 3.39 (brs, 2H), 3.22 – 3.13 (m, 4H), 2.86 (t, $J = 7.0$, 2H), 2.75 (brs, 2H), 1.85 – 1.71 (m, 2H), 1.54 – 1.40 (m, 2H), 1.40 – 1.26 (m, 4H), 0.91 (t, $J = 6.7$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 199.52, 169.49, 161.88, 133.30, 131.64, 130.33, 116.51, 113.28, 68.63, 56.71, 52.45, 49.09, 41.21, 40.02, 31.48, 28.94, 25.59, 22.56, 14.02; MS (ESI) m/z 367.4 $[\text{M}+\text{H}]^+$.

3-(4-Acetylpiperazin-1-yl)-1-(2-chloro-4-(hexyloxy)phenyl)propan-1-one 17{1,1,5}. Yield 100%; ^1H NMR (400 MHz, CDCl_3) δ 7.56 (d, $J = 8.7$, 1H), 6.91 (s, 1H), 6.81 (dd, $J = 2.3$, 8.7, 1H), 3.97 (t, $J = 6.5$, 2H), 3.57 (brs, 2H), 3.47 – 3.35 (m, 2H), 3.15 (t, $J = 7.1$, 2H), 2.79 (t, $J = 7.0$, 2H), 2.51 – 2.36 (m, 4H), 2.06 (s, 3H), 1.83 – 1.69 (m, 2H), 1.51 – 1.39 (m, 2H), 1.39 – 1.25 (m, 4H), 0.90 (t, $J = 6.3$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 199.99, 168.89, 161.76, 133.21, 131.52, 130.53, 116.46, 113.19, 68.61, 53.27, 53.16, 52.58, 46.21, 41.31, 39.98, 31.48, 28.94, 25.58, 22.55, 21.31, 14.01; MS (ESI) m/z 395.4 $[\text{M}+\text{H}]^+$.

1-(2-Chloro-4-(hexyloxy)phenyl)-3-(4-(ethylsulfonyl)piperazin-1-yl)propan-1-one 17{1,1,6}.

Yield 85%; ^1H NMR (400 MHz, CDCl_3) δ 7.57 (d, $J = 8.7$, 1H), 6.93 (d, $J = 2.4$, 1H), 6.83 (dd, $J = 2.4$, 8.7, 1H), 3.99 (t, $J = 6.5$, 2H), 3.37 – 3.24 (m, 4H), 3.15 (t, $J = 7.1$, 2H), 2.94 (q, $J = 7.4$, 2H),

2.84 (t, $J = 7.1$, 2H), 2.60 – 2.51 (m, 4H), 1.80 (dd, $J = 7.3$, 14.3, 2H), 1.45 (dd, $J = 6.3$, 14.0, 2H), 1.35 (dt, $J = 7.3$, 10.2, 7H), 0.91 (t, $J = 7.0$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 199.84, 161.80, 133.24, 131.54, 130.46, 116.49, 113.22, 68.63, 53.11, 52.64, 45.71, 43.75, 39.90, 31.49, 28.95, 25.59, 22.57, 14.02, 7.79; MS (ESI) m/z 345.5 $[\text{M}+\text{H}]^+$.

17{1,2,1} Same with **12**{24}

1-(2,3-Dichloro-4-(hexyloxy)phenyl)-3-(2-methylaziridin-1-yl)propan-1-one **17**{1,2,2}. Yield 99%; ^1H NMR (400 MHz, CDCl_3) δ 7.40 (d, $J = 8.7$, 1H), 6.79 (d, $J = 8.7$, 1H), 4.00 (t, $J = 6.5$, 2H), 3.13 (t, $J = 7.0$, 2H), 2.64 – 2.48 (m, 2H), 1.86 – 1.70 (m, 2H), 1.49 – 1.34 (m, 3H), 1.34 – 1.23 (m, 4H), 1.07 (t, $J = 5.7$, 3H), 0.84 (t, $J = 7.1$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 200.23, 157.71, 132.62, 131.47, 128.13, 123.35, 110.29, 77.39, 77.07, 76.75, 69.74, 56.01, 43.10, 34.92, 34.89, 31.43, 28.85, 25.55, 22.55, 18.31, 14.00; MS (ESI) m/z 358.3 $[\text{M}+\text{H}]^+$.

1-(2,3-Dichloro-4-(hexyloxy)phenyl)-3-morpholinopropan-1-one **17**{1,2,3}. Yield 100%; ^1H NMR (400 MHz, CDCl_3) δ 7.34 (d, $J = 8.7$, 1H), 6.79 (d, $J = 8.7$, 1H), 4.00 (t, $J = 6.5$, 2H), 3.65 – 3.53 (m, 4H), 3.06 (t, $J = 7.1$, 2H), 2.69 (t, $J = 7.1$, 2H), 2.43 – 2.32 (m, 4H), 1.85 – 1.70 (m, 2H), 1.49 – 1.35 (m, 2H), 1.35 – 1.19 (m, 4H), 0.84 (t, $J = 7.1$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 200.63, 157.63, 132.72, 131.22, 127.95, 123.20, 110.34, 69.75, 66.88, 53.78, 53.49, 40.12, 31.44, 28.86, 25.56, 22.55, 14.01; MS (ESI) m/z 388.3 $[\text{M}+\text{H}]^+$.

4-(3-(2,3-Dichloro-4-(hexyloxy)phenyl)-3-oxopropyl)piperazin-2-one **17**{1,2,4}. Yield 99%; ^1H NMR (400 MHz, CDCl_3) δ 7.42 (d, $J = 8.7$, 1H), 6.90 (s, 1H), 6.87 (d, $J = 8.7$, 1H), 4.08 (t, $J = 6.4$,

2H), 3.33 (brs, 2H), 3.19 – 3.08 (m, 4H), 2.91 – 2.82 (m, 2H), 2.72 (brs, 2H), 1.92 – 1.80 (m, 2H), 1.57 – 1.43 (m, 2H), 1.43 (brs, 4H), 0.97 – 0.82 (m, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 200.01, 169.42, 157.79, 132.39, 131.26, 128.08, 123.28, 110.42, 69.78, 56.70, 52.40, 49.01, 41.20, 40.27, 31.43, 28.84, 25.55, 22.55, 14.01; MS (ESI) m/z 401.3 $[\text{M}+\text{H}]^+$.

3-(4-Acetylpiperazin-1-yl)-1-(2,3-dichloro-4-(hexyloxy)phenyl)propan-1-one 17{1,2,5}. Yield 100%; ^1H NMR (400 MHz, CDCl_3) δ 7.34 (d, $J = 8.7$, 1H), 6.79 (d, $J = 8.7$, 1H), 4.00 (t, $J = 6.5$, 2H), 3.50 (brs, 2H), 3.42 – 3.30 (m, 2H), 3.06 (t, $J = 7.0$, 2H), 2.72 (t, $J = 7.0$, 2H), 2.44 – 2.28 (m, 4H), 2.00 (s, 3H), 1.85 – 1.71 (m, 2H), 1.52 – 1.37 (m, 2H), 1.35 – 1.23 (m, 4H), 0.84 (t, $J = 6.5$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 200.43, 168.90, 157.68, 132.59, 131.24, 127.96, 123.25, 110.34, 69.77, 53.23, 53.12, 52.56, 46.19, 41.29, 40.23, 31.42, 28.84, 25.55, 22.54, 21.31, 14.00; MS (ESI) m/z 429.4 $[\text{M}+\text{H}]^+$.

1-(2,3-Dichloro-4-(hexyloxy)phenyl)-3-(4-(ethylsulfonyl)piperazin-1-yl)propan-1-one

17{1,2,6}. Yield 100%; ^1H NMR (400 MHz, CDCl_3) δ 7.33 (d, $J = 8.7$, 1H), 6.80 (d, $J = 8.7$, 1H), 4.00 (t, $J = 6.5$, 2H), 3.27 – 3.13 (m, 4H), 3.05 (t, $J = 7.0$, 2H), 2.87 (q, $J = 7.4$, 2H), 2.74 (t, $J = 7.0$, 2H), 2.53 – 2.38 (m, 4H), 1.85 – 1.69 (m, 2H), 1.50 – 1.36 (m, 2H), 1.36 – 1.25 (m, 7H), 0.84 (t, $J = 7.0$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 200.28, 157.71, 132.51, 131.28, 127.95, 123.29, 110.34, 69.78, 53.07, 52.61, 45.70, 43.77, 40.16, 31.43, 28.85, 25.56, 22.55, 14.01, 7.79; MS (ESI) m/z 479.5 $[\text{M}+\text{H}]^+$.

17{1,3,1}

Same with **12**{25}

1-(2,5-Dichloro-4-(hexyloxy)phenyl)-3-(2-methylaziridin-1-yl)propan-1-one 17{1,3,2}. Yield 72%; ^1H NMR (400 MHz, CDCl_3) δ 7.65 (s, 1H), 6.85 (s, 1H), 3.98 (t, $J = 6.5$, 2H), 3.15 (t, $J = 7.1$, 2H), 2.63 – 2.46 (m, 2H), 1.88 – 1.72 (m, 2H), 1.51 – 1.34 (m, 3H), 1.34 – 1.24 (m, 4H), 1.07 (d, $J = 5.3$, 3H), 0.84 (dd, $J = 4.5$, 9.7, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 198.77, 156.97, 131.56, 131.52, 130.77, 121.70, 114.84, 69.74, 56.02, 42.90, 34.94, 31.42, 28.77, 25.51, 22.54, 18.31, 14.00; MS (ESI) m/z 358.3 $[\text{M}+\text{H}]^+$.

1-(2,5-Dichloro-4-(hexyloxy)phenyl)-3-morpholinopropan-1-one 17{1,3,3}. Yield 100%; ^1H NMR (400 MHz, CDCl_3) δ 7.59 (s, 1H), 6.84 (s, 1H), 3.98 (t, $J = 6.5$, 2H), 3.69 – 3.56 (m, 4H), 3.07 (t, $J = 7.1$, 2H), 2.70 (t, $J = 7.1$, 2H), 2.40 (brs, 4H), 1.85 – 1.75 (m, 2H), 1.43 (s, 2H), 1.35 – 1.22 (m, 4H), 0.84 (t, $J = 7.0$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 199.22, 168.32, 156.85, 131.38, 131.16, 130.92, 121.71, 114.70, 69.75, 66.94, 53.73, 53.54, 39.98, 31.42, 28.77, 25.51, 22.54, 14.00; MS (ESI) m/z 388.3 $[\text{M}+\text{H}]^+$.

4-(3-(2,5-Dichloro-4-(hexyloxy)phenyl)-3-oxopropyl)piperazin-2-one 17{1,3,4}. Yield 91%; ^1H NMR (400 MHz, CDCl_3) δ 7.67 (s, 1H), 6.93 (s, 1H), 6.72 (br, 1H), 4.07 (t, $J = 6.5$, 2H), 3.41 – 3.29 (m, 2H), 3.20 – 3.08 (m, 4H), 2.87 (t, $J = 7.0$, 2H), 2.74 – 2.65 (m, 2H), 1.94 – 1.80 (m, 2H), 1.56 – 1.45 (m, 2H), 1.43 – 1.28 (m, 4H), 0.92 (t, $J = 7.0$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 198.41, 169.35, 157.05, 131.45, 131.38, 130.53, 121.84, 114.78, 69.78, 56.72, 52.34, 49.16, 41.26, 40.11, 31.41, 28.75, 25.51, 22.54, 14.00; MS (ESI) m/z 401.3 $[\text{M}+\text{H}]^+$.

3-(4-Acetylpiperazin-1-yl)-1-(2,5-dichloro-4-(hexyloxy)phenyl)propan-1-one **17**{1,3,5}. Yield 35%; ¹H NMR (400 MHz, CDCl₃) δ 7.67 (s, 1H), 6.94 (s, 1H), 4.08 (t, *J* = 6.5, 2H), 3.65 – 3.53 (m, 2H), 3.53 – 3.44 (m, 2H), 3.16 (t, *J* = 7.0, 2H), 2.87 – 2.76 (m, 2H), 2.57 – 2.36 (m, 4H), 2.05 (s, 3H), 1.94 – 1.84 (m, 2H), 1.57 – 1.45 (m, 2H), 1.45 – 1.27 (m, 4H), 0.93 (t, *J* = 7.0, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 199.00, 168.90, 156.89, 131.35, 131.20, 130.76, 121.69, 114.73, 69.75, 53.18, 53.16, 52.58, 46.23, 41.33, 40.06, 31.40, 28.75, 25.49, 22.52, 21.31, 13.99; MS (ESI) *m/z* 429.4 [M+H]⁺.

1-(2,5-Dichloro-4-(hexyloxy)phenyl)-3-(4-(ethylsulfonyl)piperazin-1-yl)propan-1-one

17{1,3,6}. Yield 100%; ¹H NMR (400 MHz, CDCl₃) δ 7.57 (s, 1H), 6.85 (s, 1H), 3.99 (t, *J* = 6.5, 2H), 3.26 – 3.18 (m, 4H), 3.06 (t, *J* = 7.0, 2H), 2.87 (q, *J* = 7.4, 2H), 2.75 (t, *J* = 7.0, 2H), 2.50 – 2.41 (m, 4H), 1.87 – 1.73 (m, 2H), 1.47 – 1.36 (m, 2H), 1.36 – 1.23 (m, 7H), 0.84 (t, *J* = 7.1, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 198.95, 156.93, 131.40, 131.21, 130.77, 121.72, 114.73, 69.78, 53.05, 52.66, 45.74, 43.71, 39.99, 31.42, 28.77, 25.52, 22.54, 14.01, 7.79; MS (ESI) *m/z* 479.5 [M+H]⁺.

17{1,4,1}

Same with **12**{26}

1-(3,5-Dichloro-4-(hexyloxy)phenyl)-3-(2-methylaziridin-1-yl)propan-1-one **17**{1,4,2}. Yield 85%; ¹H NMR (400 MHz, CDCl₃) δ 6.76 (s, 2H), 3.87 (t, *J* = 6.5, 2H), 3.04 (t, *J* = 7.3, 2H), 2.58 (t, *J* = 7.3, 2H), 1.74 – 1.63 (m, 2H), 1.44 – 1.32 (m, 3H), 1.32 – 1.20 (m, 4H), 1.13 – 1.03 (m, 3H),

0.84 (t, $J = 7.0$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 201.11, 159.93, 131.93, 131.06, 114.54, 84.67, 68.86, 54.68, 44.53, 34.91, 34.86, 31.46, 28.87, 25.56, 22.57, 18.32, 14.01; MS (ESI) m/z 358.3 $[\text{M}+\text{H}]^+$.

1-(3,5-Dichloro-4-(hexyloxy)phenyl)-3-(morpholino)propan-1-one 17{1,4,3}

Yield 81%; ^1H NMR (400 MHz, CDCl_3) δ 6.76 (s, 2H), 3.87 (t, $J = 6.5$, 2H), 3.67 – 3.54 (m, 4H), 2.96 (t, $J = 7.3$, 2H), 2.73 (t, $J = 7.3$, 2H), 2.48 – 2.34 (m, 4H), 1.78 – 1.62 (m, 3H), 1.44 – 1.33 (m, 2H), 1.33 – 1.21 (m, 4H), 0.90 – 0.74 (m, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 201.23, 159.93, 131.89, 131.17, 114.56, 68.88, 66.91, 53.73, 53.58, 52.63, 41.48, 31.46, 28.87, 25.55, 22.56, 14.02; MS (ESI) m/z 388.3 $[\text{M}+\text{H}]^+$.

4-(3-(3,5-Dichloro-4-(hexyloxy)phenyl)-3-oxopropyl)piperazin-2-one 17{1,4,4}. Yield 70%;

^1H NMR (400 MHz, CDCl_3) δ 6.85 (s, 2H), 6.68 (s, 1H), 3.95 (t, $J = 6.5$, 2H), 3.36 (brs, 2H), 3.17 (s, 2H), 3.04 (t, $J = 7.0$, 2H), 2.89 (t, $J = 7.0$, 2H), 2.76 – 2.64 (m, 2H), 1.83 – 1.72 (m, 2H), 1.50 – 1.40 (m, 2H), 1.40 – 1.29 (m, $J = 8.7$, 4H), 0.92 (t, $J = 7.0$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 200.75, 169.36, 160.03, 131.61, 131.16, 114.61, 68.90, 56.75, 51.27, 49.15, 41.61, 41.27, 31.45, 28.86, 25.55, 22.56, 14.02; MS (ESI) m/z 401.3 $[\text{M}+\text{H}]^+$.

3-(4-Acetylpiperazin-1-yl)-1-(3,5-dichloro-4-(hexyloxy)phenyl)propan-1-one 17{1,4,5}. Yield

52%; ^1H NMR (400 MHz, CDCl_3) δ 6.85 (s, 2H), 3.95 (t, $J = 6.5$, 2H), 3.64 – 3.54 (m, 2H), 3.50 – 3.40 (m, 2H), 3.04 (t, $J = 7.2$, 2H), 2.83 (t, $J = 7.2$, 2H), 2.54 – 2.37 (m, 4H), 2.10 (s, 3H), 1.82 – 1.72 (m, 2H), 1.50 – 1.40 (m, 2H), 1.40 – 1.28 (m, 4H), 0.95 – 0.86 (m, 3H); ^{13}C NMR (101 MHz,

CDCl₃) δ 201.10, 168.92, 159.97, 131.78, 131.17, 114.57, 68.89, 53.25, 52.61, 52.09, 46.21, 41.62, 41.32, 31.45, 28.86, 25.55, 22.56, 21.33, 14.01; MS (ESI) m/z 429.4 [M+H]⁺.

1-(3,5-Dichloro-4-(hexyloxy)phenyl)-3-(4-(ethylsulfonyl)piperazin-1-yl)propan-1-one

17{1,4,6}.

Yield 63%; ¹H NMR (400 MHz, CDCl₃) δ 6.77 (s, 2H), 3.87 (t, J = 6.5, 2H), 3.30 – 3.15 (m, 4H), 2.94 (t, J = 7.1, 2H), 2.87 (q, J = 7.4, 2H), 2.78 (t, J = 7.1, 2H), 2.58 – 2.41 (m, 4H), 1.75 – 1.64 (m, 2H), 1.42 – 1.32 (m, 2H), 1.32 – 1.21 (m, 7H), 0.84 (t, J = 7.0, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 200.95, 159.99, 131.74, 131.17, 114.59, 68.91, 52.69, 51.92, 45.71, 43.78, 41.52, 31.46, 28.87, 25.55, 22.56, 14.02, 7.80; MS (ESI) m/z 479.5 [M+H]⁺.

17{1,5,1}

Same with **12{22}**

1-(4-(Hexyloxy)-2,6-dimethylphenyl)-3-(2-methylaziridin-1-yl)propan-1-one **17{1,5,2}**. Yield 62%; ¹H NMR (400 MHz, CDCl₃) δ 6.56 (s, 2H), 3.94 (t, J = 6.6, 2H), 3.03 – 2.93 (m, 2H), 2.70 – 2.55 (m, 2H), 2.22 (d, J = 13.8, 6H), 1.81 – 1.65 (m, 2H), 1.50 – 1.41 (m, 4H), 1.41 – 1.25 (m, 5H), 1.17 (d, J = 5.1, 3H), 0.92 (t, J = 7.0, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 209.00, 159.06, 134.90, 134.61, 113.73, 67.87, 55.13, 45.39, 34.94, 34.85, 31.58, 29.22, 25.72, 22.62, 19.60, 18.34, 14.05; MS (ESI) m/z 346.3 [M+H]⁺.

1-(4-(Hexyloxy)-2,6-dimethylphenyl)-3-morpholinopropan-1-one **17{1,5,3}**. Yield 71%; ¹H NMR (400 MHz, CDCl₃) δ 6.56 (s, 2H), 3.94 (t, J = 6.6, 2H), 3.77 – 3.66 (m, 4H), 2.91 (t, J = 7.0,

2H), 2.78 (t, $J = 7.2$, 2H), 2.48 (brs, 4H), 2.24 (s, 6H), 1.84 – 1.70 (m, 2H), 1.51 – 1.40 (m, 2H), 1.40 – 1.29 (m, 4H), 0.92 (t, $J = 7.0$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 208.99, 159.11, 134.79, 113.78, 67.88, 66.85, 53.68, 53.32, 42.21, 31.58, 29.21, 25.71, 22.62, 19.75, 14.05; MS (ESI) m/z 348.5 $[\text{M}+\text{H}]^+$.

4-(3-(4-(Hexyloxy)-2,6-dimethylphenyl)-3-oxopropyl)piperazin-2-one **17**{1,5,4}. Yield 49%;

^1H NMR (400 MHz, CDCl_3) δ 6.47 (s, 2H), 6.35 (brs, 1H), 3.86 (t, $J = 6.6$, 2H), 3.35 (brs, 2H), 3.10 (s, 2H), 2.88 – 2.75 (m, 4H), 2.70 – 2.59 (m, 2H), 2.15 (s, 6H), 1.75 – 1.63 (m, 2H), 1.44 – 1.31 (m, 2H), 1.31 – 1.21 (m, 4H), 0.84 (t, $J = 7.0$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 208.39, 159.22, 134.79, 134.47, 113.86, 67.90, 56.69, 51.99, 49.28, 42.31, 41.14, 31.57, 29.20, 25.71, 22.62, 19.72, 14.05; MS (ESI) m/z 361.5 $[\text{M}+\text{H}]^+$.

3-(4-Acetylpiperazin-1-yl)-1-(4-(hexyloxy)-2,6-dimethylphenyl)propan-1-one **17**{1,5,5}. Yield

71%; ^1H NMR (400 MHz, CDCl_3) δ 6.55 (s, 2H), 3.93 (t, $J = 6.6$, 2H), 3.64 – 3.54 (m, 2H), 3.50 – 3.39 (m, 2H), 2.90 (t, $J = 6.8$, 2H), 2.79 (t, $J = 7.0$, 2H), 2.52 – 2.46 (m, 2H), 2.46 – 2.40 (m, 2H), 2.23 (s, 6H), 2.08 (s, 3H), 1.81 – 1.67 (m, 2H), 1.50 – 1.39 (m, $J = 14.0$, 2H), 1.39 – 1.26 (m, 4H), 0.91 (t, $J = 7.0$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 208.84, 168.94, 159.15, 134.78, 134.69, 113.81, 67.89, 53.39, 52.76, 52.70, 46.16, 42.39, 41.26, 31.57, 29.20, 25.70, 22.61, 21.31, 19.77, 14.05; MS (ESI) m/z 389.6 $[\text{M}+\text{H}]^+$.

3-(4-(Ethylsulfonyl)piperazin-1-yl)-1-(4-(hexyloxy)-2,6-dimethylphenyl)propan-1-one

17{1,5,6}. Yield 29%; ^1H NMR (400 MHz, CDCl_3) δ 6.56 (s, 2H), 3.94 (t, $J = 6.6$, 2H), 3.32 (brs, 4H), 2.97 (q, $J = 7.4$, 2H), 2.93 – 2.80 (m, 4H), 2.59 (s, 4H), 2.24 (s, 6H), 1.85 – 1.70 (m, 2H),
S64

1.53 – 1.42 (m, 2H), 1.42 – 1.31 (m, $J = 6.9, 14.3, 7\text{H}$), 0.92 (t, $J = 7.0, 3\text{H}$); ^{13}C NMR (101 MHz, CDCl_3) δ 208.58, 159.19, 134.77, 134.60, 113.83, 67.91, 52.83, 52.59, 45.60, 43.92, 42.23, 31.57, 29.21, 25.71, 22.62, 19.78, 14.05, 7.81; MS (ESI) m/z 439.6 $[\text{M}+\text{H}]^+$.

1-(2-Chloro-4-(hexylthio)phenyl)-3-(dimethylamino)propan-1-one 17{2,1,1}. Yield 89%; ^1H NMR (400 MHz, CDCl_3) δ 7.39 (d, 1H, $J = 8.2$ Hz), 7.19 (t, 1H, $J = 5.1$ Hz), 7.10 (m, 1H), 3.06 (t, 2H, $J = 7.3$ Hz), 2.88 (t, 2H, $J = 7.4$ Hz), 2.64 (t, 2H, $J = 7.3$ Hz), 2.18 (s, 6H), 1.61 (m, 2H), 1.37 (m, 2H), 1.23 (m, 4H), 0.82 (t, 3H, $J = 6.8$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 200.81, 143.68, 134.95, 131.84, 129.80, 128.05, 125.06, 54.25, 45.29, 40.92, 32.23, 31.22, 28.55, 28.44, 22.44, 13.93; MS (ESI) m/z 328.8 $[\text{M}+\text{H}]^+$.

1-(2-Chloro-4-(hexylthio)phenyl)-3-(2-methylaziridin-1-yl)propan-1-one 17{2,1,2}. Yield 85%; ^1H NMR (400 MHz, CDCl_3) δ 7.51 (d, $J = 8.2$, 1H), 7.26 (d, $J = 1.8$, 1H), 7.17 (dd, $J = 1.8, 8.2$, 1H), 3.26 – 3.19 (m, 2H), 2.98 – 2.92 (m, 2H), 2.68 – 2.58 (m, 2H), 1.74 – 1.63 (m, 2H), 1.52 – 1.39 (m, 4H), 1.37 – 1.25 (m, 5H), 1.15 (t, $J = 5.4$, 3H), 0.96 (t, $J = 7.0$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 200.53, 143.94, 134.85, 132.12, 129.95, 128.16, 125.04, 55.94, 43.03, 34.92, 34.89, 32.24, 31.29, 28.60, 28.50, 22.50, 18.31, 14.00; MS (ESI) m/z 340.4 $[\text{M}+\text{H}]^+$.

1-(2-Chloro-4-(hexylthio)phenyl)-3-morpholinopropan-1-one 17{2,1,3}. Yield 82%; ^1H NMR (400 MHz, CDCl_3) δ 7.46 (d, $J = 8.2$, 1H), 7.26 (s, 1H), 7.17 (d, $J = 8.2$, 1H), 3.69 (brs, 5H), 3.16 (t, $J = 7.0$, 2H), 2.97 (t, $J = 7.4$, 2H), 2.78 (t, $J = 7.0$, 2H), 2.50 (brs, 4H), 1.76 – 1.64 (m, 2H), 1.55 – 1.41 (m, 2H), 1.38 – 1.29 (m, 4H), 0.90 (t, $J = 6.3$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 200.89,

143.81, 134.98, 131.87, 129.84, 128.06, 125.07, 66.87, 53.66, 53.49, 40.04, 32.27, 31.29, 28.60, 28.51, 22.51, 14.01; MS (ESI) m/z 370.5 [M+H]⁺.

4-(3-(2-Chloro-4-(hexylthio)phenyl)-3-oxopropyl)piperazin-2-one **17{2,1,4}**. Yield 90%; ¹H NMR (400 MHz, CDCl₃) δ 7.46 (d, J = 8.2, 1H), 7.25 (d, J = 1.6, 1H), 7.16 (dd, J = 1.7, 8.2, 1H), 6.97 (brs, 1H), 3.38 (brs, 2H), 3.22 – 3.09 (m, 4H), 2.96 (t, J = 7.4, 2H), 2.86 (t, J = 7.0, 2H), 2.77 – 2.64 (m, 2H), 1.75 – 1.61 (m, 2H), 1.52 – 1.40 (m, 2H), 1.40 – 1.23 (m, 4H), 0.89 (t, J = 6.5, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 200.25, 169.44, 144.21, 134.58, 131.96, 129.91, 128.02, 125.05, 56.66, 52.28, 49.04, 41.18, 40.18, 32.20, 31.28, 28.57, 28.50, 22.50, 14.01; MS (ESI) m/z 383.5 [M+H]⁺.

3-(4-Acetylpiperazin-1-yl)-1-(2-chloro-4-(hexylthio)phenyl)propan-1-one **17{2,1,5}**. Yield 85%; ¹H NMR (400 MHz, CDCl₃) δ 7.45 (d, J = 8.2, 1H), 7.25 (d, J = 1.7, 1H), 7.16 (dd, J = 1.8, 8.2, 1H), 3.63 – 3.54 (m, 2H), 3.50 – 3.40 (m, 2H), 3.15 (t, J = 7.0, 2H), 2.96 (t, J = 7.4, 2H), 2.80 (t, J = 7.0, 2H), 2.49 – 2.37 (m, 4H), 2.07 (s, 3H), 1.74 – 1.60 (m, 2H), 1.50 – 1.39 (m, 2H), 1.37 – 1.23 (m, 4H), 0.89 (t, J = 6.8, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 200.71, 168.89, 143.98, 134.83, 131.90, 129.83, 128.03, 125.02, 53.14, 53.12, 52.57, 46.19, 41.29, 40.15, 32.23, 31.28, 28.57, 28.50, 22.50, 21.31, 14.01; MS (ESI) m/z 411.5 [M+H]⁺.

1-(2-Chloro-4-(hexylthio)phenyl)-3-(4-(ethylsulfonyl)piperazin-1-yl)propan-1-one **17{2,1,6}**. Yield 86%; ¹H NMR (400 MHz, CDCl₃) δ 7.19 (d, J = 8.2, 1H), 6.99 (d, J = 1.8, 1H), 6.91 (dd, J = 1.8, 8.2, 1H), 3.10 – 2.96 (m, 4H), 2.88 (t, J = 7.0, 2H), 2.77 – 2.63 (m, 4H), 2.57 (t, J = 7.0, 2H), 2.36 – 2.22 (m, 4H), 1.50 – 1.37 (m, 2H), 1.28 – 1.15 (m, 2H), 1.15 – 0.99 (m, 7H), 0.64 (t, J

= 5.8, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 200.29, 143.78, 134.48, 131.67, 129.57, 127.77, 124.76, 52.69, 52.36, 45.43, 43.52, 39.81, 31.97, 31.03, 28.31, 28.24, 22.24, 13.75, 7.53; MS (ESI) m/z 461.6 $[\text{M}+\text{H}]^+$.

1-(2,3-Dichloro-4-(hexylthio)phenyl)-3-(dimethylamino)propan-1-one 17{2,2,1}. Yield 84%; ^1H NMR (400 MHz, CDCl_3) δ 7.28 (d, 1H, $J = 8.3$ Hz), 7.06 (t, 1H, $J = 7.7$ Hz), 3.05 (t, 2H, $J = 7.2$ Hz), 2.88 (t, 2H, $J = 7.4$ Hz), 2.65 (t, 2H, $J = 7.2$ Hz), 2.20 (s, 6H), 1.66 (m, 2H), 1.40 (m, 2H), 1.24 (m, 4H), 0.83 (t, 3H, $J = 6.6$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 200.88, 143.31, 136.57, 130.73, 130.02, 126.68, 123.24, 54.18, 45.22, 40.99, 32.19, 31.26, 28.60, 28.05, 22.44, 13.95; MS (ESI) m/z 363.3 $[\text{M}+\text{H}]^+$.

1-(2,3-Dichloro-4-(hexylthio)phenyl)-3-(2-methylaziridin-1-yl)propan-1-one 17{2,2,2}. Yield 97%; ^1H NMR (400 MHz, CDCl_3) δ 7.40 (d, $J = 8.3$, 1H), 7.13 (d, $J = 8.3$, 1H), 3.20 (t, $J = 7.0$, 2H), 3.01 – 2.89 (m, 2H), 2.64 (t, $J = 7.0$, 2H), 1.81 – 1.66 (m, 2H), 1.53 – 1.39 (m, 4H), 1.39 – 1.24 (m, 5H), 1.14 (d, $J = 5.3$, 3H), 0.91 (t, $J = 6.9$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 200.70, 143.53, 136.58, 130.87, 130.26, 126.81, 123.20, 55.85, 43.22, 34.93, 34.91, 32.24, 31.33, 28.66, 28.10, 22.50, 18.31, 14.01; MS (ESI) m/z 374.4 $[\text{M}+\text{H}]^+$.

1-(2,3-Dichloro-4-(hexylthio)phenyl)-3-morpholinopropan-1-one 17{2,2,3}. Yield 87%; ^1H NMR (400 MHz, CDCl_3) δ 7.35 (d, $J = 8.3$, 1H), 7.13 (d, $J = 8.3$, 1H), 3.74 – 3.61 (m, 4H), 3.14 (t, $J = 7.1$, 2H), 2.96 (t, $J = 7.4$, 2H), 2.77 (t, $J = 7.1$, 2H), 2.46 (brs, 4H), 1.82 – 1.66 (m, 2H), 1.56 – 1.40 (m, 2H), 1.40 – 1.26 (m, 4H), 0.91 (t, $J = 6.9$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 201.07,

143.38, 136.66, 130.75, 130.06, 126.73, 123.23, 66.86, 53.64, 53.46, 40.21, 32.26, 31.33, 28.66, 28.10, 22.50, 14.02; MS (ESI) m/z 404.4 [M+H]⁺.

4-(3-(2,3-Dichloro-4-(hexylthio)phenyl)-3-oxopropyl)piperazin-2-one **17**{2,2,4}Yield 83%; ¹H NMR (400 MHz, CDCl₃) δ 7.26 (d, J = 8.3, 1H), 7.05 (d, J = 8.4, 1H), 6.84 (s, 1H), 3.31 – 3.19 (m, 2H), 3.11 – 3.01 (m, 4H), 2.94 – 2.84 (m, 2H), 2.77 (t, J = 7.0, 2H), 2.64 – 2.53 (m, 2H), 1.72 – 1.60 (m, 2H), 1.48 – 1.35 (m, 2H), 1.32 – 1.19 (m, 4H), 0.88 – 0.74 (m, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 200.50, 169.41, 143.73, 136.31, 130.73, 130.07, 126.76, 123.25, 56.74, 52.26, 48.98, 41.24, 40.42, 32.23, 31.32, 28.66, 28.08, 22.50, 14.02; MS (ESI) m/z 417.4 [M+H]⁺.

3-(4-Acetylpiperazin-1-yl)-1-(2,3-dichloro-4-(hexylthio)phenyl)propan-1-one **17**{2,2,5}. Yield 89%; ¹H NMR (400 MHz, CDCl₃) δ 7.34 (d, J = 8.3, 1H), 7.12 (d, J = 8.3, 1H), 3.57 (brs, 2H), 3.50 – 3.38 (m, 2H), 3.13 (t, J = 6.9, 2H), 2.96 (t, J = 7.4, 2H), 2.79 (t, J = 6.9, 2H), 2.52 – 2.35 (m, 4H), 2.07 (s, 3H), 1.82 – 1.62 (m, 2H), 1.57 – 1.42 (m, J = 7.2, 2H), 1.38 – 1.24 (m, 4H), 0.90 (t, J = 6.9, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 200.86, 168.89, 143.56, 136.50, 130.76, 130.09, 126.72, 123.19, 53.11, 52.56, 46.17, 41.28, 40.34, 32.24, 31.32, 28.66, 28.08, 22.50, 21.32, 14.02; MS (ESI) m/z 445.46 [M+H]⁺.

1-(2,3-Dichloro-4-(hexylthio)phenyl)-3-(4-(ethylsulfonyl)piperazin-1-yl)propan-1-one **17**{2,2,6}. Yield 86%; ¹H NMR (400 MHz, CDCl₃) δ 7.07 (d, J = 8.3, 1H), 6.86 (d, J = 8.3, 1H), 3.00 (brs, 4H), 2.85 (t, J = 6.9, 2H), 2.74 – 2.62 (m, 4H), 2.55 (t, J = 6.9, 2H), 2.36 – 2.18 (m, 4H), 1.58 – 1.40 (m, 2H), 1.29 – 1.16 (m, 2H), 1.16 – 1.01 (m, 7H), 0.73 – 0.55 (m, J = 6.8, 3H); ¹³C

NMR (101 MHz, CDCl₃) δ 200.45, 143.35, 136.15, 130.51, 129.86, 126.42, 122.92, 52.67, 52.34, 45.42, 43.53, 39.99, 31.97, 31.06, 28.40, 27.82, 22.24, 13.76, 7.53; MS (ESI) m/z 495.5 [M+H]⁺.

1-(2,5-Dichloro-4-(hexylthio)phenyl)-3-(dimethylamino)propan-1-one **17**{2,3,1}. Yield 59%;

¹H NMR (400 MHz, CDCl₃) δ 7.50 (s, 1H), 7.08 (s, 1H), 3.06 (t, J = 7.2, 2H), 2.88 (t, J = 7.4, 3H), 2.65 (t, J = 7.2, 2H), 2.19 (s, 6H), 1.72 – 1.63 (m, 2H), 1.46 – 1.34 (m, 2H), 1.33 – 1.22 (m, 5H), 0.84 (t, J = 7.0, 4H); ¹³C NMR (101 MHz, CDCl₃) δ 199.50, 143.13, 135.01, 130.31, 130.20, 130.17, 126.97, 54.22, 45.34, 40.91, 32.01, 31.30, 28.62, 27.99, 22.50, 14.01; MS (ESI) m/z 362.4 [M+H]⁺.

1-(2,5-Dichloro-4-(hexylthio)phenyl)-3-(2-methylaziridin-1-yl)propan-1-one **17**{2,3,2}. Yield

71%; ¹H NMR (400 MHz, CDCl₃) δ 7.61 (s, 1H), 7.17 (s, 1H), 3.22 (t, J = 7.0, 2H), 2.97 (t, J = 7.4, 2H), 2.73 – 2.50 (m, 2H), 1.83 – 1.66 (m, 2H), 1.56 – 1.41 (m, 4H), 1.41 – 1.31 (m, 4H), 1.29 (d, J = 6.3, 1H), 1.15 (d, J = 5.4, 3H), 0.92 (t, J = 7.0, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 199.24, 143.29, 134.91, 130.40, 130.27, 130.23, 127.04, 55.90, 43.00, 34.94, 31.99, 31.29, 28.62, 27.98, 22.49, 18.32, 14.01; MS (ESI) m/z 374.4 [M+H]⁺.

1-(2,5-Dichloro-4-(hexylthio)phenyl)-3-morpholinopropan-1-one **17**{2,3,3}. Yield 92%; ¹H

NMR (400 MHz, CDCl₃) δ 7.56 (s, 1H), 7.16 (s, 1H), 3.74 – 3.63 (m, 4H), 3.14 (t, J = 7.0, 2H), 2.96 (t, J = 7.4, 2H), 2.78 (q, J = 7.0, 2H), 2.47 (brs, 4H), 1.83 – 1.68 (m, 2H), 1.61 – 1.47 (m, 2H), 1.42 – 1.28 (m, 4H), 0.92 (t, J = 7.0, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 199.60, 143.10, 135.02, 130.23, 130.13, 130.11, 126.92, 66.86, 53.60, 53.48, 40.01, 32.00, 31.29, 28.61, 27.97, 22.49, 14.01; MS (ESI) m/z 404.4 [M+H]⁺.

4-(3-(2,5-Dichloro-4-(hexylthio)phenyl)-3-oxopropyl)piperazin-2-one **17**{2,3,4}. Yield 89%;

^1H NMR (400 MHz, CDCl_3) δ 7.56 (s, 1H), 7.16 (s, 1H), 6.90 (brs, 1H), 3.42 (brs, 2H), 3.25 – 3.13 (m, 4H), 2.96 (t, $J = 7.4$, 2H), 2.87 (t, $J = 6.9$, 2H), 2.76 (brs, 2H), 1.81 – 1.66 (m, 2H), 1.57 – 1.43 (m, 2H), 1.43 – 1.26 (m, 4H), 0.91 (t, $J = 7.0$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 198.80, 169.27, 143.57, 134.58, 130.28, 130.28, 130.16, 126.94, 56.62, 52.22, 49.14, 41.17, 40.15, 31.98, 31.28, 28.61, 27.95, 22.49, 14.01; MS (ESI) m/z 417.4 $[\text{M}+\text{H}]^+$.

3-(4-Acetylpiperazin-1-yl)-1-(2,5-dichloro-4-(hexylthio)phenyl)propan-1-one **17**{2,3,5}. Yield

91%; ^1H NMR (400 MHz, CDCl_3) δ 7.55 (d, $J = 1.7$, 1H), 7.15 (d, $J = 1.3$, 1H), 3.59 (brs, 2H), 3.50 (brs, 2H), 3.14 (t, $J = 5.9$, 2H), 2.96 (t, $J = 7.4$, 2H), 2.86 – 2.72 (m, 2H), 2.44 (d, $J = 15.8$, 4H), 2.11 (s, 3H), 1.82 – 1.68 (m, 2H), 1.59 – 1.43 (m, 2H), 1.43 – 1.26 (m, 4H), 0.97 – 0.83 (m, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 199.39, 168.88, 143.27, 134.86, 130.20, 130.15, 130.11, 126.92, 53.16, 53.05, 52.57, 46.17, 41.27, 40.13, 31.99, 31.28, 28.61, 27.95, 22.48, 21.32, 14.01; MS (ESI) m/z 445.5 $[\text{M}+\text{H}]^+$.

1-(2,5-Dichloro-4-(hexylthio)phenyl)-3-(4-(ethylsulfonyl)piperazin-1-yl)propan-1-one

17{2,3,6}. Yield 93%; ^1H NMR (400 MHz, CDCl_3) δ 7.54 (s, 1H), 7.15 (s, 1H), 3.28 (s, 4H), 3.13 (t, $J = 6.8$, 2H), 3.01 – 2.90 (m, 4H), 2.81 (t, $J = 6.7$, 2H), 2.59 (brs, 4H), 1.80 – 1.68 (m, 2H), 1.55 – 1.43 (m, 2H), 1.40 – 1.26 (m, 7H), 0.91 (t, $J = 6.3$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 199.35, 143.29, 134.86, 130.15, 130.12, 126.90, 52.93, 52.62, 45.69, 43.71, 40.05, 31.98, 31.28, 28.61, 27.95, 22.48, 14.01, 7.79; MS (ESI) m/z 495.5 $[\text{M}+\text{H}]^+$.

1-(2,6-Dichloro-4-(hexylthio)phenyl)-3-(dimethylamino)propan-1-one 17{2,4,1}. Yield 92%; ¹H NMR (400 MHz, CDCl₃) δ 7.23 (s, 2H), 3.09 (t, 2H, *J* = 7.4 Hz), 3.00 (m, 2H), 2.84 (m, 2H), 2.35 (s, 6H), 1.72 (m, 2H), 1.50 (m, 2H), 1.37 (m, 4H), 0.96 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 200.83, 142.02, 135.99, 130.62, 126.20, 53.03, 45.29, 42.04, 32.66, 31.20, 28.48, 28.39, 22.44, 13.94; MS (ESI) *m/z* 363.3 [M+H]⁺.

1-(2,6-Dichloro-4-(hexylthio)phenyl)-3-(2-methylaziridin-1-yl)propan-1-one 17{2,4,2}. Yield 100%; ¹H NMR (400 MHz, CDCl₃) δ 7.17 (s, 2H), 3.12 (t, *J* = 7.2, 2H), 2.94 (t, *J* = 7.3, 2H), 2.66 (t, *J* = 7.3, 2H), 1.73 – 1.61 (m, 2H), 1.52 – 1.37 (m, 4H), 1.37 – 1.26 (m, 5H), 1.17 (d, *J* = 5.1, 3H), 0.90 (t, *J* = 6.7, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 200.71, 142.07, 136.01, 130.61, 126.21, 54.51, 44.26, 34.93, 34.86, 32.69, 31.25, 28.52, 28.44, 22.50, 18.31, 14.00; MS (ESI) *m/z* 374.4 [M+H]⁺.

1-(2,6-Dichloro-4-(hexylthio)phenyl)-3-morpholinopropan-1-one 17{2,4,3}. Yield 90%; ¹H NMR (400 MHz, CDCl₃) δ 7.18 (s, 2H), 3.72 – 3.62 (m, 4H), 3.05 (t, *J* = 7.2, 2H), 2.94 (t, *J* = 7.4, 2H), 2.82 (t, *J* = 7.3, 2H), 2.55 (brs, 4H), 1.73 – 1.61 (m, 2H), 1.50 – 1.37 (m, 2H), 1.38 – 1.23 (m, 4H), 0.91 (t, *J* = 6.9, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 200.83, 142.15, 135.94, 130.71, 126.19, 66.84, 53.56, 52.46, 41.18, 32.67, 31.25, 28.51, 28.44, 22.50, 14.00; MS (ESI) *m/z* 404.4 [M+H]⁺.

4-(3-(2,6-Dichloro-4-(hexylthio)phenyl)-3-oxopropyl)piperazin-2-one 17{2,4,4}. Yield 89%; ¹H NMR (400 MHz, CDCl₃) δ 7.09 (s, 2H), 6.84 (brs, 1H), 3.33 – 3.22 (m, 2H), 3.10 (s, 2H), 2.97 (t, *J* = 7.0, 2H), 2.92 – 2.78 (m, 4H), 2.69 – 2.55 (m, 2H), 1.68 – 1.56 (m, 2H), 1.42 – 1.31 (m, 2H), 1.33 – 1.18 (m, 5H), 0.82 (t, *J* = 7.0, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 200.35, 169.31, 142.41,

135.64, 130.67, 126.16, 56.66, 51.08, 49.14, 41.32, 41.16, 32.63, 31.25, 28.49, 28.44, 22.49; MS (ESI) m/z 417.4 $[M+H]^+$.

3-(4-Acetylpiperazin-1-yl)-1-(2,6-dichloro-4-(hexylthio)phenyl)propan-1-one **17{2,4,5}**. Yield 70%; ^1H NMR (400 MHz, CDCl_3) δ 7.18 (s, 2H), 3.59 (brs, 2H), 3.50 – 3.37 (m, 2H), 3.04 (t, $J = 7.0$, 2H), 2.94 (t, $J = 7.4$, 2H), 2.90 – 2.78 (m, 2H), 2.47 (d, $J = 19.8$, 4H), 2.08 (s, 3H), 1.76 – 1.62 (m, 2H), 1.51 – 1.39 (m, 2H), 1.38 – 1.25 (m, 4H), 0.90 (t, $J = 6.8$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 200.71, 168.90, 142.27, 135.81, 130.69, 126.16, 53.23, 52.60, 51.91, 46.15, 41.33, 41.26, 32.64, 31.25, 28.49, 28.43, 22.49, 21.32, 14.00; MS (ESI) m/z 445.5 $[M+H]^+$.

1-(2,6-Dichloro-4-(hexylthio)phenyl)-3-(4-(ethylsulfonyl)piperazin-1-yl)propan-1-one **17{2,4,6}**. Yield 87%; ^1H NMR (400 MHz, CDCl_3) δ 6.91 (s, 2H), 3.03 (s, 4H), 2.76 (t, $J = 7.0$, 2H), 2.68 (q, $J = 7.4$, 4H), 2.60 (t, $J = 7.0$, 2H), 2.31 (s, 4H), 1.49 – 1.35 (m, 2H), 1.25 – 1.15 (m, 2H), 1.15 – 1.00 (m, 8H), 0.64 (t, $J = 5.4$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 200.30, 142.06, 135.52, 130.43, 125.88, 52.41, 51.48, 45.39, 43.53, 40.96, 32.37, 30.99, 28.23, 28.17, 22.23, 13.74, 7.53; MS (ESI) m/z 495.5 $[M+H]^+$.

3-(Dimethylamino)-1-(4-(hexylthio)-2,6-dimethylphenyl)propan-1-one **17{2,5,1}**. Yield 93%; ^1H NMR (400 MHz, CDCl_3) δ 6.90 (s, 2H), 2.84 (m, 4H), 2.66 (t, 2H, $J = 7.3$ Hz), 2.22 (s, 6H), 2.16 (s, 6H), 1.59 (m, 2H), 1.36 (m, 2H), 1.31 (m, 4H), 0.84 (t, 3H, $J = 6.9$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 208.86, 139.45, 137.74, 133.32, 127.34, 53.62, 45.35, 43.01, 32.97, 31.26, 28.93, 28.44, 22.46, 19.17, 13.94; MS (ESI) m/z 322.5 $[M+H]^+$.

1-(4-(Hexylthio)-2,6-dimethylphenyl)-3-(2-methylaziridin-1-yl)propan-1-one **17{2,5,2}**. Yield 82%; ¹H NMR (400 MHz, CDCl₃) δ 6.87 (s, 2H), 2.89 (t, *J* = 7.0, 2H), 2.87 – 2.78 (m, 2H), 2.62 – 2.43 (m, 2H), 2.14 (s, 6H), 1.62 – 1.49 (m, 2H), 1.44 – 1.28 (m, 4H), 1.28 – 1.18 (m, 5H), 1.08 (d, *J* = 5.1, 3H), 0.82 (t, *J* = 6.9, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 208.76, 139.53, 137.78, 133.33, 127.40, 54.91, 45.12, 34.98, 34.87, 33.06, 31.35, 29.01, 28.53, 22.54, 19.22, 18.34, 14.03; MS (ESI) *m/z* 334.5 [M+H]⁺.

1-(4-(Hexylthio)-2,6-dimethylphenyl)-3-morpholinopropan-1-one **17{2,5,3}**. Yield 84%; ¹H NMR (400 MHz, CDCl₃) δ 6.95 (s, 2H), 3.78 – 3.64 (m, 4H), 2.98 – 2.86 (m, 4H), 2.78 (t, *J* = 6.9, 2H), 2.57 (brs, 4H), 2.29 (s, 6H), 1.74 – 1.58 (m, 2H), 1.49 – 1.38 (m, 2H), 1.38 – 1.24 (m, 4H), 0.90 (t, *J* = 6.9, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 208.78, 139.38, 137.94, 133.46, 127.37, 66.83, 53.69, 53.08, 41.99, 32.99, 31.35, 28.99, 28.53, 22.54, 19.36, 14.04; MS (ESI) *m/z* 365.6 [M+H]⁺.

4-(3-(4-(Hexylthio)-2,6-dimethylphenyl)-3-oxopropyl)piperazin-2-one **17{2,5,4}**. Yield 85%; ¹H NMR (400 MHz, CDCl₃) δ 6.87 (s, 2H), 6.54 (br, 1H), 3.33 (brs, 2H), 3.16 (brs, 2H), 2.87 – 2.73 (m, 6H), 2.69 (brs, 2H), 2.14 (s, 6H), 1.64 – 1.50 (m, 2H), 1.41 – 1.30 (m, 2H), 1.30 – 1.15 (m, 4H), 0.82 (t, *J* = 7.0, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 208.23, 139.09, 138.19, 133.43, 132.07, 127.35, 56.73, 51.73, 49.30, 42.14, 41.13, 32.95, 31.34, 28.98, 28.53, 22.54, 19.32, 14.04; MS (ESI) *m/z* 377.6 [M+H]⁺.

3-(4-Acetylpiperazin-1-yl)-1-(4-(hexylthio)-2,6-dimethylphenyl)propan-1-one **17{2,5,5}** Yield 68%; ¹H NMR (400 MHz, CDCl₃) δ 6.95 (s, 2H), 3.59 (brs, 2H), 3.50 (brs, 2H), 2.95 – 2.85 (m, 4H), 2.85 – 2.73 (m, 2H), 2.43 (t, *J* = 20.3, 4H), 2.22 (s, 6H), 2.12 (s, 3H), 1.73 – 1.57 (m, 2H), 1.50

– 1.38 (m, 2H), 1.38 – 1.24 (m, 4H), 0.90 (t, $J = 6.9$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 208.61, 168.91, 139.28, 138.04, 133.44, 127.34, 53.41, 52.72, 52.50, 46.15, 42.18, 41.24, 32.96, 31.34, 28.98, 28.52, 22.53, 21.32, 19.37, 14.03; MS (ESI) m/z 405.6 $[\text{M}+\text{H}]^+$.

3-(4-(Ethylsulfonyl)piperazin-1-yl)-1-(4-(hexylthio)-2,6-dimethylphenyl)propan-1-one

17{2,5,6}. Yield 52%; ^1H NMR (400 MHz, CDCl_3) δ 6.87 (s, 2H), 3.12 (brs, 4H), 2.93 – 2.71 (m, 8H), 2.58 (brs, 4H), 2.14 (s, 6H), 1.62 – 1.51 (m, 2H), 1.37 (d, $J = 7.9$, 2H), 1.32 (t, $J = 7.4$, 3H), 1.26 – 1.19 (m, 4H), 0.82 (t, $J = 7.0$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 208.40, 138.14, 133.42, 132.04, 127.35, 52.86, 52.52, 52.33, 45.58, 43.97, 32.96, 31.35, 28.98, 28.53, 22.54, 19.39, 14.04, 7.81; MS (ESI) m/z 455.7 $[\text{M}+\text{H}]^+$.

1-(2-Chloro-4-(hexylsulfonyl)phenyl)-3-(dimethylamino)propan-1-one **17**{3,1,1}. Yield 91%;

^1H NMR (400 MHz, CDCl_3) δ 7.89 (d, 1H, $J = 8.0$ Hz), 7.77 (dd, 1H, $J = 1.6, 8.0$ Hz), 7.55 (m, 1H), 3.04 (m, 4H), 2.64 (t, 1H, $J = 7.0$ Hz), 2.18 (s, 4H), 2.04 (s, 1H), 1.64 (m, 2H), 1.31 (m, 2H), 1.20 (m, 4H), 0.80 (t, 3H, $J = 6.8$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 201.62, 144.19, 141.93, 131.47, 129.76, 129.48, 126.50, 56.23, 53.84, 45.16, 41.29, 31.05, 27.84, 22.46, 22.22, 13.83; MS (ESI) m/z 360.0 $[\text{M}+\text{H}]^+$.

1-(2-Chloro-4-(hexylsulfonyl)phenyl)-3-(2-methylaziridin-1-yl)propan-1-one **17**{3,1,2}. Yield

40%; ^1H NMR (400 MHz, CDCl_3) δ 7.98 (s, 1H), 7.86 (d, $J = 8.0$, 1H), 7.67 (d, $J = 8.0$, 1H), 3.21 (t, $J = 6.8$, 2H), 3.17 – 3.06 (m, 2H), 2.66 (t, $J = 6.8$, 2H), 1.80 – 1.65 (m, 2H), 1.51 – 1.45 (m, 1H), 1.45 – 1.35 (m, 2H), 1.35 – 1.22 (m, 4H), 1.15 (d, $J = 5.3$, 3H), 0.94 – 0.79 (m, 4H); ^{13}C NMR (101

MHz, CDCl₃) δ 201.45, 144.26, 142.08, 131.73, 129.95, 129.54, 126.58, 56.30, 55.44, 43.47, 34.99, 31.12, 27.92, 22.53, 22.29, 18.28, 13.91; MS (ESI) *m/z* 372.4 [M+H]⁺.

1-(2-Chloro-4-(hexylsulfonyl)phenyl)-3-morpholinopropan-1-one **17**{3,1,3}. Yield 23%; ¹H NMR (400 MHz, CDCl₃) δ 7.84 (d, *J* = 1.5, 1H), 7.73 (dd, *J* = 1.7, 8.0, 1H), 7.50 (d, *J* = 8.0, 1H), 3.58 – 3.46 (m, 4H), 3.08 – 2.95 (m, 4H), 2.63 (t, *J* = 6.9, 2H), 2.36 – 2.24 (m, 4H), 1.66 – 1.48 (m, 3H), 1.31 – 1.21 (m, 2H), 1.21 – 1.06 (m, 4H), 0.75 (t, *J* = 6.9, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 201.75, 144.21, 142.05, 131.59, 129.88, 129.53, 126.51, 66.86, 56.30, 53.41, 53.26, 40.49, 31.13, 27.92, 22.54, 22.29, 13.91; MS (ESI) *m/z* 402.5 [M+H]⁺.

4-(3-(2-Chloro-4-(hexylsulfonyl)phenyl)-3-oxopropyl)piperazin-2-one **17**{3,1,4}. Yield 34%; ¹H NMR (400 MHz, C CDCl₃) δ 7.98 (d, *J* = 1.6, 1H), 7.87 (dd, *J* = 1.6, 8.0, 1H), 7.61 (d, *J* = 8.0, 1H), 6.42 (s, 1H), 3.38 – 3.30 (m, 2H), 3.23 – 3.08 (m, 6H), 2.87 (t, *J* = 6.8, 2H), 2.80 – 2.62 (m, 2H), 1.82 – 1.67 (m, 2H), 1.39 (dd, *J* = 7.1, 14.3, 2H), 1.35 – 1.19 (m, 4H), 0.88 (t, *J* = 6.9, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 201.01, 168.94, 143.89, 142.30, 131.66, 129.99, 129.52, 126.65, 56.69, 56.29, 51.87, 49.08, 41.27, 40.67, 31.12, 27.92, 22.49, 22.29, 13.91; MS (ESI) *m/z* 415.5 [M+H]⁺.

3-(4-Acetylpiperazin-1-yl)-1-(2-chloro-4-(hexylsulfonyl)phenyl)propan-1-one **17**{3,1,5}. Yield 38%; ¹H NMR (400 MHz, CDCl₃) δ 7.98 (d, *J* = 1.5, 1H), 7.86 (dd, *J* = 1.6, 8.0, 1H), 7.62 (d, *J* = 8.0, 1H), 3.64 – 3.52 (m, 2H), 3.47 – 3.39 (m, 2H), 3.20 – 3.06 (m, 4H), 2.79 (t, *J* = 6.9, 2H), 2.51 – 2.35 (m, 4H), 2.09 (s, 3H), 1.73 (dt, *J* = 7.7, 15.5, 3H), 1.46 – 1.34 (m, 2H), 1.34 (d, *J* = 3.3, 4H), 0.88 (t, *J* = 6.8, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 201.47, 168.92, 144.06, 142.16, 131.65,

129.95, 129.48, 126.54, 56.28, 53.13, 52.69, 52.53, 46.18, 41.29, 40.65, 31.12, 27.91, 22.52, 22.28, 21.32, 13.91; MS (ESI) m/z 443.5 $[M+H]^+$.

1-(2-Chloro-4-(hexylsulfonyl)phenyl)-3-(4-(ethylsulfonyl)piperazin-1-yl)propan-1-one

17{3,1,6}. Yield 21%; ^1H NMR (400 MHz, CDCl_3) δ 7.98 (d, $J = 1.6$, 1H), 7.87 (dd, $J = 1.7$, 8.0, 1H), 7.61 (d, $J = 8.0$, 1H), 3.35 – 3.23 (m, 4H), 3.20 – 3.06 (m, 4H), 2.96 (q, $J = 7.4$, 2H), 2.83 (t, $J = 6.8$, 2H), 2.63 – 2.50 (m, 4H), 1.81 – 1.68 (m, 2H), 1.46 – 1.35 (m, 5H), 1.35 – 1.20 (m, 4H), 0.89 (t, $J = 6.9$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 201.32, 144.00, 142.22, 131.69, 129.99, 129.44, 126.56, 56.28, 52.63, 52.54, 45.69, 43.91, 40.54, 31.13, 27.92, 22.52, 22.29, 13.91, 7.81; MS (ESI) m/z 493.6 $[M+H]^+$.

1-(2,3-Dichloro-4-(hexylsulfonyl)phenyl)-3-(dimethylamino)propan-1-one **17{3,2,1}**. Yield

88%; ^1H NMR (400 MHz, CDCl_3) δ 8.12 (d, 1H, $J = 8.1$ Hz), 7.47 (d, 1H, $J = 8.1$ Hz), 3.42 (m, 2H), 3.09 (t, 2H, $J = 6.9$), 2.71 (t, 2H, $J = 7.0$ Hz), 2.25 (s, 6H), 1.69 (m, 2H), 1.41 (m), 1.27 (m, 4H), 0.86 (t, 3H, $J = 6.9$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 201.29, 146.28, 139.57, 132.28, 131.23, 129.95, 125.89, 54.11, 53.84, 45.19, 41.38, 31.06, 27.87, 22.32, 22.22, 13.86; MS (ESI) m/z 395.3 $[M+H]^+$.

1-(2,3-Dichloro-4-(hexylsulfonyl)phenyl)-3-(2-methylaziridin-1-yl)propan-1-one **17{3,2,2}**.

Yield 66%; ^1H NMR (400 MHz, CDCl_3) δ 8.12 (d, $J = 8.1$, 1H), 7.50 (d, $J = 8.1$, 1H), 3.47 – 3.37 (m, 2H), 3.15 (t, $J = 6.8$, 2H), 2.64 (t, $J = 6.8$, 2H), 1.76 – 1.59 (m, 2H), 1.45 – 1.34 (m, 2H), 1.34 – 1.21 (m, 5H), 1.14 (d, $J = 5.3$, 3H), 0.87 (t, $J = 6.9$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 201.01,

146.34, 139.73, 132.43, 131.41, 130.02, 125.91, 55.33, 54.14, 43.44, 34.98, 34.95, 31.09, 27.90, 22.37, 22.27, 18.29, 13.90; MS (ESI) m/z 406.4 $[M+H]^+$.

1-(2,3-Dichloro-4-(hexylsulfonyl)phenyl)-3-morpholinopropan-1-one **17{3,2,3}**. Yield 44%;

^1H NMR (400 MHz, CDCl_3) δ 8.13 (d, $J = 8.1$, 1H), 7.49 (d, $J = 8.1$, 1H), 3.69 – 3.63 (m, 4H), 3.51 – 3.36 (m, 2H), 3.10 (t, $J = 6.9$, 2H), 2.74 (t, $J = 6.9$, 2H), 2.51 – 2.38 (m, 4H), 1.75 – 1.65 (m, 2H), 1.49 – 1.35 (m, 2H), 1.35 – 1.17 (m, 4H), 0.88 (t, $J = 7.0$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 201.25, 146.21, 139.71, 132.39, 131.35, 129.93, 125.94, 66.85, 54.14, 53.39, 53.20, 40.47, 31.10, 27.91, 22.38, 22.27, 13.91; MS (ESI) m/z 436.4 $[M+H]^+$.

4-(3-(2,3-Dichloro-4-(hexylsulfonyl)phenyl)-3-oxopropyl)piperazin-2-one **17{3,2,4}**. Yield

69%; ^1H NMR (400 MHz, CDCl_3) δ 8.11 (d, $J = 8.1$, 1H), 7.45 (d, $J = 8.1$, 1H), 6.94 (s, 1H), 3.49 – 3.37 (m, 2H), 3.32 (brs, 2H), 3.20 – 3.05 (m, 4H), 2.93 (t, $J = 6.6$, 2H), 2.75 (brs, 2H), 1.77 – 1.63 (m, 2H), 1.46 – 1.35 (m, 2H), 1.35 (brs, 4H), 0.96 – 0.79 (m, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 200.56, 169.13, 145.93, 139.92, 132.51, 131.38, 130.06, 125.86, 56.62, 54.14, 51.77, 49.03, 41.17, 40.64, 31.09, 27.90, 22.31, 22.27, 13.91; MS (ESI) m/z 449.4 $[M+H]^+$.

3-(4-Acetylpiperazin-1-yl)-1-(2,3-dichloro-4-(hexylsulfonyl)phenyl)propan-1-one **17{3,2,5}**.

Yield 86%; ^1H NMR (400 MHz, CDCl_3) δ 8.11 (d, $J = 8.1$, 1H), 7.46 (d, $J = 8.1$, 1H), 3.56 (d, $J = 4.6$, 2H), 3.47 – 3.38 (m, 4H), 3.09 (t, $J = 6.8$, 2H), 2.76 (t, $J = 6.8$, 2H), 2.46 – 2.35 (m, 4H), 2.06 (s, 3H), 1.75 – 1.62 (m, 2H), 1.45 – 1.33 (m, 2H), 1.33 – 1.20 (m, 4H), 0.86 (t, $J = 6.8$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 200.98, 168.89, 146.06, 139.80, 132.46, 131.39, 129.94, 125.87, 54.12,

53.10, 52.61, 52.51, 46.16, 41.26, 40.62, 31.09, 27.88, 22.35, 22.25, 21.31, 13.90; MS (ESI) m/z 477.5 $[M+H]^+$.

1-(2,3-Dichloro-4-(hexylsulfonyl)phenyl)-3-(4-(ethylsulfonyl)piperazin-1-yl)propan-1-one

17{3,2,6}. Yield 38%; ^1H NMR (400 MHz, CDCl_3) δ 8.13 (d, $J = 8.1$, 1H), 7.45 (d, $J = 8.1$, 1H), 3.48 – 3.38 (m, 2H), 3.32 – 3.21 (m, 4H), 3.10 (t, $J = 6.7$, 2H), 2.96 (q, $J = 7.4$, 2H), 2.81 (t, $J = 6.7$, 2H), 2.59 – 2.46 (m, 4H), 1.77 – 1.64 (m, 2H), 1.48 – 1.34 (m, $J = 22.9$, 5H), 1.34 – 1.23 (m, 4H), 0.88 (t, $J = 6.8$, 3H); MS (ESI) m/z 527.5 $[M+H]^+$.

1-(2,3-Dichloro-4-(hexylsulfonyl)phenyl)-3-(dimethylamino)propan-1-one **17{3,3,1}**. Yield

57%; ^1H NMR (400 MHz, CDCl_3) δ 8.08 (s, 1H), 7.53 (s, 1H), 3.39 – 3.28 (m, 3H), 3.05 (t, $J = 6.9$, 2H), 2.68 (t, $J = 6.9$, 2H), 2.23 (s, 6H), 1.73 – 1.55 (m, 2H), 1.41 – 1.31 (m, 2H), 1.31 – 1.16 (m, 4H), 0.80 (t, $J = 6.9$, 5H); ^{13}C NMR (101 MHz, CDCl_3) δ 200.29, 144.84, 139.05, 133.16, 131.92, 131.34, 129.63, 54.31, 53.85, 45.19, 41.31, 31.08, 27.90, 22.30, 22.27, 13.90; MS (ESI) m/z 394.4 $[M+H]^+$.

1-(2,3-Dichloro-4-(hexylsulfonyl)phenyl)-3-(2-methylaziridin-1-yl)propan-1-one **17{3,3,2}**.

Yield 74%; ^1H NMR (400 MHz, CDCl_3) δ 8.17 (s, 1H), 7.67 (s, 1H), 3.48 – 3.35 (m, 2H), 3.19 (t, $J = 6.8$, 2H), 2.65 (t, $J = 6.7$, 2H), 1.76 – 1.66 (m, 2H), 1.48 – 1.35 (m, 3H), 1.35 – 1.24 (m, 6H), 1.15 (d, $J = 5.4$, 3H), 0.94 (t, $J = 6.9$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 200.11, 144.86, 139.16, 133.27, 131.97, 131.35, 129.83, 55.47, 54.31, 43.40, 35.00, 31.08, 27.91, 22.30, 22.27, 18.28, 13.90; MS (ESI) m/z 406.4 $[M+H]^+$.

1-(2,5-Dichloro-4-(hexylsulfonyl)phenyl)-3-morpholinopropan-1-one 17{3,3,3}. Yield 73%;

^1H NMR (400 MHz, CDCl_3) δ 8.09 (s, 1H), 7.56 (s, 1H), 3.64 – 3.55 (m, 4H), 3.38 – 3.27 (m, 2H), 3.04 (t, $J = 6.8$, 2H), 2.66 (t, $J = 6.8$, 2H), 2.42 – 2.32 (m, 4H), 1.72 – 1.55 (m, 2H), 1.41 – 1.28 (m, 2H), 1.28 – 1.14 (m, 4H), 0.80 (t, $J = 7.0$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 200.45, 144.87, 139.08, 133.16, 131.96, 131.25, 129.60, 66.85, 54.32, 53.39, 53.26, 40.44, 31.08, 27.90, 22.30, 22.26, 13.90; MS (ESI) m/z 436.4 $[\text{M}+\text{H}]^+$.

4-(3-(2,3-Dichloro-4-(hexylsulfonyl)phenyl)-3-oxopropyl)piperazin-2-one 17{3,3,4}. Yield 77%;

^1H NMR (400 MHz, CDCl_3) δ 8.10 (s, 1H), 7.52 (s, 1H), 6.55 (s, 1H), 3.38 – 3.30 (m, 2H), 3.30 – 3.22 (m, 2H), 3.12 – 3.03 (m, 4H), 2.78 (t, $J = 6.8$, 2H), 2.65 – 2.56 (m, 2H), 1.70 – 1.58 (m, 2H), 1.40 – 1.29 (m, 2H), 1.26 – 1.15 (m, 4H), 0.81 (t, $J = 6.9$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 199.55, 168.97, 144.45, 139.39, 133.32, 131.88, 131.46, 129.76, 56.59, 54.32, 51.82, 49.14, 41.21, 40.60, 31.08, 27.90, 22.27, 22.24, 13.91; MS (ESI) m/z 449.4 $[\text{M}+\text{H}]^+$.

3-(4-Acetylpiperazin-1-yl)-1-(2,3-dichloro-4-(hexylsulfonyl)phenyl)propan-1-one 17{3,3,5}.

Yield 60%; ^1H NMR (400 MHz, CDCl_3) δ 8.16 (s, 1H), 7.61 (s, 1H), 3.65 – 3.52 (m, 2H), 3.46 – 3.33 (m, 4H), 3.12 (t, $J = 6.8$, 2H), 2.76 (t, $J = 6.8$, 2H), 2.47 – 2.33 (m, 4H), 2.08 (s, 3H), 1.78 – 1.62 (m, 2H), 1.47 – 1.36 (m, 2H), 1.34 – 1.20 (m, 4H), 0.87 (t, $J = 7.0$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 200.13, 168.90, 144.68, 139.19, 133.22, 131.89, 131.28, 129.67, 54.30, 53.10, 52.65, 52.51, 46.15, 41.26, 40.59, 31.07, 27.88, 22.27, 22.25, 21.32, 13.90; MS (ESI) m/z 477.5 $[\text{M}+\text{H}]^+$.

1-(2,3-Dichloro-4-(hexylsulfonyl)phenyl)-3-(4-(ethylsulfonyl)piperazin-1-yl)propan-1-one

17{3,3,6}. Yield 56%; ^1H NMR (400 MHz, CDCl_3) δ 8.18 (s, 1H), 7.61 (s, 1H), 3.45 – 3.37 (m, 2H), 3.34 – 3.25 (m, 4H), 3.13 (t, $J = 6.7$, 2H), 2.96 (q, $J = 7.4$, 2H), 2.81 (t, $J = 6.7$, 2H), 2.59 – 2.46 (m, 4H), 1.78 – 1.68 (m, 2H), 1.48 – 1.35 (m, 5H), 1.35 – 1.21 (m, 4H), 0.89 (t, $J = 7.0$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 200.03, 144.66, 139.27, 133.28, 131.87, 131.29, 129.73, 54.33, 52.62, 52.56, 45.69, 43.86, 40.49, 31.08, 27.90, 22.27, 13.91, 7.80; MS (ESI) m/z 527.5 $[\text{M}+\text{H}]^+$.

1-(2,6-Dichloro-4-(hexylsulfonyl)phenyl)-3-(dimethylamino)propan-1-one **17{3,4,1}**. Yield 93%; ^1H NMR (400 MHz, CDCl_3) δ 7.80 (s, 2H), 3.05 (m, 5H), 2.76 (t, 2H, $J = 7.3$ Hz), 2.24 (s, 6H), 1.68 (m, 2H), 1.34 (m, 2H), 1.24 (m, 4H), 0.84 (t, 4H, $J = 6.8$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 199.62, 143.94, 141.84, 131.90, 127.68, 56.31, 52.71, 45.24, 41.51, 31.05, 27.85, 22.42, 22.24, 13.84; MS (ESI) m/z 395.3 $[\text{M}+\text{H}]^+$.

1-(2,6-Dichloro-4-(hexylsulfonyl)phenyl)-3-(4-(ethylsulfonyl)piperazin-1-yl)propan-1-one **17{3,4,2}**. Yield 59%; ^1H NMR (400 MHz, CDCl_3) δ 7.86 (s, 2H), 3.17 – 3.08 (m, 4H), 2.78 – 2.62 (m, 2H), 1.81 – 1.66 (m, 2H), 1.57 – 1.46 (m, 1H), 1.40 (s, 2H), 1.35 (dd, $J = 4.9, 13.7$, 6H), 1.17 (d, $J = 5.1$, 3H), 0.89 (t, $J = 6.8$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 199.49, 144.01, 141.92, 131.90, 127.72, 56.35, 54.16, 43.81, 35.05, 34.92, 31.10, 27.90, 22.46, 22.30, 18.30, 13.90; MS (ESI) m/z 406.4 $[\text{M}+\text{H}]^+$.

3-(4-Acetylpiperazin-1-yl)-1-(2,6-dichloro-4-(hexylsulfonyl)phenyl)propan-1-one **17{3,4,3}**. Yield 39%; ^1H NMR (400 MHz, CDCl_3) δ 7.87 (s, 2H), 3.71 – 3.64 (m, 4H), 3.16 – 3.00 (m, 4H), 2.85 (t, $J = 7.2$, 2H), 2.53 – 2.42 (m, 4H), 1.80 – 1.64 (m, 2H), 1.48 – 1.36 (m, 2H), 1.36 – 1.17 (m, $J = 3.3$, 4H), 0.98 (t, $J = 7.0$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 199.70, 144.01, 141.92, 131.97,

127.73, 66.85, 56.36, 53.58, 52.14, 40.79, 31.11, 27.90, 22.49, 22.30, 13.91; MS (ESI) m/z 436.4 [M+H]⁺.

4-(3-(2,6-Dichloro-4-(hexylsulfonyl)phenyl)-3-oxopropyl)piperazin-2-one 17{3,4,4}. Yield 94%;

¹H NMR (400 MHz, CDCl₃) δ 7.86 (s, 2H), 7.05 – 6.66 (m, 1H), 3.34 (brs, 2H), 3.17 (brs, 2H), 3.14 – 3.08 (m, 2H), 3.08 (t, $J = 6.8$, 2H), 2.93 (t, $J = 7.0$, 2H), 2.74 – 2.64 (m, 2H), 1.73 (s, 2H), 1.39 (s, 2H), 1.28 (s, 4H), 0.88 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 199.15, 169.25, 143.74, 142.07, 131.91, 127.77, 56.69, 56.30, 50.72, 49.21, 43.93, 41.17, 40.95, 31.09, 27.88, 22.43, 22.29, 13.90; MS (ESI) m/z 449.4 [M+H]⁺.

1-(2,6-Dichloro-4-(hexylsulfonyl)phenyl)-3-morpholinopropan-1-one 17{3,4,5}. Yield 63%; ¹H

NMR (400 MHz, CDCl₃) δ 7.86 (s, 2H), 3.62 – 3.56 (m, 2H), 3.46 – 3.42 (m, 2H), 3.15 – 3.09 (m, 2H), 3.06 (t, $J = 7.0$, 2H), 2.86 (t, $J = 7.0$, 2H), 2.53 – 2.40 (m, $J = 17.1$, 4H), 2.08 (s, 3H), 1.78 – 1.64 (m, $J = 7.6$, 2H), 1.47 – 1.36 (m, 2H), 1.36 (d, $J = 3.5$, 4H), 0.95 (d, $J = 7.1$, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 199.52, 168.91, 143.91, 141.99, 131.93, 127.74, 56.32, 53.31, 52.62, 51.56, 46.17, 41.27, 40.97, 31.10, 27.89, 22.47, 22.29, 21.32, 13.90; MS (ESI) m/z 477.5 [M+H]⁺.

1-(2,6-Dichloro-4-(hexylsulfonyl)phenyl)-3-(2-methylaziridin-1-yl)propan-1-one 17{3,4,6}.

Yield 31%; ¹H NMR (400 MHz, CDCl₃) δ 7.87 (s, 2H), 3.28 (brs, 4H), 3.16 – 3.09 (m, 2H), 3.09 – 3.02 (m, 2H), 3.00 – 2.94 (m, 2H), 2.94 – 2.86 (m, 2H), 2.63 (brs, 4H), 1.79 – 1.69 (m, 2H), 1.47 – 1.35 (m, 5H), 1.35 – 1.23 (m, 4H), 0.90 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 199.43, 143.95, 142.03, 131.95, 127.75, 56.34, 52.73, 51.43, 45.68, 43.82, 40.84, 31.10, 27.90, 22.47, 22.30, 13.91, 7.79; MS (ESI) m/z 527.5 [M+H]⁺.

3-(Dimethylamino)-1-(4-(hexylsulfonyl)-2,6-dimethylphenyl)propan-1-one 17{3,5,1}. Yield 90%; ^1H NMR (400 MHz, CDCl_3) δ 7.54 (s, 2H), 3.05 (m, 2H), 2.87 (t, 2H, $J = 7.2$ Hz), 2.71 (t, 2H, $J = 7.1$ Hz), 2.29 (s, 6H), 2.24 (m, 6H), 1.68 (m, 2H), 1.34 (m, 2H), 1.24 (m, 4H), 0.84 (t, 3H, $J = 6.9$ Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 207.76, 146.72, 139.05, 134.43, 127.18, 56.19, 53.28, 45.33, 42.58, 31.07, 27.87, 22.47, 22.23, 19.09, 13.83; MS (ESI) m/z 354.4 $[\text{M}+\text{H}]^+$.

1-(4-(Hexylsulfonyl)-2,6-dimethylphenyl)-3-(2-methylaziridin-1-yl)propan-1-one 17{3,5,2}. Yield 100%; ^1H NMR (400 MHz, CDCl_3) δ 7.49 (s, 2H), 3.05 – 2.96 (m, 2H), 2.91 (t, $J = 7.0$, 2H), 2.69 – 2.49 (m, 2H), 2.26 (s, 6H), 1.69 – 1.56 (m, 2H), 1.42 (dd, $J = 3.9, 9.3$, 2H), 1.30 (dt, $J = 7.0, 14.1$, 2H), 1.26 – 1.14 (m, 5H), 1.08 (d, $J = 5.1$, 3H), 0.80 (t, $J = 6.8$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 207.59, 146.83, 139.14, 134.43, 127.25, 56.28, 54.50, 44.68, 35.11, 34.92, 31.16, 27.96, 22.55, 22.32, 19.15, 18.30, 13.92; MS (ESI) m/z 366.2 $[\text{M}+\text{H}]^+$.

1-(4-(Hexylsulfonyl)-2,6-dimethylphenyl)-3-morpholinopropan-1-one 17{3,5,3}. Yield 58%; ^1H NMR (400 MHz, CDCl_3) δ 7.51 (s, 2H), 3.66 – 3.55 (m, 4H), 3.03 – 2.94 (m, 2H), 2.82 (t, $J = 7.0$, 2H), 2.71 (t, $J = 6.8$, 2H), 2.49 – 2.34 (m, 4H), 2.27 (s, 6H), 1.71 – 1.50 (m, 3H), 1.35 – 1.25 (m, 2H), 1.25 – 1.09 (m, 4H), 0.80 (t, $J = 6.7$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 207.73, 146.74, 139.20, 134.52, 127.29, 66.87, 56.28, 53.74, 52.65, 41.72, 31.17, 27.97, 22.56, 22.32, 19.26, 13.93; MS (ESI) m/z 396.2 $[\text{M}+\text{H}]^+$.

4-(3-(4-(Hexylsulfonyl)-2,6-dimethylphenyl)-3-oxopropyl)piperazin-2-one 17{3,5,4}. Yield 56%; ^1H NMR (400 MHz, CDCl_3) δ 7.50 (s, 2H), 6.52 (s, 1H), 3.27 (s, 2H), 3.09 (s, 2H), 3.06 – 2.93 (m, 2H), 2.82 (s, 4H), 2.64 (t, $J = 5.4$, 2H), 2.22 (d, $J = 21.0$, 6H), 1.69 – 1.56 (m, 2H), 1.34 –

S82

1.25 (m, 2H), 1.25 – 1.10 (m, 4H), 0.80 (t, $J = 6.8$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 207.14, 169.07, 146.53, 139.33, 134.48, 127.34, 56.86, 56.27, 51.28, 49.42, 41.91, 41.23, 31.16, 27.96, 22.53, 22.32, 19.19, 13.93; MS (ESI) m/z 409.2 $[\text{M}+\text{H}]^+$.

3-(4-Acetylpiperazin-1-yl)-1-(4-(hexylsulfonyl)-2,6-dimethylphenyl)propan-1-one 17{3,5,5}.




Yield 100%; ^1H NMR (400 MHz, CDCl_3) δ 7.58 (s, $J = 9.1$, 2H), 3.64 (brs, 2H), 3.51 – 3.39 (m, 2H), 3.13 – 3.01 (m, 2H), 2.90 (t, $J = 6.6$, 2H), 2.81 (t, $J = 6.5$, 2H), 2.55 – 2.40 (m, 4H), 2.33 (s, 6H), 2.06 (s, 3H), 1.78 – 1.64 (m, 2H), 1.42 – 1.32 (m, 2H), 1.32 – 1.17 (m, 4H), 0.87 (t, $J = 6.8$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 207.52, 168.93, 146.66, 139.26, 134.47, 127.30, 56.26, 53.49, 52.76, 52.03, 46.16, 41.91, 41.26, 31.16, 27.96, 22.55, 22.31, 21.32, 19.25, 13.92; MS (ESI) m/z 437.22 $[\text{M}+\text{H}]^+$.

3-(4-(Ethylsulfonyl)piperazin-1-yl)-1-(4-(hexylsulfonyl)-2,6-dimethylphenyl)propan-1-one

7{3,5,6}.


Yield 54%; ^1H NMR (400 MHz, CDCl_3) δ 7.50 (s, 2H), 3.22 (brs, 4H), 3.03 – 2.95 (m, 2H), 2.94 – 2.84 (m, 2H), 2.84 – 2.71 (m, 4H), 2.49 (s, 4H), 2.26 (s, 6H), 1.71 – 1.56 (m, 3H), 1.30 (t, $J = 7.4$, 5H), 1.26 – 1.10 (m, 4H), 0.80 (t, $J = 6.8$, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 207.53, 146.63, 139.31, 134.45, 127.32, 56.27, 52.94, 51.87, 45.69, 43.97, 41.84, 31.17, 27.97, 22.55, 22.32, 19.26, 13.93, 7.81; MS (ESI) m/z 487.2 $[\text{M}+\text{H}]^+$.

Spectral and Chromatographic Data




(1) ELSD Signal




34.564
Range: 34.551



Peak ID	Compound Found	Time	Mass Found
1	Found	0.73	278.40


1: MS ES+
5.9e+007






(1) ELSD Signal




51.194
Range: 51.184



Peak ID	Compound	Time	Mass Found
1	Found	0.73	278.30


1: MS ES+
1.1e+008





(1) ELSD Signal


30.172
Range: 30.121






Peak ID	Compound Found	Time	Mass Found
2		0.80	292.22


2: (Time: 0.80)

1: MS ES+
1.3e+008









(1) ELSD Signal 36.992
Range: 36.953



Peak ID	Compound	Time	Mass Found
2	Found	0.91	292.43


2: (Time: 0.91) 1:MS ES+
7.0e+007





(1) ELSD Signal


83.425
Range: 83.385






Peak ID	Compound	Time	Mass Found
1	Found	0.77	292.22

1: (Time: 0.77)


1: MS ES+
8.7e+007






(1) ELSD Signal




60.061
Range: 60.058



Peak ID	Compound Found	Time	Mass Found
1	Found	0.69	308.43


1:MS ES+
8.7e+007






(1) ELSD Signal





60.014
Range: 60.007






Peak ID	Compound Found	Time	Mass Found
1		0.70	308.43

1: MS ES+
5.9e+007








(1) ELSD Signal

18.819
Range: 18.791






Peak ID	Compound Found	Time	Mass Found
2		0.85	324.49

2: (Time: 0.85)



1: MS ES+
9.7e+007








(1) ELSD Signal


144.943
Range: 144.941





(1) ELSD Signal





15.335
Range: 15.324




Peak ID	Compound Found	Time	Mass Found
2		1.09	334.51

2: (Time: 1.09)

1:MS ES+
1.1e+008








Peak ID	Compound	Time	Mass Found
1	Found	0.77	296.39


1: (Time: 0.77) 1:MS ES+
9.1e+007

Mass spectrum showing a single peak at m/z 297.2. The y-axis is labeled 'abundance' and the x-axis is 'm/z'.




(1) ELSD Signal




86.897
Range: 86.870




Peak ID	Compound	Time	Mass Found
1	Found	0.81	312.85

1: MS ES+
8.8e+007









(1) ELSD Signal 60.100
 Range: 60.097



Peak ID	Compound Found	Time	Mass Found
2	Found	0.78	312.85


1: MS ES+ 9.3e+007
 2: (Time: 0.78)





(1) ELSD Signal

53.128
Range: 53.108



Peak ID	Compound	Time	Mass Found
1	Found	0.86	357.30




1: MS ES+
9.0e+007



Peak ID	Compound	Time	Mass Found
2	Found	0.89	357.30


1: MS ES+
1.1e+008






(1) ELSD Signal






Range: 32.440 32.480






Peak ID	Compound Found	Time	Mass Found
1	1	0.89	357.20

1: MS ES+ 6.5e+007








天

(1) ELSD Signal


13.357
Range: 13.338




Peak ID	Compound Found	Time	Mass Found
2		0.92	404.30



2: (Time: 0.92)

1: MS ES+
7.8e+007






12{16}



(1) ELSD Signal


56.625
Range: 56.625






Peak ID	Compound Found	Time	Mass Found
1		0.64	356.39

1: (Time: 0.64)


1:MS ES+
1.1e+008






(1) ELSD Signal




55.397
Range: 55.320



Peak ID	Compound	Time	Mass Found
1	Found	0.76	356.39


1:MS ES+
1.3e+008





(1) ELSD Signal





28.162
Range: 28.145



Peak ID	Compound	Time	Mass Found
1	Found	0.91	346.30


1: (Time: 0.91)

1: MS ES+
9.8e+007



(1) ELSD Signal

8.324
Range: 8.274






Peak ID	Compound	Time	Mass Found
2	Found	0.96	346.40

2: (Time: 0.96)


1: MS ES+
1.1e+008





(1) ELSD Signal




3.022
Range: 3.007



Peak ID	Compound	Time	Mass Found
2	Found	0.80	323.40


1:MS ES+
7.7e+007






(1) ELSD Signal




39.986
Range: 39.943



Peak ID	Compound	Time	Mass Found
1	Found	0.86	306.45


1:MS ES+
8.5e+007





(1) ELSD Signal

27.566
Range: 27.481




Peak ID	Compound	Time	Mass Found
2	Found	0.84	306.45



2: (Time: 0.84)

1:MS ES+
8.8e+007






12{23}




(1) ELSD Signal



17.933
Range: 17.897




Peak ID	Compound	Time	Mass Found
3	Found	1.12	334.51

3: (Time: 1.12) 1:MS ES+ 1.3e+008











(1) ELSD Signal 9.402
Range: 9.394







Peak ID	Compound	Time	Mass Found
2	Found	0.95	347.29

2: (Time: 0.95) 1:MS ES+
1.1e+08











Peak ID	Compound Found	Time	Mass Found
4	Found	0.97	346.30

4: (Time: 0.97) 1:MS ES+
3.5e+007






12{27}



(1) ELSD Signal


7.467
Range: 7.421




Peak ID	Compound	Time	Mass Found
1	Found	1.02	354.50




1: (Time: 1.02)


1:MS ES+
8.6e+007







12{28}






13{1}




(1) ELSD Signal




41.771
Range: 41.765





Peak ID	Compound Found	Time	Mass Found
2	Found	1.01	328.46




1:MS ES+
1.3e+008






(1) ELSD Signal






(1) ELSD Signal





Range: 14.935 14.990











Peak ID	Compound	Time	Mass Found
2	Found	0.99	328.46

2: (Time: 0.99) 1:MS ES+ 1.3e+008











(1) ELSD Signal




96.190
Range: 96.175



Peak ID	Compound Found	Time	Mass Found
2		1.01	354.50


1:MS ES+
1.3e+008





(1) ELSD Signal


42.401
Range: 42.382






Peak ID	Compound	Time	Mass Found
1	Found	0.76	290.31

1: (Time: 0.76)


1:MS ES+
1.0e+008





(1) ELSD Signal




17.695
Range: 17.692



Peak ID	Compound Found	Time	Mass Found
1		0.85	304.44


1:MS ES+
9.5e+007





(1) ELSD Signal




11.436
Range: 11.387



Peak ID	Compound	Time	Mass Found
2	Found	0.83	306.41


1:MS ES+
1.2e+008





(1) ELSD Signal




15.432
Range: 15.419



Peak ID	Compound Found	Time	Mass Found
2	Found	1.10	362.56


2: (Time: 1.10) 1: MS ES+ 1.2e+008

Mass spectrum showing relative intensity (%) vs m/z. Major peak at 362.3 and minor peak at 364.3.



(1) ELSD Signal

71.677
Range: 71.600






(2)
 100%
 318.5
 0.81
 3982


Peak ID	Compound Found	Time	Mass Found
2		0.80	318.47

1: MS ES+
8.4e+007









(1) ELSD Signal 47.509
Range: 47.506



Peak ID	Compound	Time	Mass Found
2	Found	0.82	304.44


2: (Time: 0.82) 1:MS ES+
1.3e+008





(1) ELSD Signal

70.510
Range: 70.495




Peak ID	Compound	Time	Mass Found
2	Found	0.73	290.41



2: (Time: 0.73)

1: MS ES+
6.9e+007






15{5}




(1) ELSD Signal




72.854
Range: 72.836



Peak ID	Compound	Time	Mass Found
1	Found	0.68	333.48


1:MS ES+
9.0e+007






(1) ELSD Signal




30.863
Range: 30.810



Peak ID	Compound Found	Time	Mass Found
2	Found	0.97	395.55


1: MS ES+
8.8e+007





(1) ELSD Signal




Range: 74.545
74.539



Peak ID	Compound Found	Time	Mass Found
1	Found	0.73	320.44



1: MS ES+
7.8e+007








(1) ELSD Signal


377.755
Range: 377.713





(1) ELSD Signal

24.758
Range: 24.742






Peak ID	Compound Found	Time	Mass Found
2	Found	1.44	326.44

2: (Time: 1.44)


1: MS ES+
9.2e+007






(1) ELSD Signal




73.001
Range: 72.998



Peak ID	Compound Found	Time	Mass Found
1		1.59	360.89


1:MS ES+
1.0e+008





(1) ELSD Signal

15.614
Range: 15.608






Peak ID	Compound	Time	Mass Found
2	Found	0.82	301.40

2: (Time: 0.82)


1:MS ES+
8.0e+007





(1) ELSD Signal

245.149
Range: 245.122






(2)
 100%
 332.4
 1.16
 4871

Peak ID	Compound	Time	Mass Found
2	Found	1.17	332.41


1:MS ES+
8.2e+007






(1) ELSD Signal




67.192
Range: 67.162



Peak ID	Compound Found	Time	Mass Found
1	1	0.39	266.35


1:MS ES+
1.1e+008






(1) ELSD Signal




37.345
Range: 37.268



Peak ID	Compound	Time	Mass Found
1	Tentative	0.93	303.35




1:MS ES+
1.1e+008












(1) ELSD Signal

Range: 3.602 - 3.612









(1) ELSD Signal




11.912
Range: 11.872



Peak ID	Compound	Time	Mass Found
2	Found	0.61	326.37



1:MS ES+
9.1e+007












(1) ELSD Signal

32.534
Range: 32.472








(1) ELSD Signal

68.376
Range: 68.346







Peak ID	Compound Found	Time	Mass Found
1		0.47	327.35


1: (Time: 0.47)

1: MS ES+
9.5e+007









17{1,1,1} Same with 12{11}







17{1,1,2}




(1) ELSD Signal 320.968
Range: 320.955










Peak ID	Compound	Time	Mass Found
2	Found	0.77	354.39




2: (Time: 0.77) 1:MS ES+
1.0e+008






(1) ELSD Signal 885.760
Range: 885.751







(1) ELSD Signal 567.788
Range: 567.766






Peak ID	Compound	Time	Mass Found
5	Found	0.76	395.44

5: (Time: 0.76) 1:MS ES+ 1.2e+008






17{1,1,6}




Peak ID	Compound	Time	Mass Found
3	Found	0.84	445.52



3: (Time: 0.84) 1:MS ES+
6.5e+007




17{1,2,1} Same with 12{24}



17{1,2,2}





(1) ELSD Signal 380.806
Range: 380.775





Peak ID	Compound	Time	Mass Found
3	Found	0.88	358.31

3: (Time: 0.88) 1:MS ES+ 1.2e+008






17{1,2,3}





(1) ELSD Signal 462.836
Range: 462.813





Peak ID	Compound	Time	Mass Found
7	Found	0.89	388.34

7: (Time: 0.89) 1:MS ES+
9.6e+007






17{1,2,4}







(1) ELSD Signal 1731.822
Range: 1731.788




Peak ID	Compound	Time	Mass Found
5	Found	0.89	401.33

5: (Time: 0.89) 1:MS ES+
8.9e+007









(1) ELSD Signal 540.592
Range: 540.565




Peak ID	Compound	Time	Mass Found
4	Found	0.81	429.39

4: (Time: 0.81) 1:MS ES+
8.0e+007






(1) ELSD Signal 673.807
 Range: 673.793




Peak ID	Compound	Time	Mass Found
5	Found	0.91	479.47



5: (Time: 0.91) 1:MS ES+
6.4e+007




17{1,3,1} Same with 12{25}



17{1,3,2}





(1) ELSD Signal 363.422
Range: 363.408





Peak ID	Compound	Time	Mass Found
4	Found	0.84	358.31

4: (Time: 0.84) 1:MS ES+
9.6e+007






17{1,3,3}







(1) ELSD Signal 439.841
Range: 439.836




Peak ID	Compound	Time	Mass Found
5	Found	0.83	388.34

5: (Time: 0.83) 1:MS ES+
8.1e+007









(1) ELSD Signal 1684.140
 Range: 1684.123




Peak ID	Compound	Time	Mass Found
3	Found	0.89	401.33

3: (Time: 0.89) 1:MS ES+
8.4e+007









(1) ELSD Signal 498.296
 Range: 498.291




Peak ID	Compound	Time	Mass Found
5	Found	0.89	429.39

5: (Time: 0.89) 1:MS ES+
6.6e+007






(1) ELSD Signal 670.705
 Range: 670.685




Peak ID	Compound	Time	Mass Found
8	Found	0.97	479.47



8: (Time: 0.97) 1:MS ES+
7.3e+007





17{1,4,1} Same with 12{26}







17{1,4,2}




(1) ELSD Signal 319.277
 Range: 319.252










Peak ID	Compound Found	Time	Mass Found
3	Found	0.84	388.34




1:MS ES+
7.3e+007






(1) ELSD Signal 1747.322
Range: 1747.305









(1) ELSD Signal 625.483
Range: 625.458



Peak ID	Compound	Time	Mass Found
5	Found	0.83	429.39

5: (Time: 0.83) 1:MS ES+ 1.0e+008








(1) ELSD Signal

846.584



Range: 846.541



17{1,5,1} Same with 12{22}




17{1,5,2}



(1) ELSD Signal




79.395

Range: 79.364



Peak ID	Compound	Time	Mass Found
4	Found	0.97	346.30


4: (Time: 0.97) 1:MS ES+ 3.5e+007



(1) ELSD Signal


443.455




Range: 443.433




Peak ID	Compound	Time	Mass Found
3	Found	0.79	348.50

3: (Time: 0.79) 1:MS ES+ 9.5e+007









(1) ELSD Signal 1084.732
Range: 1084.710



Peak ID	Compound	Time	Mass Found
6	Found	0.86	361.50

6: (Time: 0.86) 1:MS ES+
8.7e+007






(1) ELSD Signal


552.602




Range: 552.596




Peak ID	Compound	Time	Mass Found
4	Found	0.78	389.55

4: (Time: 0.78) 1:MS ES+ 1.0e+008









(1) ELSD Signal 749.914
 Range: 749.907



Peak ID	Compound	Time	Mass Found
7	Found	0.87	439.63


7: (Time: 0.87) 1:MS ES+
6.4e+007





(1) ELSD Signal

73.590
Range: 73.565






Peak ID	Compound	Time	Mass Found
1	Found	0.90	328.81


1: (Time: 0.90)

1:MS ES+
1.1e+008










(1) ELSD Signal 343.447
 Range: 343.444



Peak ID	Compound	Time	Mass Found
4	Found	0.84	340.43


4: (Time: 0.84) 1:MS ES+
8.9e+007









Peak ID	Compound	Time	Mass Found
4	Found	0.82	370.46

4: (Time: 0.82) 1:MS ES+
1.0e+008









(1) ELSD Signal 1642.389
 Range: 1642.373




Peak ID	Compound	Time	Mass Found
4	Found	0.88	383.46

4: (Time: 0.88) 1:MS ES+
7.9e+007









(1) ELSD Signal 687.943
 Range: 687.936




Peak ID	Compound	Time	Mass Found
6	Found	0.83	411.51

6: (Time: 0.83) 1:MS ES+
1.3e+008









(1) ELSD Signal 651.623
Range: 651.616



Peak ID	Compound	Time	Mass Found
5	Found	0.90	461.59


5: (Time: 0.90) 1:MS ES+ 9.4e+007





(1) ELSD Signal

84.951
Range: 84.905




Peak ID	Compound	Time	Mass Found
1	Found	0.99	363.26



1: (Time: 0.99)

1: MS ES+
1.1e+008






17{2,2,2}



(1) ELSD Signal

322.687


Range: 322.681




Peak ID	Compound	Time	Mass Found
4	Found	0.91	374.38



4: (Time: 0.91)

1: MS ES+
5.3e+007






17{2,2,3}



(1) ELSD Signal


550.622





Range: 550.589



Peak ID	Compound	Time	Mass Found
3	Found	0.88	404.40


3: (Time: 0.88) 1:MS ES+
8.8e+007










Peak ID	Compound	Time	Mass Found
4	Found	1.00	417.40




4: (Time: 1.02) 1:MS ES+
1.3e+008






(1) ELSD Signal 634.959
 Range: 634.927







(1) ELSD Signal 881.200
Range: 881.164





Peak ID	Compound	Time	Mass Found
6	Found	0.98	495.54

6: (Time: 0.98) 1:MS ES+
9.9e+007






17{2,3,1}







(1) ELSD Signal 84.939
Range: 84.937




Peak ID	Compound Found	Time	Mass Found
3	Found	1.03	362.37

3: (Time: 1.03) 1:MS ES+
3.2e+007









(1) ELSD Signal 433.096
 Range: 433.066



Peak ID	Compound	Time	Mass Found
5	Found	0.89	374.38

5: (Time: 0.89) 1:MS ES+
2.9e+007






(1) ELSD Signal


477.906


Range: 477.863





Peak ID	Compound	Time	Mass Found
3	Found	0.89	404.40

1:MS ES+
3.9e+007







17{2,3,4}






(1) ELSD Signal


1747.445

Range: 1747.428









(1) ELSD Signal 892.008
Range: 891.964




Peak ID	Compound	Time	Mass Found
5	Found	0.85	445.46

5: (Time: 0.85) 1:MS ES+ 7.8e+007









(1) ELSD Signal 823.722
 Range: 823.714



Peak ID	Compound	Time	Mass Found
7	Found	0.98	495.54


7: (Time: 0.98) 1:MS ES+
9.2e+007





(1) ELSD Signal


61.913
Range: 61.812




Peak ID	Compound Found	Time	Mass Found
1	Found	0.98	363.26



1: (Time: 0.98)

1:MS ES+
4.2e+007






17{2,4,2}



(1) ELSD Signal

358.156

Range: 358.134







Peak ID	Compound	Time	Mass Found
4	Found	0.89	374.38

4: (Time: 0.89)


1: MS ES+

3.2e+007









(1) ELSD Signal 468.228
 Range: 468.224




Peak ID	Compound	Time	Mass Found
1	Found	0.90	404.40

1: (Time: 0.90) 1:MS ES+
1.0e+008









(1) ELSD Signal 1747.507
Range: 1747.437




Peak ID	Compound	Time	Mass Found
6	Found	1.09	417.40

1:MS ES+
1.3e+008









(1) ELSD Signal 615.112
Range: 615.081




Peak ID	Compound	Time	Mass Found
5	Found	0.94	445.46

5: (Time: 0.94) 1:MS ES+ 1.0e+008









(1) ELSD Signal 1066.109
Range: 1066.088



Peak ID	Compound Found	Time	Mass Found
8	Found	1.04	495.54


8: (Time: 1.04) 1:MS ES+ 9.2e+007





(1) ELSD Signal


35.933
Range: 35.924





Peak ID	Compound	Time	Mass Found
2	Found	0.92	322.52

2 : (Time: 0.92) 1:MS ES+ 8.6e+007






17{2,5,2}







(1) ELSD Signal 422.509
Range: 422.441



Peak ID	Compound	Time	Mass Found
3	Found	0.85	334.54

3: (Time: 0.85) 1:MS ES+ 3.3e+007






(1) ELSD Signal

467.440

Range: 467.421







Peak ID	Compound	Time	Mass Found
2	Found	0.89	364.57

2: (Time: 0.89)


1: MS ES+

1.3e+008









(1) ELSD Signal 1147.845
Range: 1147.810




Peak ID	Compound	Time	Mass Found
6	Found	0.96	377.57

6: (Time: 0.96) 1:MS ES+
9.1e+007









(1) ELSD Signal 487.872
Range: 487.833




Peak ID	Compound	Time	Mass Found
4	Found	0.86	405.62

1:MS ES+
1.1e+008









(1) ELSD Signal 594.953
Range: 594.935



Peak ID	Compound	Time	Mass Found
5	Found	0.96	455.70


5: (Time: 0.96) 1:MS ES+
8.1e+007





(1) ELSD Signal


35.800
Range: 35.755




Peak ID	Compound	Time	Mass Found
2	Found	0.67	360.81



2: (Time: 0.67)

1: MS ES+
1.0e+008






17{3,1,2}



(1) ELSD Signal

131.216

Range: 131.177





Peak ID	Compound	Time	Mass Found
2	Found	0.70	372.43

2: (Time: 0.70)



1: MS ES+

8.0e+007






17{3,1,3}







(1) ELSD Signal 487.661
Range: 487.642





Peak ID	Compound Found	Time	Mass Found
1	Found	0.62	402.45




1: (Time: 0.62) 1: MS ES+ 1.2e+008






(1) ELSD Signal 1587.138
 Range: 1587.122









(1) ELSD Signal 543.464
Range: 543.442




Peak ID	Compound Found	Time	Mass Found
1	Found	0.60	443.51

1: (Time: 0.60) 1:MS ES+
1.1e+008









(1) ELSD Signal 654.907
Range: 654.881




Peak ID	Compound Found	Time	Mass Found
1	Found	0.69	493.59

1: (Time: 0.69) 1: MS ES+
9.9e+007





(1) ELSD Signal




Peak ID	Compound	Time	Mass Found
1	Found	0.74	395.26



1: (Time: 0.74)

1: MS ES+
9.4e+007






17{3,2,2}





(1) ELSD Signal 502.354
Range: 502.314





Peak ID	Compound	Time	Mass Found
4	Found	0.77	406.37

1:MS ES+
6.5e+007






17{3,2,3}



(1) ELSD Signal

542.988

Range: 542.967





Peak ID	Compound Found	Time	Mass Found
2	Found	0.68	436.40

2: (Time: 0.68)



1: MS ES+

1.1e+008






17{3,2,4}



(1) ELSD Signal

1743.555


Range: 1743.520






Peak ID	Compound Found	Time	Mass Found
2	Found	0.76	449.40


2: (Time: 0.76)

1: MS ES+
1.0e+008








(1) ELSD Signal 655.307
 Range: 655.287




Peak ID	Compound Found	Time	Mass Found
3	Found	0.66	477.45

1:MS ES+
9.6e+007







(1) ELSD Signal 753.702
Range: 753.695







Peak ID	Compound	Time	Mass Found
2	Found	0.81	527.53


2: (Time: 0.81) 1:MS ES+
1.3e+008










17{3,3,1}








17{3,3,2}







17{3,3,3}







Peak ID	Compound	Time	Mass Found
3	Found	0.72	436.40




3: (Time: 0.72) 1: MS ES+
9.9e+007






17{3,3,4}










(1) ELSD Signal 539.990
 Range: 539.979



Peak ID	Compound	Time	Mass Found
4	Found	0.67	477.45


4: (Time: 0.67) 1:MS ES+
1.1e+008













Peak ID	Compound	Time	Mass Found
3	Found	0.78	527.53


3: (Time: 0.78) 1:MS ES+
8.7e+007









(1) ELSD Signal 489.209
 Range: 489.200





Peak ID	Compound	Time	Mass Found
3	Found	0.75	406.37

3: (Time: 0.75) 1:MS ES+
1.3e+008








17{3,4,3}










(1) ELSD Signal 597.025
Range: 597.007






17{3,4,4}






(1) ELSD Signal




648.330
Range: 648.304




Peak ID	Compound	Time	Mass Found
3	Found	0.72	477.45

3: (Time: 0.72) 1: MS ES+
1.3e+008







(1) ELSD Signal 979.472
Range: 979.463





Peak ID	Compound Found	Time	Mass Found
2	Found	0.85	527.53

2: (Time: 0.85) 1: MS ES+
1.3e+008






17{3,5,1}



(1) ELSD Signal

230.699
Range: 230.688






Peak ID	Compound Found	Time	Mass Found
1	Found	0.62	354.42

1: (Time: 0.62)

1:MS ES+
1.1e+008






(1) ELSD Signal

141.760

Range: 141.749





Peak ID	Compound	Time	Mass Found
3	Found	0.73	366.20

3:(Time: 0.73)



1:MS ES+

5.4e+007






17{3,5,3}



(1) ELSD Signal


151.625


Range: 151.615





Peak ID	Compound Found	Time	Mass Found
1	Found	0.76	396.21

1: (Time: 0.76) 1: MS ES+ 1.1e+008






17{3,5,4}



(1) ELSD Signal


76.326




Range: 76.308




Peak ID	Compound Found	Time	Mass Found
2	Found	0.77	409.21

2: (Time: 0.77) 1:MS ES+ 1.0e+008









(1) ELSD Signal 197.183
Range: 197.179



Peak ID	Compound	Time	Mass Found
1	Found	0.72	437.24

1:(Time: 0.72) 1:MS ES+
8.4e+007






(1) ELSD Signal

31.583

Range: 31.580



Peak ID	Compound	Time	Mass Found
5	Found	0.91	487.22

5:(Time: 0.91) 1:MS ES+ 1.2e+008

